WO2023165574A1 - 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用 - Google Patents

用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
WO2023165574A1
WO2023165574A1 PCT/CN2023/079387 CN2023079387W WO2023165574A1 WO 2023165574 A1 WO2023165574 A1 WO 2023165574A1 CN 2023079387 W CN2023079387 W CN 2023079387W WO 2023165574 A1 WO2023165574 A1 WO 2023165574A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
methyl
dimethylsulfoximine
carboxamide
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2023/079387
Other languages
English (en)
French (fr)
Inventor
张南
陈义朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Zhigen Pharmaceutical & Technology Co Ltd
Original Assignee
Shanghai Zhigen Pharmaceutical & Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Zhigen Pharmaceutical & Technology Co Ltd filed Critical Shanghai Zhigen Pharmaceutical & Technology Co Ltd
Priority to AU2023227024A priority Critical patent/AU2023227024A1/en
Priority to KR1020247032854A priority patent/KR20240158943A/ko
Priority to JP2024552772A priority patent/JP2025508011A/ja
Priority to CA3245417A priority patent/CA3245417A1/en
Priority to CN202380025084.1A priority patent/CN119317622A/zh
Priority to EP23762972.0A priority patent/EP4488268A4/en
Priority to US18/843,972 priority patent/US20250179022A1/en
Publication of WO2023165574A1 publication Critical patent/WO2023165574A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the invention relates to the field of small molecule medicine, in particular to a compound used as a TYK2 inhibitor, its preparation method and its application in medicine.
  • Autoimmune disease is an inflammatory disease in which the body's own immune system attacks normal cells, causing the decline of normal immunity and the highlight of abnormal immunity, eventually leading to tissue damage or organ dysfunction.
  • Currently, more than 80 autoimmune diseases have been reported, affecting about 5%-8% of the world's population.
  • Psoriasis PSO
  • RA rheumatoid arthritis
  • PsA psoriatic arthritis
  • UC ulcerative colitis
  • CD Crohn's disease
  • MS multiple Sexual sclerosis
  • type 1 diabetes spondyloarthritis
  • SpA chronic graft-versus-host disease
  • atopic dermatitis alopecia areata
  • asthma systemic lupus erythematosus
  • SLE systemic lupus erythematosus
  • autoimmune diseases can be systemic, such as SLE, which can affect the skin, joints, kidneys, and central nervous system; or organ-specific, such as type 1 diabetes (pancreas), UC (colon) [Cell 2020 181(1):63 -80].
  • SLE systemic
  • organ-specific such as type 1 diabetes (pancreas), UC (colon) [Cell 2020 181(1):63 -80].
  • autoimmune diseases are called "cancers that never die”.
  • JAK Janus kinase
  • JAK 1 JAK 2
  • JAK 3 JAK 3
  • STAT signal transducer
  • JAK inhibitors Tofacitinib, Baricitinib and Upadacitinib that have been clinically approved for use all act on the kinase domain (JH1 domain) of the JAK family and compete with ATP in vivo to play a role.
  • the aforementioned JAK inhibitors exhibit a series of severe clinical side effects such as anemia, infection, creatinine, liver transaminases, creatine phosphokinase, LDL-cholesterol, HDL-cholesterol levels, NK due to their poor selectivity for kinase subtypes. Cells, lymphocytes, neutrophils, and platelet counts decreased. Therefore, the above three marketed drugs all carry The black box warning of serious infection, malignant tumor and thrombosis risk, the clinical application is greatly limited.
  • TYK2 which belongs to the JAK family, is the optimal target for balancing drug efficacy and safety in autoimmune diseases [J.Med.Chem.2019, 62, 20, 8953–8972].
  • TYK2 cooperates with JAK2 to mediate signaling through IL-12 and IL-23 (p40 subunit containing cytokines), induces/stabilizes the expression of IL-17 and other pro-inflammatory factors; and cooperates with JAK1 to mediate type 1 interference Signal transmission of factors (IFN- ⁇ , etc.).
  • IFN- ⁇ IFN- ⁇
  • the blockade of the above-mentioned inflammatory cytokine signaling pathways has shown excellent pharmacodynamic activity in animal models such as rheumatoid arthritis, multiple sclerosis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, and spondyloarthritis[ J.Med.Chem.2019,62,20,8973–8995; Science Translational Medicine 2019, 502(11),:eaaw1736; J Clin Invest.2020,130(4),1863–1878].
  • the monoclonal antibody drugs developed against the above-mentioned inflammatory factors IL-12, IL-23, IL-17 and IFN- ⁇ have shown excellent effects in the clinical treatment of multiple autoimmune diseases.
  • TYK2 as a key kinase mediating the inflammatory signal transduction cascade of IL-12, IL-23, IL-17 and IFN- ⁇ , is a good druggable target for inflammatory and autoimmune diseases.
  • highly isoform-selective (JAK1, JAK2, JAK3) TYK2 inhibitors have the potential to avoid severe side effects of existing JAK inhibition.
  • BMS-986165 (Deucravacitinib), a highly subtype-selective TYK2 inhibitor developed by Bristol-Myers Squibb, has shown excellent efficacy and safety in two phase III clinical studies of moderate to severe psoriasis.
  • BMS-986165 is in the clinical phase II evaluation stage in the indication fields of psoriatic arthritis, systemic lupus erythematosus, ulcerative colitis and Crohn's disease, showing strong potential for the treatment of autoimmune diseases.
  • Representative patents for developing TYK2 inhibitors with high kinase (subtype) selectivity include WO2014074660, WO2014074661, and WO2019103952.
  • the invention provides a class of TYK2 inhibitors with stronger kinase inhibitory activity, high subtype selectivity, good metabolic properties, stronger drug efficacy in vivo and novel structure.
  • the TYK2 inhibitor disclosed in the present invention can be used to prevent and/or treat related diseases mediated by TYK2, especially autoimmune diseases related to IL-12, IL-23, IL-17 and type 1 interferon (IFN- ⁇ , etc.) .
  • the object of the present invention is to provide a compound represented by formula (I), its preparation method and its use in preventing and/or treating related diseases mediated by TYK2.
  • the first aspect of the present invention provides a compound represented by formula (I) or its tautomer, mesomer, racemate, enantiomer, diastereomer, or its mixture, or its pharmaceutical acceptable salt,
  • R 1 is selected from the following group: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, said substitution refers to one or more substituents selected from the following group Substitution: deuterium, halogen;
  • A is NH or CH 2 ;
  • B is CH or N
  • L is selected from the group:
  • R 2 is selected from the following group: H, -CD 3 , C1-C6 alkyl, C3-C6 cycloalkyl;
  • X is CH or N
  • Y is NH, O or S
  • R 3 , R 4 , and R 5 are each independently selected from the following group: H, -NH 2 , -OH, C1-C6 alkoxy, C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C6 ring Alkyl, -CONH 2 , -CN, halogen, -O(CH 2 ) n R 9 , C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl substituted C2-C6 alkynyl, and - NR 8 (CH 2 ) n R 9 ;
  • n 1, 2, 3, 4 or 5;
  • R9 is selected from the group consisting of -OH, C1-C6 alkoxy, C4-C6 cycloalkoxy, 4-8 membered heterocyclyl containing 1, 2 or 3 heteroatoms selected from N, O or S and -CN;
  • R 8 is H or C1-C6 alkyl
  • R 6 and R 7 are each independently selected from the following group: H, C1-C6 alkyl, halogen.
  • R 1 is selected from the following group: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, the substitution means one selected from the following group Or multiple substituents: deuterium, halogen;
  • A is NH or CH 2 ;
  • B is CH or N
  • L is selected from the group:
  • R 2 is selected from the following group: H, -CD 3 , C1-C6 alkyl, C3-C6 cycloalkyl;
  • X is CH or N
  • Y is NH, O or S
  • R 3 , R 4 , and R 5 are each independently selected from the following group: H, -NH 2 , -OH, C1-C6 alkoxy, C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C6 ring Alkyl, -CONH 2 , -CN, halogen, -O(CH 2 ) n R 9 and -NR 8 (CH 2 ) n R 9 ;
  • n 1, 2, 3, 4 or 5;
  • R9 is selected from the group consisting of -OH, C1-C6 alkoxy, C4-C6 cycloalkoxy, 4-8 membered heterocyclyl containing 1, 2 or 3 heteroatoms selected from N, O or S and -CN;
  • R 8 is H or C1-C6 alkyl
  • R 6 and R 7 are each independently selected from the following group: H, C1-C6 alkyl, halogen.
  • the additional condition is: when R 2 is H, R 3 is -NH 2 or R 4 and R 5 are not H at the same time.
  • R 1 is deuterated or unsubstituted C1-C6 alkyl.
  • R 1 is a fully deuterated C1-C6 alkyl group.
  • the full deuteration means that all H of the group are replaced by D.
  • R 1 is C1-C6 alkyl.
  • R 1 is a fully deuterated C1-C6 alkyl group
  • A is NH
  • B is CH or N.
  • R 1 is selected from the following group: -CH 3 and -CD 3 ;
  • A is NH
  • B is CH or N.
  • L is N
  • R 2 is selected from the following group: H, -CD 3 , C1-C6 alkyl;
  • X is N
  • R 3 , R 4 , and R 5 are each independently selected from the following group: H, -NH 2 , -OH, C1-C6 alkoxy, C1-C6 alkyl, C3-C6 cycloalkyl, -CONH 2 , - CN, halogen, -O(CH 2 ) n R 9 , C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl substituted C2-C6 alkynyl, and -NR 8 (CH 2 ) n R 9 ;
  • n 1, 2, 3, 4 or 5;
  • R is selected from the group consisting of C1-C6 alkoxy, C4-C6 cycloalkoxy, 4-8 membered heterocyclyl containing 1, 2 or 3 heteroatoms selected from N, O or S, and -CN ;
  • R 8 is H or C1-C6 alkyl.
  • L is N
  • R 2 is selected from the following group: H, -CD 3 , C1-C6 alkyl;
  • X is N
  • R 3 , R 4 , and R 5 are each independently selected from the following group: H, -NH 2 , -OH, C1-C6 alkoxy, C1-C6 alkyl, C3-C6 cycloalkyl, -CONH 2 , - CN, halogen, -O(CH 2 ) n R 9 and -NR 8 (CH 2 ) n R 9 ;
  • n 1, 2, 3, 4 or 5;
  • R is selected from the group consisting of C1-C6 alkoxy, C4-C6 cycloalkoxy, 4-8 membered heterocyclyl containing 1, 2 or 3 heteroatoms selected from N, O or S, and -CN ;
  • R 8 is H or C1-C6 alkyl.
  • R 2 is H, -CD 3 and -CH 3 .
  • R 9 is selected from the group consisting of -OCH 3 , -CN,
  • R 3 and R 4 are each independently selected from the following group: -NH 2 , -OH, C1-C6 alkoxy, C1-C6 alkyl, C3-C6 cycloalkyl, -CONH 2 , -CN, halogen, -O(CH 2 ) n R 9 , C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl substituted C2-C6 alkynyl, and -NR 8 (CH 2 ) n R 9 .
  • R 3 and R 4 are each independently selected from the following group: -NH 2 , C1-C6 alkyl, halogen, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl , C2-C6 alkynyl substituted by C3-C6 cycloalkyl.
  • R 3 is -NH 2 .
  • R is C1-C6 alkyl, halogen, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl substituted C2-C6 alkynyl .
  • R 3 is -NH 2 ; R 4 is halogen.
  • R 3 is -NH 2 ; R 4 is Cl or Br.
  • R 1 is a fully deuterated C1-C6 alkyl group
  • A is NH
  • R 2 is selected from the following group: H, -CD 3 , C1-C6 alkyl;
  • X is N
  • R 3 is -NH 2 ;
  • R is selected from the group consisting of halogen, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl substituted C2-C6 alkynyl;
  • R5 is H.
  • R 1 is a fully deuterated C1-C6 alkyl group
  • A is NH
  • R 2 is selected from the group consisting of H, C1-C6 alkyl
  • X is N
  • R 3 is -NH 2 ;
  • R 4 is halogen
  • R5 is H.
  • R 1 is a fully deuterated C1-C6 alkyl group
  • A is NH
  • R 2 is -CD 3 ;
  • X is N
  • R 3 is -NH 2 ;
  • R is selected from the group consisting of halogen, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl substituted C2-C6 alkynyl;
  • R5 is H.
  • the compound is selected from the following group:
  • the second aspect of the present invention provides a compound described in the first aspect of the present invention or its tautomer, mesoform, racemate, enantiomer, diastereoisomer , or a mixture thereof, or a preparation method of a pharmaceutically acceptable salt thereof, comprising the steps of:
  • R 1 , A, B, L are as defined in the first aspect of the present invention.
  • G is halogen
  • the third aspect of the present invention provides a pharmaceutical composition, comprising a pharmaceutically acceptable carrier and one or more safe and effective amounts of the compound or its tautomer, internal Racemization body, racemate, enantiomer, diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition is an oral preparation.
  • the fourth aspect of the present invention provides a compound described in the first aspect of the present invention or its tautomer, mesomer, racemate, enantiomer, diastereoisomer , or a mixture thereof, or a pharmaceutically acceptable salt thereof, for preparing a medicament for preventing and/or treating related diseases mediated by TYK2.
  • the related diseases mediated by TYK2 are inflammatory or autoimmune diseases in mammals.
  • the inflammatory or autoimmune disease is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, cutaneous lupus, inflammatory bowel disease, psoriasis , Crohn's disease, psoriatic arthritis, Sjögren's syndrome (Sjogren's Syndrome, ss), systemic scleroderma, ulcerative colitis, Gray's disease, discoid lupus erythematosus, adult Still's disease, systemic Juvenile idiopathic arthritis, gout, gouty arthritis, type 1 diabetes, insulin-dependent diabetes, sepsis, septic shock, shigellosis, pancreatitis, glomerulonephritis, autoimmune gastritis, autoimmunity Hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic rhinitis
  • Figure 1 is the single crystal diffraction data of compound 28e of the present invention.
  • the present inventor After long-term and in-depth research, the present inventor has obtained a compound represented by formula (I) with high TYK2 inhibitory activity and high selectivity, excellent metabolic properties and druggability, and its preparation method and its therapeutic and therapeutic properties through structural optimization. /or use for preventing TYK2-mediated related diseases. On this basis, the inventors have completed the present invention.
  • halogen refers to F, Cl, Br or I.
  • C1-C6 alkyl refers to a linear or branched alkyl group including 1-6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl group, tert-butyl group, neopentyl group, tertyl group, or similar groups.
  • C2-C6 alkenyl refers to a straight chain or branched alkenyl group with 2-6 carbon atoms containing a double bond, including non-limiting ethenyl, propenyl, butenyl , Isobutenyl, Pentenyl and Hexenyl etc.
  • C2-C6 alkynyl refers to a straight-chain or branched-chain alkynyl group with 2-6 carbon atoms containing a triple bond, including without limitation ethynyl, propynyl, butynyl, group, isobutynyl, pentynyl and hexynyl, etc.
  • C3-C8 cycloalkyl refers to a cyclic alkyl group having 3-8 carbon atoms in the ring, including without limitation cyclopropyl, cyclobutyl, cyclopentyl, cyclo Hexyl, cycloheptyl, cyclooctyl, etc.
  • C3-C6 cycloalkyl has a similar meaning.
  • C1-C6 alkoxy refers to a straight-chain or branched alkoxy group with 1-6 carbon atoms, including without limitation methoxy, ethoxy, propoxy, Isopropoxy and butoxy, etc. Preference is given to C1-C4 alkoxy.
  • heterocyclic group is a 4-8 membered heterocyclic group containing 1, 2 or 3 heteroatoms selected from N, O, S, including (but not limited to) the following groups:
  • aromatic ring or “aryl” has the same meaning, preferably “C6-C10 aryl”.
  • C6-C10 aryl refers to an aromatic ring group having 6-10 carbon atoms without heteroatoms in the ring, such as phenyl, naphthyl and the like.
  • heteroaryl has the same meaning and refers to a heteroaromatic group containing one to more heteroatoms.
  • C3-C10 heteroaryl refers to containing 1 to 4 selected from oxygen, sulfur And heteroatoms in nitrogen and aromatic heterocycles of 3-10 carbon atoms.
  • Non-limiting examples include: furyl, thienyl, pyridyl, pyrazolyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, and the like.
  • the heteroaryl ring may be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring bonded to the parent structure is a heteroaryl ring.
  • Heteroaryl groups can be optionally substituted or unsubstituted.
  • halo refers to substitution by halogen.
  • deuterated refers to substitution by deuterium.
  • substituted means that one or more hydrogen atoms on a specific group are replaced by a specific substituent.
  • the specific substituents are the corresponding substituents described above, or the substituents appearing in each embodiment.
  • a substituted group may have a substituent selected from a specific group at any substitutable position of the group, and the substituents may be the same or different at each position.
  • substituents contemplated by this invention are those that are stable or chemically feasible.
  • the substituents are for example (but not limited to): halogen, hydroxyl, carboxyl (-COOH), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3- to 12-membered heterocyclic group, aryl group, heteroaryl group, C1-C8 aldehyde group, C2-C10 acyl group, C2-C10 ester group, amino group, C1-C6 alkoxy group, C1-C10 sulfonyl group, etc.
  • the term 1-6 means 1, 2, 3, 4, 5 or 6. Other similar terms each independently have a similar meaning.
  • the term “plurality” refers to 2-6, such as 2, 3, 4, 5 or 6.
  • the general formula (I) represents that the compound may contain one or more chiral centers, which exist as enantiomers and diastereomers.
  • two enantiomers can be obtained by general chiral resolution or asymmetric synthesis. Diastereomers can be separated by fractional recrystallization or chromatographic separation.
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 Any one of R 9 , A, B, L, X, Y, and n is independently the corresponding group in the specific compound of the present invention.
  • the term "pharmaceutically acceptable salt” refers to a salt of a compound of the present invention with an acid or a base which is suitable for use as a medicine.
  • Pharmaceutically acceptable salts include inorganic salts and organic salts.
  • a preferred class of salts are the salts of the compounds of the invention with acids.
  • Acids suitable for forming salts include, but are not limited to: inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid; formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, Fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid and other organic acids; Amino acids such as amino acid, phenylalanine, aspartic acid, and glutamic acid.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid
  • salts of the compounds of the present invention with bases such as alkali metal salts (e.g. sodium or potassium salts), alkaline earth metal salts (e.g. magnesium or calcium salts), ammonium salts (e.g.
  • lower alkanolammonium salts and other pharmaceutically acceptable amine salts such as methylamine salts, ethylamine salts, propylamine salts, dimethylamine salts, trimethylamine salts, diethylamine salts, triethylamine salts, tert-butyl amine salts, ethylenediamine salts, hydroxyethylamine salts, dihydroxyethylamine salts, trihydroxyethylamine salts, and amine salts formed from morpholine, piperazine, and lysine, respectively.
  • methylamine salts such as methylamine salts, ethylamine salts, propylamine salts, dimethylamine salts, trimethylamine salts, diethylamine salts, triethylamine salts, tert-butyl amine salts, ethylenediamine salts, hydroxyethylamine salts, dihydroxyethylamine salts, trihydroxyethylamine salt
  • the preparation method of the compound of formula I of the present invention is described in more detail below, but these specific methods do not constitute any limitation to the present invention.
  • the compounds of the present invention can also be conveniently prepared by optionally combining various synthetic methods described in the specification or known in the art, and such combinations can be easily performed by those skilled in the art to which the present invention belongs.
  • the preparation process of the compound of the present invention is as follows, wherein the raw materials and reagents used can be purchased through commercial channels unless otherwise specified.
  • the compound is prepared as follows:
  • L of formula Ia is When, provide the compound shown in formula Ia-1 or its tautomer, mesomer, racemate, enantiomer, diastereoisomer or its mixture form, or its
  • the preparation method of pharmaceutically acceptable salt, described method comprises the following steps:
  • the formula Ia-1A introduces a methylthio group to obtain the formula Ia-1B, and the formula Ia-1B is oxidized to obtain the sulfoxide compound formula Ia-1E, and the sulfoxide compound formula Ia-1E is oxidized again to obtain the sulfoximine compound formula Ia-1C
  • Formula Ia-1B can also be oxidized into sulfoximine compound formula Ia-1C in one step, the sulfoximine compound formula Ia-1C introduces a substituent to obtain formula Ia-1D, and formula Ia-1D deprotects to obtain formula Ia-1;
  • Z1 and Z2 are the same or different, and each independently selected from the following group: H, -COtBu, -Boc, -Ts, -Ns, -Bn, -PMB, -DMB;
  • Z3 is H or halogen;
  • X , R 2 , R 3 , R 4 , R 5 are as described in the first
  • a method for preparing a compound of a single chiral configuration represented by formula Ia-2 or a pharmaceutically acceptable salt thereof is provided, the method further comprising the following steps:
  • Formula Ia-2A introduces a methylthio group after extracting H from a strong base to obtain Formula Ia-2B, and Formula Ia-2B is oxidized by a suitable chiral oxidation method to obtain a sulfoxide compound of a single chiral configuration Formula Ia-2C, Formula Ia- 2C removes the tert-butyryl group to obtain the formula Ia-2D, and the formula Ia-2D is oxidized again to obtain the sulfoximine compound formula Ia-2E of the single chiral configuration, and the formula Ia-2E obtains the single chiral configuration after the substitution reaction Compound formula Ia-2; X, R 2 , R 3 , R 4 , R 5 As described in the first aspect of the present invention.
  • a method for preparing a compound of a single chiral configuration represented by formula Ia-3 or a pharmaceutically acceptable salt thereof is provided, the method further comprising the following steps:
  • Carboxylic acid compound formula Ia-3A is condensed with chiral benzylamine to obtain amide compound formula Ia-3B, formula Ia-3B is substituted by methylthio to obtain formula Ia-3C, and formula Ia-2B is oxidized by a suitable chiral oxidation method
  • the sulfoxide compound formula Ia-3D is obtained, the benzyl fragment of the formula Ia-3D is removed to obtain the amide compound formula Ia-3E, the formula Ia-3E is rearranged to obtain the amino compound formula Ia-3F, and the formula Ia-3F is oxidized again to obtain the mono
  • the sulfoximine compound formula Ia-3G with one chiral configuration, the compound formula Ia-3 with a single chiral configuration can be obtained after the substitution reaction of formula Ia-3G; wherein G is selected from halogen; R 2 , R 3 , R 4 , R 5 , R 10 , m are as described in the first aspect of the present invention.
  • the method also includes the following steps:
  • the obtained product is further reacted with the first substance to obtain the compound represented by formula (I); the first substance is selected from the group consisting of HCl, H 2 SO 4 , methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid.
  • those skilled in the art can use common protecting groups such as TBS, TMS, TBDPS, Bn, THP, Tf in advance to protect and deprotect the hydroxyl groups in the compounds participating in the reaction, and use Boc , Cbz, Bn, Ts, THP and other common protecting groups to protect and deprotect NH or NH 2 in the compounds participating in the reaction.
  • common protecting groups such as TBS, TMS, TBDPS, Bn, THP, Tf in advance to protect and deprotect the hydroxyl groups in the compounds participating in the reaction
  • Boc , Cbz, Bn, Ts, THP and other common protecting groups to protect and deprotect NH or NH 2 in the compounds participating in the reaction.
  • compositions and methods of administration are provided.
  • the pharmaceutical composition of the present invention comprises the compound of the present invention or a pharmacologically acceptable salt thereof within a safe and effective amount range and a pharmaceutically acceptable excipient or carrier.
  • safe and effective dose refers to: the amount of the compound is sufficient to obviously improve the condition without causing severe side effects.
  • the pharmaceutical composition contains 1-2000 mg of the compound of the present invention per dose, more preferably 10-1000 mg of the compound of the present invention per dose.
  • the "one dose” is a capsule or tablet.
  • “Pharmaceutically acceptable carrier” refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use, and must have sufficient purity and low enough toxicity. "Compatibility” herein means that the components of the composition can be blended with the compound of the present invention and with each other without significantly reducing the efficacy of the compound.
  • Examples of pharmaceutically acceptable carrier parts include cellulose and derivatives thereof (such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid , magnesium stearate), calcium sulfate, vegetable oil (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agent (such as sodium lauryl sulfate), coloring agent, flavoring agent, stabilizer, antioxidant, preservative, pyrogen-free water, etc.
  • cellulose and derivatives thereof such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.
  • gelatin such as talc
  • solid lubricants such as stearic acid , magnesium stearate
  • calcium sulfate such
  • the pharmaceutical composition is injection, capsule, tablet, pill, powder or granule.
  • the mode of administration of the compound or pharmaceutical composition of the present invention is not particularly limited, and representative modes of administration include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration .
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
  • the active compound is admixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with (a) fillers or extenders, for example, Starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders such as hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, For example, glycerol; (d) disintegrants, such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) slow agents, such as paraffin; (f) Absorption accelerators such as quaternary ammonium compounds; (g) wetting agents such as cetyl alcohol and glyceryl monostea, or
  • Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shell materials, such as enteric coatings and others well known in the art. They may contain opacifying agents and, in such compositions, the release of the active compound or compounds may be in a certain part of the alimentary canal in a delayed manner.
  • coatings and shell materials such as enteric coatings and others well known in the art. They may contain opacifying agents and, in such compositions, the release of the active compound or compounds may be in a certain part of the alimentary canal in a delayed manner.
  • Examples of usable embedding components are polymeric substances and waxy substances.
  • the active compounds can also be in microencapsulated form, if desired, with one or more of the above-mentioned excipients.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures.
  • liquid dosage forms may contain inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1 , 3-butanediol, dimethylformamide and oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances, etc.
  • inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1 , 3-butanediol, dimethylformamide and
  • compositions can also contain adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • Suspensions in addition to the active compounds, may contain suspending agents, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
  • suspending agents for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
  • compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • Suitable aqueous and non-aqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols, and suitable mixtures thereof.
  • Dosage forms for topical administration of a compound of this invention include ointments, powders, patches, sprays and inhalants.
  • the active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants which may be required, if necessary.
  • the compounds of the present invention can be administered alone or in combination with other pharmaceutically acceptable compounds such as anti-inflammatory drugs.
  • the treatment method of the present invention can be used alone or in combination with other treatment methods or drugs.
  • a safe and effective amount of the compound of the present invention is applied to a mammal (such as a human) in need of treatment, wherein the dosage is a pharmaceutically effective dosage when administered, for a person with a body weight of 60kg, the daily
  • the dosage is usually 1-2000 mg, preferably 50-1000 mg.
  • the specific dose Factors such as route of administration, patient health, etc. should also be considered, which are within the skill of the skilled physician.
  • the present invention has the following main advantages:
  • the compound of the present invention has excellent TYK2 inhibitory activity
  • the compounds of the present invention have no inhibitory activity on JAK1, JAK2, and JAK3 kinases, and the selectivity of JAK family kinases is very high;
  • the compound of the present invention has excellent IFN- ⁇ inflammatory pathway inhibitory activity
  • the compound of the present invention has no hERG potassium channel inhibitory activity, and the risk of cardiotoxicity is low;
  • the compound of the present invention has excellent drug metabolism properties and druggability
  • the compound of the present invention has excellent water solubility.
  • the structure of the compound is determined by nuclear magnetic resonance (NMR) or/and mass spectrometry (MS). NMR was determined with a Bruker AVANCE-400 nuclear magnetic instrument. The determination of LCMS uses a Waters2695 liquid phase mass spectrometer (MS model: Micromass ZQ).
  • the known starting materials of the present invention can be adopted or synthesized according to methods known in the art, or can be purchased from companies such as Acros Organics, Aldrich Chemical Company, J&Chem, Shaoyuan Chemical Technology, Darui Chemicals, Anaiji Chemicals, etc. .
  • reaction temperature is room temperature (20° C. to 35° C.).
  • the specification of the silica gel plate used in the thin layer chromatography (TLC) in the embodiment is 0.2mm ⁇ 0.03mm.
  • the thin layer chromatography separation and purification (prep-TLC) specification used for purifying compounds is 0.4mm-0.5mm; column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier; the fully automatic medium pressure rapid purification instrument (Combi Flash Rf+UV-VIS), the separation column models are: Silica Flash Column 4g, 12g, 25g.
  • the eluent system of the column chromatography and the developing system of the thin layer chromatography include: A: dichloromethane and methanol system; B: petroleum ether and ethyl acetate system.
  • the volume ratio of the solvent is adjusted according to the polarity of the compound, and it can also be adjusted by adding a small amount of ammonia or acetic acid and other alkaline or acidic reagents.
  • N-(4-chloro-5-propionylpyridin-2-yl)cyclopropylcarboxamide (1e) refers to WO2020/086616.
  • N-(4-chloro-5-propionylpyridin-2-yl)cyclopropylcarboxamide (1e) (90mg, 0.36mmol) in 1,4-dioxane (4mL), add 3-(N , S-dimethylsulfoximine) pyridine-2-ammonia (1d) (61mg, 0.21 mmol), Pb 2 (dba) 3 (33 mg, 0.035 mmol), BINAP (44 mg, 0.071 mmol) and CsCO 3 (232 mg, 0.71 mmol). Under the protection of nitrogen, react at 110°C for 3 hours.
  • Step 2 6-(cyclopropanecarboxamido)-4-((3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl-d3) Synthesis of Pyridazine-3-Carboxamide (2)
  • Step 1 Synthesis of 6-chloro-4-((2-(N,S-dimethylsulfoximine)phenyl)amino)-N-methylpyridazine-3-carboxamide (3c)
  • the synthetic method refers to 6-(cyclopropanecarboxamido)-4-((3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl-d3) Synthesis of pyridazine-3-carboxamide (Example 2), yield 40%.
  • the synthesis method refers to the synthesis of 6-chloro-4-((2-(N,S-dimethylsulfoximine)phenyl)amino)-N-methylpyridazine-3-carboxamide (3c), Yield 26%.
  • Step 4 6-(cyclopropylcarboxamido)-4-((2-(N-ethyl-S-methylsulfoximine)phenyl)amino)-N-methylpyridazine-3- Synthesis of formamide (4)
  • the synthetic method refers to 6-(cyclopropanecarboxamido)-4-((3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl-d3) Synthesis of pyridazine-3-carboxamide (Example 2), yield 41.0%.
  • N-(6-methylpyridine-2-methyl)trimethylacetamide (5a) refers to Org.Process Res.Dev.2010,14(1),263–271.
  • N-(6-methylpyridine-2-methyl)trimethylacetamide (5a) (5.5g, 28.6mmol) in anhydrous tetrahydrofuran (30mL), lower the temperature to 0°C under a nitrogen atmosphere, and slowly drop Add n-butyllithium in n-hexane (35 mL, 2.5 M, 85.9 mmol), warm to room temperature and stir for 2 hours. Cool the reaction solution to -78°C and slowly add After the addition of dimethyl disulfide (5.5 mL, 57.2 mL), it was slowly warmed to room temperature and continued to stir for 1 hour.
  • the synthesis method refers to the synthesis of 3-(S-methylsulfoximine)-2-nitropyridine, and the yield is 12%.
  • N-(6-methyl-3-(S-methylsulfoximino)pyridine-2-methyl)trimethylacetamide (5c) (370mg, 1.38mmol) was dissolved in dichloromethane (6mL ), added trimethoxonium tetrafluoroborate (265 mg, 1.79 mmol), and stirred at room temperature for 1 hour. Water was added to quench the reaction and stirred for 10 minutes. The aqueous phase was extracted with dichloromethane, and the combined organic phases were dried over anhydrous sodium sulfate.
  • Step 6 6-(Cyclopropylcarboxamido)-4-((3-(N,S-dimethylsulfoximine)-6-methylpyridin-2-yl)amino)-N-methyl Synthesis of Pyridazine-3-Carboxamide (5)
  • the synthetic method refers to 6-(cyclopropanecarboxamido)-4-((3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl-d3) Synthesis of pyridazine-3-carboxamide (Example 2), yield 33%.
  • Example 6 4-((6-carbamoyl-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylcarboxamido)-N -Preparation of methylpyridazine-3-carboxamide
  • the synthesis method refers to the synthesis of 3-(N,S-dimethylsulfoximine)-6-picoline-2-ammonia, and the yield is 89%.
  • 6-chloro-3-(methylthio)pyridine-2-ammonia (6b) (6.0g, 34.4mmol) in a round bottom bottle, slowly add Boc anhydride (21.7g, 99.7mmol), and stir at room temperature for 10 minutes Afterwards, DMAP (840 mg, 6.88 mmol) was added, and stirring was continued at room temperature for 1 hour. Petroleum ether was added to dilute the solution, and after concentration, the Boc anhydride was removed through a short column of silica gel to obtain 14.7 g of crude product.
  • Step 3 Synthesis of N,N-(di-tert-butoxycarbonyl)-6-chloro-3-(S-methylsulfoximine)pyridine-2-ammonia (6d)
  • the synthesis method refers to the synthesis of 3-(S-methylsulfoximine)-2-nitropyridine, and the yield is 84%.
  • Step 4 Synthesis of N,N-(di-tert-butoxycarbonyl)-6-chloro-3-(N,S-dimethylsulfoximine)pyridine-2-ammonia (6e)
  • the synthesis method refers to the synthesis of N-(6-methyl-3-(N,S-dimethylsulfoximine)pyridine-2-methyl)trimethylacetamide, and the crude product is directly carried out to the next step without separation reaction.
  • the synthesis method refers to the synthesis of 3-(N,S-dimethylsulfoximine)-6-picoline-2-ammonia, and the two-step yield is 34%.
  • the synthetic method refers to 6-chloro-4-((3-(N,S-dimethylsulfoximine)-6-methylpyridin-2-yl)amino)-N-methylpyridazine-3- Formamide was synthesized with a yield of 39%.
  • Step 7 6-chloro-4-((6-cyano-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-methylpyridazine-3- Synthesis of formamide (6h)
  • 6-chloro-4-((6-chloro-3-(N, S-dimethylsulfoximine) pyridin-2-yl) amino)-N-methylpyridazine-3-carboxamide 6g (133mg, 0.343mmol), Zn(CN) 2 (22mg, 0.189mmol), Pd2 (dba) 3 (31mg, 0.0343mmol) and xantphos (40mg, 0.0686mmol) were dissolved in anhydrous DMF (2mL) , under nitrogen atmosphere, 80°C, 80W microwave reaction for 45 minutes.
  • Step 8 4-((6-cyano-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylcarboxamido)-N-methyl Synthesis of Pyridazine-3-Carboxamide (6i)
  • the synthetic method refers to 6-(cyclopropanecarboxamido)-4-((3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl-d3) Synthesis of pyridazine-3-carboxamide, yield 21%.
  • Step 9 4-((6-carbamoyl-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylcarboxamido)-N- Synthesis of Methylpyridazine-3-Carboxamide (6)
  • Oxyzine-3-carboxamide (6i) (15mg, 0.035mmol) was dissolved in DMSO (1mL), anhydrous potassium carbonate (12mg, 0.088mmol) was added, and after stirring at room temperature for 5 minutes, 30% aqueous hydrogen peroxide ( 39mg, 0.35mmol), stirring was continued at room temperature for 30 minutes.
  • Example 7 4-((6-amino-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylcarboxamido)-N-methyl Preparation of pyridazine-3-carboxamide
  • Step 1 6-chloro-4-((3-(N,S-dimethylsulfoximine)-6-((diphenylmethylene)amino)pyridin-2-yl)amino)- Synthesis of N-methylpyridazine-3-carboxamide (7a)
  • 6-chloro-4-((6-chloro-3-(N, S-dimethylsulfoximine) pyridin-2-yl) amino)-N-methylpyridazine-3-carboxamide 6g (4.1 g, 10.6 mmol), Pd 2 (dba) 3 (484 mg, 0.53 mmol), xantphos (611 mg, 1.06 mmol) and Cs 2 CO 3 (10.3 g, 31.7 mmol) were dissolved in anhydrous DMF (30 mL) , added benzophenone imine (3.8 g, 21.1 mmol), and stirred at 125° C. for 4 hours under a nitrogen atmosphere.
  • Step 2 and 3 4-((6-amino-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylcarboxamido)-N- Synthesis of Methylpyridazine-3-Carboxamide (7)
  • Example 8 4-((5-cyano-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylcarboxamide)-N-methyl Preparation of pyridazine-3-carboxamide
  • the synthetic method refers to 6-chloro-4-((3-(N,S-dimethylsulfoximine)-6-methylpyridin-2-yl)amino)-N-methylpyridazine-3- Formamide was synthesized with a yield of 61%.
  • Step 3 and 4 4-((5-cyano-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylcarboxamide)-N- Synthesis of Methylpyridazine-3-Carboxamide (8)
  • reaction solution was cooled to room temperature, and cyclopropanamide (44mg, 0.519mmol), Pd 2 (dba) 3 (43mg, 0.0472mmol), xantphos (55mg, 0.0944mmol) and Cs 2 CO 3 (308mg, 0.944mmol) were added to the reaction system. mmol), under a nitrogen atmosphere, microwave at 110°C and 50W for 1 hour.
  • Step 1 6-((6-chloro-3-(methylcarbamoyl)pyridazin-4-yl)amino)-5-(N,S-dimethylsulfoximine)nicotinic acid-2 , Synthesis of 4,6-trichlorophenyl ester (9a)
  • reaction solution was cooled to room temperature, filtered through celite, and rinsed with ethyl acetate.
  • Step 2 6-((6-chloro-3-(methylcarbamoyl)pyridazin-4-yl)amino)-5-(N,S-dimethylsulfoximine)nicotinic acid (9b )Synthesis
  • 6-((6-Chloro-3-(methylcarbamoyl)pyridazin-4-yl)amino)-5-(N,S-dimethylsulfoximino)nicotinic acid-2,4 , 6-Trichlorophenyl ester (9a) (175mg, 0.3mmol) was dissolved in DMSO (6.5mL), and 40% sodium hydroxide aqueous solution (500mg, 40%w/w) was added under ice-cooling, and the addition was completed and stirred at room temperature 20 minutes. Adjust the pH to 3-4 with 1N hydrochloric acid, extract with dichloromethane, combine the organic phases, and dry over anhydrous sodium sulfate.
  • Step 3 tert-butyl (6-((6-chloro-3-(methylcarbamoyl)pyridazin-4-yl)amino)-5-(N,S-dimethylsulfoximine) Synthesis of pyridin-3-yl) carbamate (9c)
  • Step 4 tert-butyl(6-((6-(cyclopropylcarboxamido)-3-(methylcarbamoyl)pyridazin-4-yl)amino)-5-(N,S-dimethyl Synthesis of sulfoximino)pyridin-3-yl)carbamate (9d)
  • the synthetic method refers to 6-(cyclopropanecarboxamido)-4-((3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl-d3) Synthesis of pyridazine-3-carboxamide, yield 29%.
  • Step 5 4-((5-amino-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylcarboxamido)-N-methyl Synthesis of Pyridazine-3-Carboxamide (9)
  • Example 10 4-((5-amino-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylcarboxamido)-N-( Preparation of methyl-d3)pyridazine-3-carboxamide
  • Step 1 4-((5-bromo-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylcarboxamido)-N-methyl Synthesis of Pyridazine-3-Carboxamide (10a)
  • the synthesis method refers to the synthesis of 5-bromo-3-(N,S-dimethylsulfoximine)pyridine-2-ammonia, and the yield is 16%.
  • Step 2 6-((6-(cyclopropylcarboxamido)-3-(methylcarbamoyl)pyridazin-4-yl)amino)-5-(N,S-dimethylsulfoximine Base) Synthesis of Nicotinic Acid-2,4,6-Trichlorophenyl Ester (10b)
  • the synthetic method refers to 6-((6-chloro-3-(methylcarbamoyl)pyridazin-4-yl)amino)-5-(N,S-dimethylsulfoximine)nicotinic acid-2 , Synthesis of 4,6-trichlorophenyl ester with a yield of 82%.
  • Step 3 6-((6-(cyclopropylcarboxamido)-3-(methylcarbamoyl)pyridazin-4-yl)amino)-5-(N,S-dimethylsulfoximine Base) Synthesis of Nicotinic Acid (10c)
  • the synthetic method refers to the synthesis of 6-((6-chloro-3-(methylcarbamoyl)pyridazin-4-yl)amino)-5-(N,S-dimethylsulfoximine)nicotinic acid , the crude product was directly carried to the next step without separation.
  • Step 4 tert-butyl(6-((6-(cyclopropylcarboxamido)-3-((methyl-d3)carbamoyl))pyridazin-4-yl)amino)-5-(N, Synthesis of S-Dimethylsulfoximino)pyridin-3-yl)carbamate (10d)
  • the synthetic method refers to tert-butyl (6-((6-chloro-3-(methylcarbamoyl)pyridazin-4-yl)amino)-5-(N,S-dimethylsulfoximine) Synthesis of pyridin-3-yl) carbamate in 25% yield in two steps.
  • Step 5 4-((5-amino-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylcarboxamido)-N-(form Synthesis of base-d3)pyridazine-3-carboxamide (10)
  • the synthetic method refers to 4-((5-amino-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylcarboxamido)-N-methyl Synthesis of pyridazine-3-carboxamide, yield 16%.
  • Step 1 6-chloro-4-((3-(N,S-dimethylsulfoximine)-5-hydroxypyridin-2-yl)amino)-N-methylpyridazine-3-methanol Synthesis of Amide (11a)
  • aqueous hydrogen peroxide solution (103 mg, 0.909 mmol) was added to the reaction solution, and stirred at room temperature for 30 minutes. Ethyl acetate and water were added to dilute the reaction solution, the aqueous phase was extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate.
  • the synthetic method refers to 6-(cyclopropanecarboxamido)-4-((3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl-d3) Synthesis of pyridazine-3-carboxamide with a yield of 69%.
  • Step 1 Synthesis of N-(5-fluoro-3-methylthiopyridin-2-yl)trimethylacetamide (12b), yield 26%.
  • N-(5-fluoropyridin-2-yl)trimethylacetamide (12a) refers to Org. Lett. 2013, 15(13), 3460–3463.
  • Step 2 Synthesis of N-(3-(S-methylsulfoximino)-5-fluoropyridin-2-yl)trimethylacetamide (12c), yield 28%.
  • Step 3 Synthesis of N-(3-(N,S-dimethylsulfoximine)-5-fluoropyridin-2-yl)trimethylacetamide (12d), yield 14%.
  • Step 4 Synthesis of 3-(N,S-dimethylsulfoximine)-5-fluoropyridine-2-ammonia (12e), with a yield of 47%.
  • Step 5 6-chloro-4-((3-(N,S-dimethylsulfoximine)-5-fluoropyridin-2-yl)amino)-N-methylpyridazine-3-methanol Preparation of Amide Synthesis of (12f) in 32% yield.
  • Step 6 6-(cyclopropylcarboxamido)-4-((3-(N,S-dimethylsulfoximine)-5-fluoropyridin-2-yl)amino)-N-methyl
  • pyridazine-3-carboxamide Synthesis of (12), yield 29%.
  • Example 13 4-((5-bromo-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylcarboxamido)-N-methyl Preparation of pyridazine-3-carboxamide
  • the synthetic method refers to 6-chloro-4-((3-(N,S-dimethylsulfoximine)-6-methylpyridin-2-yl)amino)-N-methylpyridazine-3-
  • the synthesis of formamide has a yield of 40%.
  • Step 2 6-(Cyclopropylcarboxamido)-4-((3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-methylpyridazine-3 -Synthesis of formamide (13b)
  • the synthetic method refers to 6-(cyclopropanecarboxamido)-4-((3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl-d3) Synthesis of pyridazine-3-carboxamide, yield 44%.
  • Step 3 4-((5-bromo-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylcarboxamido)-N-methyl Synthesis of Pyridazine-3-Carboxamide (13)
  • N-(5-methoxy-pyridin-2-yl)trimethylacetamide (14a) refers to US2011/178053.
  • the synthetic method of 14b refers to the synthesis of N-(6-methyl-3-methylthiopyridine-2-methyl) trimethylacetamide, producing rate 58%.
  • the synthesis method refers to the synthesis of 3-(N,S-dimethylsulfoximine)-6-picoline-2-ammonia, and the yield is 84%.
  • the synthesis method refers to the synthesis of N,N-(di-tert-butoxycarbonyl)-6-chloro-3-methylthiopyridine-2-ammonia, and the yield is 70%.
  • Step 4 Synthesis of N,N-(di-tert-butoxycarbonyl)-3-(S-methylsulfoximine)-5-methoxypyridine-2 ammonia (14e)
  • the synthesis method refers to the synthesis of 3-(S-methylsulfoximine)-2-nitropyridine, and the yield is 85%.
  • Step 5 Synthesis of N,N-(di-tert-butoxycarbonyl)-3-(N,S-dimethylsulfoximine)-5-methoxypyridine-2amine (14f)
  • the synthesis method refers to the synthesis of N-(6-methyl-3-(N,S-dimethylsulfoximine)pyridine-2-methyl)trimethylacetamide, and the yield is 80%.
  • the synthesis method refers to the synthesis of 6-chloro-3-(N,S-dimethylsulfoximine)pyridine-2-ammonia, and the yield is 23%.
  • Step 7 6-chloro-4-((3-(N,S-dimethylsulfoximine)-5-methoxypyridin-2-yl)amino)-N-methylpyridazine-3 -Synthesis of formamide (14h)
  • the synthetic method refers to 6-chloro-4-((3-(N,S-dimethylsulfoximine)-6-methylpyridin-2-yl)amino)-N-methylpyridazine-3- Formamide was synthesized with a yield of 14%.
  • Step 8 6-(cyclopropylamido)-4-((3-(N,S-dimethylsulfoximine)-5-methoxypyridin-2-yl)amino)-N- Synthesis of Methylpyridazine-3-Carboxamide (14)
  • the synthetic method refers to 6-(cyclopropanecarboxamido)-4-((3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl-d3) Synthesis of pyridazine-3-carboxamide with a yield of 79%.
  • the synthetic method refers to 6-chloro-4-((3-(N,S-dimethylsulfoximine)-6-methylpyridin-2-yl)amino)-N-methylpyridazine-3- Synthesis of formamide, yield 22%.
  • the synthetic method refers to 6-(cyclopropanecarboxamido)-4-((3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl-d3) Synthesis of pyridazine-3-carboxamide, yield 62%.
  • Example 16 6-(Cyclopropylcarboxamido)-4-((3-(N,S-dimethylsulfoximine)-5-(3-methoxypropoxy)pyridine-2 Preparation of -yl)amino)-N-methylpyridazine-3-carboxamide
  • Step 1 Synthesis of N,N-(di-tert-butoxycarbonyl)-5-bromo-3-(N,S-dimethylsulfoximine)pyridine-2-amine (16a)
  • the synthesis method refers to the synthesis of N,N-(di-tert-butoxycarbonyl)-6-chloro-3-methylthiopyridine-2-ammonia, and the yield is 91%.
  • Step 2 Synthesis of N,N-(di-tert-butoxycarbonyl)-3-(N,S-dimethylsulfoximine)-5-hydroxypyridine-2-amine (16b)
  • the synthetic method refers to 6-chloro-4-((3-(N,S-dimethylsulfoximine)-5-hydroxypyridin-2-yl)amino)-N-methylpyridazine-3-methyl Synthesis of amides with a yield of 96%.
  • reaction solution was lowered to room temperature, diluted with water (50 mL), extracted with ethyl acetate, combined organic phases, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain a yellow oily crude product.
  • Step 4 6-chloro-4-((3-(N,S-dimethylsulfoximine)-5-(3-methoxypropoxy)pyridin-2-yl)amino)-N Synthesis of -methylpyridazine-3-carboxamide (16d)
  • the synthetic method refers to 6-chloro-4-((3-(N,S-dimethylsulfoximine)-6-methylpyridin-2-yl)amino)-N-methylpyridazine-3- Formamide was synthesized with a yield of 39%.
  • Step 5 6-(Cyclopropylcarboxamido)-4-((3-(N,S-dimethylsulfoximine)-5-(3-methoxypropoxy)pyridine-2- Synthesis of (yl)amino)-N-methylpyridazine-3-carboxamide (16)
  • the synthetic method refers to 6-(cyclopropanecarboxamido)-4-((3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl-d3) Synthesis of pyridazine-3-carboxamide with a yield of 58%.
  • Example 17 6-(cyclopropylcarboxamido)-4-((3-(N,S-dimethylsulfoximine)-5-(2-(epoxybutan-3-yl) Preparation of ethoxy)pyridin-2-yl)amino)-N-methylpyridazine-3-carboxamide
  • N, N-(di-tert-butoxycarbonyl)-3-(N,S-dimethylsulfoximine)-5-hydroxypyridine-2-ammonia (16b) (300mg, 0.748mmol), 3- Hydroxyethyloxetane (76mg, 0.748mmol) and triphenylphosphine (393mg, 1.5mmol) were dissolved in anhydrous tetrahydrofuran (5mL), and DIAD (303mg, 1.5mmol) was added under nitrogen atmosphere, and reacted at room temperature for 2 Hour. Add water to quench the reaction, extract with ethyl acetate, wash with saturated brine, and dry over anhydrous sodium sulfate.
  • Step 4 6-(Chloro-4-((3-(N,S-dimethylsulfoximine)-5-(2-(epoxybutan-3-yl)ethoxy)pyridine- Synthesis of 2-yl)amino)-N-methylpyridazine-3-carboxamide (17d)
  • the synthetic method refers to 6-chloro-4-((3-(N,S-dimethylsulfoximine)-6-methylpyridin-2-yl)amino)-N-methylpyridazine-3- Formamide was synthesized with a yield of 18%.
  • Step 5 6-(Cyclopropylcarboxamido)-4-((3-(N,S-dimethylsulfoximine)-5-(2-(epoxybutan-3-yl)ethane Synthesis of oxy)pyridin-2-yl)amino)-N-methylpyridazine-3-carboxamide (17)
  • the synthetic method refers to 6-(cyclopropanecarboxamido)-4-((3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl-d3) Synthesis of pyridazine-3-carboxamide with a yield of 60%.
  • Example 18 6-(Cyclopropylcarboxamido)-4-((3-(N,S-dimethylsulfoximine)-5-(2-morpholinoethoxy)pyridine-2 Preparation of -yl)amino)-N-(methyl-d3)pyridazine-3-carboxamide
  • Step 4 6-chloro-4-((3-(N,S-dimethylsulfoximine)-5-(2-morpholinoethoxy)pyridin-2-yl)amino)-N -Synthesis of (methyl-d3)pyridazine-3-carboxamide (18d)
  • the synthetic method refers to 6-chloro-4-((3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl-d3)pyridazine-3-methanol Synthesis of amides with a yield of 41%.
  • Step 5 6-(Cyclopropylcarboxamido)-4-((3-(N,S-dimethylsulfoximine)-5-(2-morpholinoethoxy)pyridine-2- Synthesis of (yl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (18)
  • the synthetic method refers to 6-(cyclopropanecarboxamido)-4-((3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl-d3) Synthesis of pyridazine-3-carboxamide, yield 28%.
  • Example 19 4-((5-(3-cyanopropoxy)-3-(N,S-dimethylsulfoximino)pyridin-2-yl)amine Preparation of -6-(cyclopropylcarboxamido)-N-(methyl-d3)pyridazine-3-carboxamide
  • the synthetic method refers to 6-chloro-4-((3-(N,S-dimethylsulfoximine)-5-hydroxypyridin-2-yl)amino)-N-methylpyridazine-3-methyl Synthesis of amides with a yield of 63%.
  • Step 3 6-chloro-4-((5-(3-cyanopropoxy)-3-(N,S-dimethylsulfoximine)pyridin-2-yl) Synthesis of amino)-N-(methyl-d3)pyridazine-3-carboxamide (19c)
  • the synthetic method refers to 6-chloro-4-((3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl-d3)pyridazine-3-methanol Synthesis of amides with a yield of 49%.
  • Step 4 4-((5-(3-cyanopropoxy)-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylmethyl Synthesis of Amino)-N-(methyl-d3)pyridazine-3-carboxamide (19)
  • the synthetic method refers to 6-(cyclopropanecarboxamido)-4-((3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl-d3) Synthesis of pyridazine-3-carboxamide, yield 28%.
  • Example 20 6-(cyclopropylcarboxamido)-4-((3-(N,S-dimethylsulfoximine)-5-((2-methoxyethyl)amino)pyridine Preparation of -2-yl)amino)-N-methylpyridazine-3-carboxamide
  • Step 1 (6-((6-chloro-3-(methylcarbamoyl)pyridazin-4-yl)amino)-5-(N,S-dimethylsulfoximine)pyridine-3 -yl) synthesis of boronic acid (20a)
  • Step 2 6-chloro-4-((3-(N,S-dimethylsulfoximine)-5-((2-methoxyethyl)amino)pyridin-2-yl)amino) Synthesis of -N-methylpyridazine-3-carboxamide (20b)
  • Step 3 6-(cyclopropylcarboxamido)-4-((3-(N,S-dimethylsulfoximine)-5-((2-methoxyethyl)amino)pyridine- Synthesis of 2-yl)amino)-N-methylpyridazine-3-carboxamide (20)
  • the synthetic method refers to 6-(cyclopropanecarboxamido)-4-((3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl-d3) Synthesis of pyridazine-3-carboxamide with a yield of 45%.
  • Example 21 4-((5-bromo-3-(N,S-dimethylsulfoximine)-6-methylpyridin-2-yl)amino)-6-(cyclopropylcarboxamide Preparation of )-N-methylpyridazine-3-carboxamide
  • Oxyzine-3-carboxamide (5) (10 mg, 0.024 mmol) was dissolved in acetonitrile (0.5 mL), and a solution of NBS (4.3 mg, 0.024 mmol) in acetonitrile (0.5 mL) was added at 0°C, and stirred at 0°C for 1 hour. Add water to quench the reaction, extract with ethyl acetate, wash with saturated brine, and dry over anhydrous sodium sulfate. After concentration, 21 (6 mg, yellow solid) was prepared in 50% yield.
  • Example 22 4-((6-amino-3-(N,S-dimethylsulfoximine)-5-fluoropyridin-2-yl)amino)-6-(cyclopropylcarboxamido) Preparation of -N-methylpyridazine-3-carboxamide
  • Step 1 6-chloro-4-((6-chloro-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl-d3)pyridazine -Synthesis of 3-carboxamide (25a)
  • Step 2 6-chloro-4-((3-(N,S-dimethylsulfoximine)-6-((diphenylmethylene)amino)pyridin-2-yl)amino)- Synthesis of N-(methyl-d3)pyridazine-3-carboxamide (25b)
  • the synthetic method refers to 6-chloro-4-((3-(N,S-dimethylsulfoximine)-6-((diphenylmethylene)amino)pyridin-2-yl)amino)- Synthesis of N-methylpyridazine-3-carboxamide, yield 82%.
  • Step 3 6-(Cyclopropylcarboxamido)-4-((3-(N,S-dimethylsulfoximine)-6-((diphenylmethylene)amino)pyridine-2 Synthesis of -yl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (25c)
  • the synthetic method refers to 6-(cyclopropyl carboxamide)-4-((3-(N,S-dimethylsulfoximine)-6-((diphenylmethylene)amino)pyridine-2 -base)amino)-N-methylpyridazine-3-carboxamide synthesis, the crude product is directly carried out to the next step without separation.
  • Step 4 4-((6-amino-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylcarboxamido)-N-(form Synthesis of base-d3)pyridazine-3-carboxamide (25d)
  • the synthetic method refers to 4-((6-amino-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylcarboxamido)-N-methyl Synthesis of pyridazine-3-carboxamide, two-step yield 63%.
  • Step 5 4-(6-amino-5-chloro-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropanecarboxamido)-N -Synthesis of (methyl-d3)pyridazine-3-carboxamide (25)
  • the synthetic method refers to 4-(6-amino-5-chloro-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropanecarboxamido)-N - Synthesis of methylpyridazine-3-carboxamide, yield 50%.
  • Example 26 4-((6-amino-3-(N,S-dimethylsulfoximine)-5-methylpyridin-2-yl)amino)-6-(cyclopropanecarboxamido )-N-methylpyridazine-3-carboxamide preparation
  • Example 27 4-((6-amino-3-(N,S-dimethylsulfoximine)-5-methoxypyridin-2-yl)amino)-6-(cyclopropanecarboxamide base)-N-methylpyridazine-3-carboxamide preparation
  • Step 1 4-((6-amino-3-(N,S-dimethylsulfoximine)-5-hydroxypyridin-2-yl)amino)-6-(cyclopropylcarboxamido)- Synthesis of N-methylpyridazine-3-carboxamide (27a)
  • reaction solution was cooled to room temperature, tetrahydrofuran (3mL) and hydrogen peroxide (0.10mL, 0.88mmol) were added, and stirred at room temperature for 30 minutes Add water (20mL) to quench the reaction, add methylene chloride to dilute the reaction solution, filter with suction, and rinse the filter cake with methylene chloride.
  • Step 2 4-((6-amino-3-(N,S-dimethylsulfoximine)-5-methoxypyridin-2-yl)amino)-6-(cyclopropanecarboxamido Synthesis of )-N-methylpyridazine-3-carboxamide (27)
  • reaction solution was quenched with water (5 mL), extracted with ethyl acetate, and the organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. After concentration, prep-HPLC prepared 4-((6-amino-3-(N,S-dimethylsulfoximine)-5-methoxypyridin-2-yl)amino)-6-(cyclo Propanecarboxamido)-N-methylpyridazine-3-carboxamide (27) (2.2 mg, white solid), yield 22%.
  • Hydrogen peroxide (26.5 g, 234.0 mmol) was added dropwise under ice-cooling, and the reaction was continued for 1 hour after adding hydrogen peroxide (3.6 mL, 36.0 mmol) and stirring at room temperature for 2 hours.
  • Hydrogen peroxide (3.6 mL, 36.0 mmol)
  • stirring at room temperature for 2 hours Add saturated sodium sulfite solution (150 mL) to the reaction solution to quench the reaction, extract with ethyl acetate, combine the organic phases, wash with saturated brine, and dry over anhydrous sodium sulfate.
  • the synthesis method refers to the synthesis of 3-(S-methylsulfoximine)-2-nitropyridine, and the yield is 70%.
  • Step 5 (R)-6-chloro-4-((6-chloro-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl- d3) Synthesis of pyridazine-3-carboxamide (28f)
  • the synthetic method refers to 6-chloro-4-((6-chloro-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl-d3)pyridazine - Synthesis of 3-carboxamide, yield 79%.
  • Step 6 (R)-6-chloro-4-((3-(N,S-dimethylsulfoximine)-6-((diphenylmethylene)amino)pyridin-2-yl )amino)-N-(methyl-d3)pyridazine-3-carboxamide (28g) synthesis
  • the synthetic method refers to 6-chloro-4-((3-(N,S-dimethylsulfoximine)-6-((diphenylmethylene)amino)pyridin-2-yl)amino)- Synthesis of N-methylpyridazine-3-carboxamide, yield 68%.
  • Step 7 (R)-6-(cyclopropylcarboxamido)-4-((3-(N,S-dimethylsulfoximine)-6-((diphenylmethylene)amino Synthesis of )pyridin-2-yl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (28h)
  • the synthetic method refers to 6-(cyclopropyl carboxamide)-4-((3-(N,S-dimethylsulfoximine)-6-((diphenylmethylene)amino)pyridine-2 Synthesis of -yl)amino)-N-methylpyridazine-3-carboxamide with a yield of 91%.
  • Step 8 (R)-4-((6-amino-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylcarboxamido)- Synthesis of N-(methyl-d3)pyridazine-3-carboxamide (28i)
  • the synthetic method refers to 4-((6-amino-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylcarboxamido)-N-methyl Synthesis of pyridazine-3-carboxamide with a yield of 69%.
  • Step 9 (R)-4-((6-amino-5-chloro-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropyl Synthesis of formyl)-N-(methyl-d3)pyridazine-3-carboxamide (28)
  • the synthetic method refers to 4-(6-amino-5-chloro-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropanecarboxamido)-N -Synthesis of methylpyridazine-3-carboxamide, ee value 98.2%, yield 50%.
  • the synthesis method refers to the synthesis of (R)-N-(6-chloro-3-(methylsulfinyl)pyridin-2-yl)trimethylacetamide, the post-treatment uses ethanol for recrystallization, and the yield is 64%. d.e. value 99.9%.
  • Extract with ethyl acetate combine the organic phases, wash with saturated brine, and dry over anhydrous sodium sulfate. After concentration, dichloromethane (100mL) and petroleum ether (100mL) were added to make a slurry, suction filtered and rinsed with petroleum ether, and dried to obtain (R)-6-chloro-3-(methylsulfinyl)-pyridine-2 - Ammonia (28c) (39.4 g, white solid), yield 82%.
  • Step 1 Synthesis of 6-chloro-3-(S-methyl-N-(4-nitrobenzenesulfonyl)-sulfoximino)pyridine-2-amine (29a)
  • Step 2 6-chloro-4-((6-chloro-3-(S-methyl-N-(4-nitrobenzenesulfonyl)sulfoximino)pyridin-2-yl)amino)-N -Synthesis of (methyl-d3)pyridazine-3-carboxamide (29b)
  • the synthetic method refers to 6-chloro-4-((6-chloro-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl-d3)pyridazine - Synthesis of 3-carboxamide, yield 50%.
  • Step 3 6-chloro-4-((6-((diphenylmethylene)amino)-3-(S-methyl-N-((4-nitrobenzenesulfonyl)sulfoximine Synthesis of )pyridin-2-yl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (29c)
  • the synthetic method refers to 6-chloro-4-((3-(N,S-dimethylsulfoximine)-6-((diphenylmethylene)amino)pyridin-2-yl)amino)-
  • dioxane was used as the solvent instead of DMF, the reaction temperature was 110° C., and the yield was 25%.
  • Step 4 6-(Cyclopropylcarboxamido)-4-((6-((diphenylmethylene)amino)-3-(S-methyl-N-((4-nitrobenzenesulfonyl ) sulfoximino) pyridin-2-yl) amino) -N- (methyl-d3) pyridazine-3-carboxamide (29d) synthesis
  • the synthetic method refers to 6-(cyclopropanecarboxamido)-4-((3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-N-(methyl-d3)
  • Step five 4-((6-amino-3-(S-methyl-N-(4-nitrobenzenesulfonyl)-sulfoximine)pyridin-2-yl)amino)-6-( Synthesis of Cyclopropylcarboxamido)-N-(methyl-d3)pyridazine-3-carboxamide (29e)
  • the synthetic method refers to 4-((6-amino-3-(N,S-dimethylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylcarboxamido)-N-methyl Synthesis of pyridazine-3-carboxamide, using crude 29d instead of 6-(cyclopropylcarboxamido)-4-((3-(N,S-dimethylsulfoximine)-6-((di Phenylmethylene)amino)pyridin-2-yl)amino)-N- Methylpyridazine-3-carboxamide, 43% yield over two steps.
  • Step 6 (R)-4-((6-amino-5-chloro-3-(S-methylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylcarboxamido Synthesis of )-N-(methyl-d3)pyridazine-3-carboxamide (29)
  • racemic compound was subjected to SFC chiral resolution to obtain (S)-4-((6-amino-5-chloro-3-(S-methylsulfoximine)pyridin-2-yl)amino) -6-(Cyclopropylcarboxamido)-N-(methyl-d3)pyridazine-3-carboxamide (29f) (85 mg, white solid, yield 10%) and (R)-4-((6 -Amino-5-chloro-3-(S-methylsulfoximine)pyridin-2-yl)amino)-6-(cyclopropylcarboxamido)-N-(methyl-d3)pyridazine -3-Carboxamide (29) (85 mg, pale yellow solid, yield 10%).
  • Step 1 6-(Cyclopropylcarboxamido)-4-((5-(N,S-dimethylsulfoximine)-1H-pyrrolo[2,3-b]pyridin-6-yl )amino)-N-methylpyridazine-3-carboxamide (31) synthesis
  • reaction solution was cooled to room temperature, 25% aqueous hydrochloric acid (53 mg) was added, and the reaction was carried out at 50° C. for 1 hour. Add water to quench the reaction, extract with ethyl acetate, wash with saturated brine, and dry over anhydrous sodium sulfate.
  • Example 32 4-((3-Chloro-5-(N,S-dimethylsulfoximine)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino)-6 Preparation of -(cyclopropylamido)-N-methylpyridazine-3-carboxamide
  • Example 34 4-((3-Bromo-5-(N,S-dimethylsulfoximine)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino)-6 Preparation of -(cyclopropylamido)-N-methylpyridazine-3-carboxamide
  • Example 39 6-(Cyclopropanecarboxamido)-N-(methyl-d3)-4-((3-(S-methyl-N-(methyl-d3)sulfoximino)pyridine Preparation of -2-yl)amino)pyridazine-3-carboxamide
  • Step 1 Synthesis of (R)-6-chloro-3-(S-methyl-N-(methyl-d 3 )sulfonimide)pyridine-2-amine (40a)
  • Step 2 (R)-6-chloro-4-((6-chloro-3-(S-methyl-N-(methyl-d 3 )sulfonimide)pyridin-2-yl)amino)- Synthesis of N-(methyl-d 3 )pyridazine-3-carboxamide (40b)
  • Step 3 (R)-6-chloro-4-((6-((dibenzylidene)amino)-3-(S-methyl-N-(methyl-d 3 )sulfonimide) Synthesis of pyridin-2-yl)amino)-N-(methyl-d 3 )pyridazine-3-carboxamide (40c)
  • Step 4 (R)-6-(cyclopropanecarboxamide)-4-((6-((dibenzylidene)amino)-3-(S-methyl-N-(form Synthesis of -d 3 )sulfonylimide)pyridin-2-yl)amino)-N-(methyl-d 3 )pyridazine-3-carboxamide (40d)
  • Step 5 (R)-4-((6-amino-3-(S-methyl-N-(methyl-d 3 )sulfonimide)pyridin-2-yl)amino)-6-(cyclo Synthesis of propanecarboxamide)-N-(methyl-d 3 )pyridazine-3-carboxamide (40e)
  • Step 6 (R)-4-((6-amino-5-chloro-3-(S-methyl-N-(methyl-d 3 )sulfonimide)pyridin-2-yl)amino)- Synthesis of 6-(cyclopropanecarboxamide)-N-(methyl-d 3 )pyridazine-3-carboxamide (40)
  • Example 46 (R)-4-((6-Amino-5-(cyclopropylethynyl)-3-(S-methyl-N-(methyl-d 3 )sulfonimide)pyridine- Preparation of 2-yl)amino)-6-(cyclopropanecarboxamide)-N-(methyl-d 3 )pyridazine-3-carboxamide
  • the TYK2 kinase gene was introduced into wild-type mouse B lymphocytes (BaF3) to construct Ba/F3-FL-TYK2-E957D stable cell line.
  • Ba/F3-FL-TYK2-E957D stable cell line.
  • the growth and proliferation of Ba/F3-FL-TYK2-E957D were separated from IL-3, and instead depended on exogenously transferred TYK2 kinase. If the compound selectively inhibits the activity of TYK2 kinase, it will inhibit the proliferation of this cell line.
  • test compound the powder was stored at room temperature, prepared into a 10 mM stock solution with DMSO, and stored at -20°C in the dark until use.
  • Cells (provided by Sandia Pharmaceutical Technology (Shanghai) Co., Ltd.) were resuspended and counted using an automatic cell counter. According to the BaF3 seeding density, 2000 cells per well, the cell suspension was diluted to the desired density. 95ul of cells were plated in each well, and cultured at 37°C for stable equilibrium. Add 5ul of 20-fold compound to each well, and use the same volume of DMSO as a control. Incubate at 37°C, 5% CO2 for 72 hours.
  • Max signal is the positive control well, which only has the same volume of DMSO as the compound.
  • Min signal is a negative control well, only culture medium
  • Table 1 The inhibitory activity of representative compounds of the present invention to TYK2 kinase
  • the test results show that the compounds provided by the invention have excellent TYK2 inhibitory activity, most of the compounds have better TYK2 inhibitory activity than the positive control BMS-986165, and the IC 50 value reaches pM level.
  • the TYK2 inhibitory activity of Example 28, Example 32, Example 40, Example 41, Example 42 and Example 44 is 4 to 7 times higher than that of BMS-986165, and Example 45 and Example 46 are higher than BMS-986165
  • the TYK2 inhibitory activity was increased more than 20-fold.
  • the JAK family kinase gene was introduced into wild-type mouse B lymphocytes (BaF3), and four kinds of BaF3 engineered cell lines (Ba/F3-FL-TYK2-E957D, Ba/F3-TEL-JAK1, Ba/F3-TEL-JAK2 , Ba/F3-TEL-JAK3).
  • BaF3-FL-TYK2-E957D wild-type mouse B lymphocytes
  • Ba/F3-TEL-JAK1 Ba/F3-TEL-JAK2
  • Ba/F3-TEL-JAK3 Ba/F3-TEL-JAK3
  • the growth and proliferation of these engineered cell lines are separated from the dependence on IL-3, and instead rely on the exogenously transferred JAK family kinases. If the compound selectively inhibits the activity of a certain JAK kinase, it will inhibit the proliferation of the corresponding cell line.
  • the inhibitory activity of the compound on TYK2, JAK1, JAK2, and JAK3 kinases was evaluated according to the IC 50 value, so as to evaluate the JAK family kinase selectivity of the compound.
  • test compound the powder was stored at room temperature, prepared into a 10 mM stock solution with DMSO, and stored at -20°C in the dark until use.
  • Cells (provided by Sandia Pharmaceutical Technology (Shanghai) Co., Ltd.) were resuspended and counted using an automatic cell counter. According to the BaF3 seeding density, 2000 cells per well, the cell suspension was diluted to the desired density. 95ul of cells were plated in each well, and cultured at 37°C for stable equilibrium. Add 5ul of 20-fold compound to each well, and use the same volume of DMSO as a control. Incubate at 37°C, 5% CO2 for 72 hours.
  • Max signal is the positive control well, which only has the same volume of DMSO as the compound.
  • Min signal is a negative control well, only culture medium
  • test results show that the compound provided by the invention has excellent TYK2 inhibitory activity, and has no inhibitory activity on JAK1, JAK2, and JAK3 kinases, and the selectivity of JAK family kinases is very high.
  • JAK kinase inhibitors Basic research and clinical results of existing JAK kinase inhibitors have shown that non-selective kinase inhibitors cause serious side effects, including thrombosis, anemia, and severe infection. Therefore, poor kinase subtype selectivity is an urgent problem to be overcome in the development of next-generation JAK inhibitors difficulty.
  • the compound of the present invention has excellent kinase selectivity and shows high drug safety.
  • Test Example 3 IFN- ⁇ -induced STAT phosphorylation in human whole blood
  • Cytokine receptors to which TYK2 attaches mediate signaling of type 1 interferon (IFN- ⁇ ), which has been identified as the most important inflammatory factor of the autoimmune system.
  • IFN- ⁇ type 1 interferon
  • Human whole blood was induced with IFN- ⁇ , and TYK2 in lymphocytes in whole blood triggered STAT phosphorylation, which mediated subsequent inflammatory signals. Therefore, TYK2 inhibitors can inhibit the signal transmission of IFN- ⁇ . The stronger the TYK2 inhibitory activity, the lower the STAT phosphorylation level, and the stronger the corresponding anti-inflammatory effect.
  • the inhibitory ability of the compound on IFN- ⁇ -induced STAT phosphorylation in human whole blood was tested, and the IC 50 value was calculated.
  • the inhibitory activity of the compounds on the IFN- ⁇ inflammatory pathway was evaluated according to the IC 50 size, and the anti-inflammatory activity of the compounds was evaluated at the tissue level.
  • test compound the powder was stored at room temperature, prepared into a 10mM stock solution with DMSO, and stored in a -80°C refrigerator.
  • the positive control compound BMS-986165 the powder was stored at room temperature, prepared into a 10mM stock solution with DMSO, and stored in a -80°C refrigerator.
  • Flow cytometry staining buffer preparation add 1g bovine serum albumin (BSA) and 1mL EDTA (0.5M) solution to 500mL phosphate buffered saline (PBS), store in 4°C refrigerator.
  • BSA bovine serum albumin
  • EDTA 0.5M
  • BSA bovine serum albumin
  • PBS phosphate buffered saline
  • the 10 mM test compound and the positive compound BMS-986165 were diluted with DMSO into a 5 mM working solution, and further diluted into 8 concentrations with DMSO in a 3-fold gradient.
  • the compound to be tested with 8 concentration gradients and each concentration point of BMS-986165 were diluted 25 times with the compound diluent, and then used.
  • PE-CD3 BD 555333
  • BD 555333 BD 555333
  • the whole blood was transferred to a 96-well deep-well plate with a row gun, and the preheated 1X Fix/Lysis solution was added, and the cells were lysed and fixed in a 37°C incubator for 12 minutes.
  • the expression of pSTAT5 was quantified by the median fluorescence intensity after gating for the CD3 positive signal population.
  • test results show that the compound provided by the invention has high inhibitory activity on STAT phosphorylation induced by IFN- ⁇ in human whole blood, indicating that the compound of the invention can strongly inhibit the IFN- ⁇ inflammatory pathway at the tissue level.
  • the present invention exhibits better IFN- ⁇ inflammatory pathway inhibitory activity, especially, the anti-inflammatory activity of Example 28 and Example 29 is increased by about 6 times.
  • Test example 4 hERG potassium channel inhibition experiment of the compound of the present invention
  • the blocking effect of the compound of the present invention on hERG potassium current was tested on a stable cell line transfected with hERG potassium channel by automatic patch clamp.
  • CHO-hERG cells were cultured in a 175cm 2 culture flask. When the cell density grew to 60-80%, the culture medium was removed, washed once with 7ml PBS (Phosphate Buffered Saline), and then digested by adding 3ml Detachin.
  • PBS Phosphate Buffered Saline
  • the single-cell high-impedance sealing and whole-cell pattern formation processes are all automatically completed by the Qpatch instrument.
  • the cells are clamped at -80 mV, and before a +40 mV depolarization stimulus is given for 5 seconds, first A pre-voltage of -50 mV was given for 50 msec, followed by repolarization to -50 mV for 5 s and back to -80 mV. Apply this voltage stimulation every 15 seconds, give extracellular fluid for 5 minutes after recording for 2 minutes, and then start the administration process.
  • the compound concentration starts from the lowest test concentration, and each test concentration is given for 2.5 minutes. After all concentrations are given continuously, a positive control is given.
  • Compound 3 ⁇ M Cisapride At least 3 cells (n ⁇ 3) were tested for each concentration.
  • the highest test concentration is 40 ⁇ M, and there are 6 concentrations in total of 40, 13.33, 4.44, 1.48, 0.49 and 0.16 ⁇ M respectively.
  • the DMSO content in the final test concentration did not exceed 0.2%, and this concentration of DMSO had no effect on the hERG potassium channel.
  • the experimental data were analyzed by XLFit software.
  • Test results show that the compound provided by the invention has no hERG potassium channel inhibitory activity and has low risk of cardiotoxicity.
  • Test Example 5 In vivo pharmacokinetic experiment of the compound of the present invention
  • mice Healthy male SD rats were randomly divided into three groups, and the test compound was orally administered. Fasting for 12 hours before gavage experiment, drinking water freely, eating uniformly 4 hours after administration. Before administration (0h) and 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0 and 24h after administration; 0.2mL blood was collected from the jugular vein at the above set time points, Place the whole blood in EDTA-K2 test tubes, temporarily store in an ice-water bath after collection, centrifuge at 11,000 rpm for 5 minutes within 30 minutes, separate the plasma, and freeze it in a -70°C refrigerator for testing.
  • Test Example 5.1 Results: See Table 5.1 below.
  • Test Example 5.2 Results: See Table 5.2 below.
  • test results show that the compound provided by the invention has good drug metabolism properties, good druggability, and high plasma exposure (AUC).
  • AUC high plasma exposure
  • the oral bioavailability (F%) and plasma exposure of the compound provided by the present invention in rats and dogs has significant advantages, showing excellent oral absorption properties and excellent metabolic characteristics.
  • Water solubility is an important index to evaluate the druggability of small molecule oral drugs. Only when the drug is dissolved can it be absorbed into the systemic circulation through the gastrointestinal tract. Drugs with poor water solubility are slowly absorbed and have low bioavailability, which affects blood drug concentration and pharmacological effects, directly leading to a high clinical failure rate. Compared with BMS-986165, the compound provided by the invention has higher solubility, so it has better oral absorption properties and pharmaceutical properties.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

公开了用作TYK2抑制剂的化合物、其制备方法及其在医药上的应用。具体地，所述化合物具有式(I)所示结构，其中各基团和取代基的定义如说明书中所述。另外，还公开了所述化合物的制备方法及其在预防和/或治疗由TYK2介导相关疾病方面的用途。

Description

用作TYK2抑制剂的化合物、其制备方法及其在医药上的应用 技术领域
本发明涉及小分子医药领域，具体地涉及用作TYK2抑制剂的化合物、其制备方法及其在医药上的应用。
背景技术
自身免疫疾病是一种人体自身免疫系统攻击正常细胞引起正常免疫能力下降、异常免疫能力突显，最终导致组织损伤或器官功能障碍的炎症性疾病。目前，已有80多种自身免疫性疾病被报道，影响大约5％-8％的世界人口。其中发病率较高的有银屑病(PSO)、类风湿性关节炎(RA)、银屑病关节炎(PsA)、溃疡性结肠炎(UC)、克罗恩氏病(CD)、多发性硬化症(MS)、1型糖尿病、脊柱关节炎(SpA)、慢性移植物抗宿主病(cGVHD)、特应性皮炎、斑秃、哮喘、系统性红斑狼疮(SLE)。这些疾病的发病部位几乎涵盖了所有人体器官。它们可以是全身性的，比如可以影响皮肤、关节、肾脏和中枢神经系统的SLE；或者是器官特异性的，比如1型糖尿病(胰腺)、UC(结肠)[Cell 2020 181(1):63-80]。自身免疫疾病发病机制复杂，疾病致残率高，尚无根治方法，大多患者终身承受巨大痛苦。因此，自身免疫疾病被称作“不死的癌症”。
2000年以来，临床批准治疗自身免疫性疾病的小分子药物主要为Janus激酶(JAK)抑制剂。该家族包括JAK 1、JAK 2、JAK 3和TYK2。JAK家族成员通过磷酸化他们的受体来调节免疫调节细胞因子启动信号，进而导致信号转化器的招募、磷酸化和转录(STAT)蛋白的激活，从而影响STAT依赖性的转录和功能反应。这些细胞因子信号通路在自身免疫性疾病和炎症性疾病的发病机制中发挥关键作用。迄今为止，已经获得临床批准使用的JAK抑制剂Tofacitinib,Baricitinib和Upadacitinib等均作用于JAK家族的激酶结构域(JH1结构域)，与体内ATP竞争结合发挥作用。上述JAK抑制剂由于激酶亚型选择性差，表现出一系列严重的临床副作用如贫血，感染、肌酸酐、肝脏转氨酶、肌酸磷酸激酶、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇水平增加，NK细胞、淋巴细胞、中性粒细胞、血小板计数减少等。因此，上述三个已上市药物都带有关于引发 严重感染、恶性肿瘤和血栓风险的黑框警告，临床应用受到很大限制。
最新的研究表明同属JAK家族的TYK2是平衡自身免疫疾病药效与安全的最优靶点[J.Med.Chem.2019,62,20,8953–8972]。TYK2与JAK2联合，通过IL-12和IL-23(含有细胞因子的p40亚基)介导信号传递，诱导/稳定IL-17及其它促炎因子的表达；并与JAK1联合介导1型干扰素(IFN-α等)的信号传递。TYK2介导的上述细胞因子已被确认为自身免疫系统最重要的致炎因子[Nature Reviews Drug Discovery 2021，20,39–63]。对上述炎症细胞因子信号通路的阻断已在类风湿性关节炎、多发性硬化、银屑病、系统性红斑狼疮、炎症性肠炎和脊柱关节炎等动物模型上表现出优异的药效活性[J.Med.Chem.2019,62,20,8973–8995；Science Translational Medicine 2019，502(11),:eaaw1736；J Clin Invest.2020,130(4),1863–1878]。而针对上述炎症因子IL-12、IL-23、IL-17和IFN-α开发的单抗药物在多个自身免疫系统疾病临床治疗中表现出优异效果。
以上证据表明，TYK2作为介导IL-12、IL-23、IL-17和IFN-α炎症信号转导级联的关键激酶，是炎症和自身免疫疾病良好的成药靶点。显然，高亚型选择性(JAK1、JAK2、JAK3)TYK2抑制剂有可能避免已有JAK抑制严重的副作用。Bristol-Myers Squibb公司开发的高亚型选择性TYK2抑制剂BMS-986165(Deucravacitinib)，在两项中重度银屑病的III期临床研究中，显示出了优异的药效和安全性。同时，BMS-986165在银屑病关节炎、系统性红斑狼疮、溃疡性结肠炎和克罗恩氏病等适应症领域处于临床II期评价阶段，表现出强大的自身免疫疾病治疗潜力。开发高激酶(亚型)选择性的TYK2抑制剂代表性专利有WO2014074660、WO2014074661、WO2019103952。
本发明提供一类激酶抑制活性更强、高亚型选择性、同时代谢性质好、体内药效更强、结构新颖的TYK2抑制剂。本发明公开的TYK2抑制剂可用于预防和/或治疗由TYK2介导相关疾病，尤其是IL-12、IL-23、IL-17和1型干扰素(IFN-α等)相关的自身免疫疾病。
发明内容
本发明的目的在于提供一种式(I)所示化合物及其制备方法和其在预防和/或治疗由TYK2介导相关疾病方面的用途。
本发明的第一方面，提供了一种式(I)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、或其药学 上可接受的盐，
其中，R1选自下组：H、取代或未取代的C1-C6烷基、取代或未取代的C3-C6环烷基，所述取代指被选自下组的一个或多个取代基取代：氘、卤素；
A为NH或CH2；
B为CH或N；
L选自下组：
R2选自下组：H、-CD3、C1-C6烷基、C3-C6环烷基；
X为CH或N；
Y为NH、O或S；
R3、R4、R5各自独立地选自下组：H、-NH2、-OH、C1-C6烷氧基、C1-C6烷基、卤代C1-C6烷基、C3-C6环烷基、-CONH2、-CN、卤素、-O(CH2)nR9、C2-C6烯基、C2-C6炔基、C3-C6环烷基取代的C2-C6炔基、和-NR8(CH2)nR9；
n为1、2、3、4或5；
R9选自下组：-OH、C1-C6烷氧基、C4-C6环烷氧基、含1、2或3个选自N、O或S的杂原子的4-8元杂环基和-CN；
R8为H或C1-C6烷基；
R6、R7各自独立地选自下组：H、C1-C6烷基、卤素。
在另一优选例中，R1选自下组：H、取代或未取代的C1-C6烷基、取代或未取代的C3-C6环烷基，所述取代指被选自下组的一个或多个取代基取代：氘、卤素；
A为NH或CH2；
B为CH或N；
L选自下组：
R2选自下组：H、-CD3、C1-C6烷基、C3-C6环烷基；
X为CH或N；
Y为NH、O或S；
R3、R4、R5各自独立地选自下组：H、-NH2、-OH、C1-C6烷氧基、C1-C6烷基、卤代C1-C6烷基、C3-C6环烷基、-CONH2、-CN、卤素、-O(CH2)nR9和-NR8(CH2)nR9；
n为1、2、3、4或5；
R9选自下组：-OH、C1-C6烷氧基、C4-C6环烷氧基、含1、2或3个选自N、O或S的杂原子的4-8元杂环基和-CN；
R8为H或C1-C6烷基；
R6、R7各自独立地选自下组：H、C1-C6烷基、卤素。
在另一优选例中，附加条件是：当R2为H时，R3为-NH2或者R4和R5不同时为H。
在另一优选例中，R1为氘代或者未取代的C1-C6烷基。
在另一优选例中，R1为全氘代的C1-C6烷基。
在另一优选例中，所述全氘代是指所述基团的全部H均被D取代。
在另一优选例中，R1为C1-C6烷基。
在另一优选例中，R1为全氘代的C1-C6烷基；
A为NH；
B为CH或N。
在另一优选例中，R1选自下组：-CH3和-CD3；
A为NH；
B为CH或N。
在另一优选例中，L为
R2选自下组：H、-CD3、C1-C6烷基；
X为N；
R3、R4、R5各自独立地选自下组：H、-NH2、-OH、C1-C6烷氧基、C1-C6烷基、C3-C6环烷基、-CONH2、-CN、卤素、-O(CH2)nR9、C2-C6烯基、C2-C6炔基、C3-C6环烷基取代的C2-C6炔基、和-NR8(CH2)nR9；
n为1、2、3、4或5；
R9选自下组：C1-C6烷氧基、C4-C6环烷氧基、含1、2或3个选自N、O或S的杂原子的4-8元杂环基和-CN；
R8为H或C1-C6烷基。
在另一优选例中，L为
R2选自下组：H、-CD3、C1-C6烷基；
X为N；
R3、R4、R5各自独立地选自下组：H、-NH2、-OH、C1-C6烷氧基、C1-C6烷基、C3-C6环烷基、-CONH2、-CN、卤素、-O(CH2)nR9和-NR8(CH2)nR9；
n为1、2、3、4或5；
R9选自下组：C1-C6烷氧基、C4-C6环烷氧基、含1、2或3个选自N、O或S的杂原子的4-8元杂环基和-CN；
R8为H或C1-C6烷基。
在另一优选例中，R2为H、-CD3和-CH3。
在另一优选例中，R9选自下组：-OCH3、-CN、
在另一优选例中，R3、R4各自独立地选自下组：-NH2、-OH、C1-C6烷氧基、C1-C6烷基、C3-C6环烷基、-CONH2、-CN、卤素、-O(CH2)nR9、C2-C6烯基、C2-C6炔基、C3-C6环烷基取代的C2-C6炔基、和-NR8(CH2)nR9。
在另一优选例中，R3、R4各自独立地选自下组：-NH2、C1-C6烷基、卤素、C3-C6环烷基、C2-C6烯基、C2-C6炔基、C3-C6环烷基取代的C2-C6炔基。
在另一优选例中，R3为-NH2。
在另一优选例中，R4为C1-C6烷基、卤素、C3-C6环烷基、C2-C6烯基、C2-C6炔基、C3-C6环烷基取代的C2-C6炔基。
在另一优选例中，R3为-NH2；R4为卤素。
在另一优选例中，R3为-NH2；R4为Cl或Br。
在另一优选例中，R1为全氘代的C1-C6烷基；
A为NH；
B为N；
L为
R2选自下组：H、-CD3、C1-C6烷基；
X为N；
R3为-NH2；
R4选自下组：卤素、C3-C6环烷基、C2-C6烯基、C2-C6炔基、C3-C6环烷基取代的C2-C6炔基；
R5为H。
在另一优选例中，R1为全氘代的C1-C6烷基；
A为NH；
B为N；
L为
R2选自下组：H、C1-C6烷基；
X为N；
R3为-NH2；
R4为卤素；
R5为H。
在另一优选例中，R1为全氘代的C1-C6烷基；
A为NH；
B为N；
L为
R2为-CD3；
X为N；
R3为-NH2；
R4选自下组：卤素、C3-C6环烷基、C2-C6烯基、C2-C6炔基、C3-C6环烷基取代的C2-C6炔基；
R5为H。
在另一优选例中，所述化合物选自下组：


本发明的第二方面，提供了一种本发明第一方面所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、或其药学上可接受的盐的制备方法，包括如下步骤：
式I-c与环丙基酰胺反应得到式(I)化合物；
其中，R1、A、B、L如本发明第一方面所定义；
G为卤素。
本发明的第三方面，提供了一种药物组合物，包含药学上可接受的载体和一种或多种安全有效量的本发明第一方面所述的化合物或其互变异构体、内消旋 体、外消旋体、对映异构体、非对映异构体、或其混合物形式、或其药学上可接受的盐。
在另一优选例中，所述药物组合物为口服制剂。
本发明的第四方面，提供了一种本发明第一方面所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、或其药学上可接受的盐的用途，用于制备药物，所述药物用于预防和/或治疗由TYK2介导相关疾病。
在另一优选例中，所述由TYK2介导相关疾病为哺乳动物体内炎性或自身免疫疾病。
在另一优选例中，所述炎性或自身免疫疾病选自下组：类风湿性关节炎、多发性硬化、系统性红斑狼疮、狼疮肾炎、皮肤性狼疮、炎性肠病、银屑病、克罗恩病、银屑病关节炎、干燥综合征(Sjogren’s Syndrome,ss)、系统性硬皮病、溃疡性结肠炎、格雷氏病、盘状红斑狼疮、成人斯蒂尔病、全身型幼年特发关节炎、痛风、痛风性关节炎、1型糖尿病,、胰岛素依赖型糖尿病、败血症、败血性休克、志贺杆菌病、胰腺炎、肾小球性肾炎、自体免疫性胃炎、自体免疫性溶血性贫血、自体免疫性嗜中性粒细胞减少症、血小板减少症、特应性皮炎、重症肌无力、胰腺炎、强直性脊椎炎、寻常型天胞疮、抗磷脂综合征、特发性血小板减少症、ANCA相关性血管炎、川崎病、慢性炎性脱髓鞘性多发性神经根神经病、皮肌炎、多肌炎、眼色素层炎、格巴二氏综合征、自体免疫性肺炎、自体免疫性甲状腺炎、自体免疫性炎性眼病和慢性脱髓鞘性多发性神经病。
应理解，在本发明范围内中，本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合，从而构成新的或优选的技术方案。限于篇幅，在此不再一一累述。
附图说明
图1是本发明化合物28e的单晶衍射数据。
具体实施方式
本发明人经过长期而深入的研究，通过结构优化获得了一种具有TYK2高抑制活性和高选择性、代谢性质和成药性优异的式(I)所示化合物及其制备方法和其在治疗和/或预防TYK2介导相关疾病方面的用途。在此基础上，发明人完成了本发明。
术语
在本发明中，除非特别指出，所用术语具有本领域技术人员公知的一般含义。
在本发明中，术语“卤素”指F、Cl、Br或I。
在本发明中，“C1-C6烷基”是指包括1-6个碳原子的直链或支链的烷基，例如甲基、乙基、丙基、异丙基、丁基、异丁基、叔丁基、新戊基、特戊基、或类似基团。
在本发明中，术语“C2-C6烯基”是指具有2-6个碳原子的含有一个双键的直链或支链烯基，非限制性地包括乙烯基、丙烯基、丁烯基、异丁烯基、戊烯基和己烯基等。
在本发明中，术语“C2-C6炔基”是指具有2-6个碳原子的含有一个三键的直链或支链炔基，非限制性地包括乙炔基、丙炔基、丁炔基、异丁炔基、戊炔基和己炔基等。
在本发明中，术语“C3-C8环烷基”是指在环上具有3-8个碳原子的环状烷基，非限制性地包括环丙基、环丁基、环戊基、环己基、环庚基、环辛基等。术语“C3-C6环烷基”具有类似含义。
在本发明中，术语“C1-C6烷氧基”是指具有1-6个碳原子的直链或支链烷氧基，非限制性地包括甲氧基、乙氧基、丙氧基、异丙氧基和丁氧基等。优选为C1-C4烷氧基。
在本发明中，术语“杂环基”为含1、2或3个选自N、O、S的杂原子的4-8元杂环基，包括(但并不限于)如下基团：
在本发明中，术语“芳环”或“芳基”具有相同的含义，优选为“C6-C10芳基”。术语“C6-C10芳基”是指在环上不含杂原子的具有6-10个碳原子的芳香族环基，如苯基、萘基等。
在本发明中，术语“芳香杂环”或“杂芳基”具有相同的含义，指包含一个到多个杂原子的杂芳族基团。例如“C3-C10杂芳基”是指含有1～4个选自氧、硫 和氮中的杂原子以及3-10个碳原子的芳香杂环。非限制性例子包括：呋喃基、噻吩基、吡啶基、吡唑基、吡咯基、N-烷基吡咯基、嘧啶基、吡嗪基、咪唑基、四唑基等。所述杂芳基环可以稠合于芳基、杂环基或环烷基环上，其中与母体结构连接在一起的环为杂芳基环。杂芳基可以是任选取代的或未取代的。
在本发明中，术语“卤代”是指被卤素取代。
在本发明中，术语“氘代”是指被氘取代。
在本发明中，术语“取代”指特定的基团上的一个或多个氢原子被特定的取代基所取代。特定的取代基为在前文中相应描述的取代基，或各实施例中所出现的取代基。除非特别说明，某个取代的基团可以在该基团的任何可取代的位点上具有一个选自特定组的取代基，所述的取代基在各个位置上可以是相同或不同的。本领域技术人员应理解，本发明所预期的取代基的组合是那些稳定的或化学上可实现的组合。所述取代基例如(但并不限于)：卤素、羟基、羧基(-COOH)、C1-C6烷基、C2-C6烯基、C2-C6炔基、C3-C8环烷基、3-至12元杂环基、芳基、杂芳基、C1-C8醛基、C2-C10酰基、C2-C10酯基、氨基、C1-C6烷氧基、C1-C10磺酰基等。
在本发明中，术语1-6个指1、2、3、4、5或6个。其他类似术语各自独立地具有类似含义。术语“多个”指2-6个，如2、3、4、5或6个。
应理解，当某一基团同时存在于化合物的多个不同位置时，其在各位置的定义是相互独立的，可以相同也可以不同。亦即，术语“选自下组：”与术语“各独立地选自下组：”具有相同含义。
化合物
对于本发明的第一方面，通式(I)表示化合物中可含有一个或多个手性中心，其存在对映异构体和非对映异构体。本发明的通式(I)表示化合物中也可含有烯烃、C＝N双键等许多几何异构体。除非另有指明，以上所述所有手性(对映异构体和非对映异构体)、消旋体、顺式几何异构体、反式几何异构体、顺式和反式几何异构体混合物都包括在本发明内。对于对映异构体，采用一般的手性拆分方法或不对称合成方法可以得到两个对映体。对于非对映异构体，可以通过分步重结晶或者色谱分离等方法分离。
在另一优选例中，所述的化合物中，R1、R2、R3、R4、R5、R6、R7、R8、 R9、A、B、L、X、Y、n中任一个分别独立地为本发明所述具体化合物中所对应的基团。
如本文所用，术语“药学上可接受的盐”指本发明化合物与酸或碱所形成的适合用作药物的盐。药学上可接受的盐包括无机盐和有机盐。一类优选的盐是本发明化合物与酸形成的盐。适合形成盐的酸包括但并不限于：盐酸、氢溴酸、氢氟酸、硫酸、硝酸、磷酸等无机酸；甲酸、乙酸、三氟乙酸、丙酸、草酸、丙二酸、琥珀酸、富马酸、马来酸、乳酸、苹果酸、酒石酸、柠檬酸、苦味酸、苯甲酸、甲磺酸、乙磺酸、对甲苯磺酸、苯磺酸、萘磺酸等有机酸；以及脯氨酸、苯丙氨酸、天冬氨酸、谷氨酸等氨基酸。
另一类优选的盐是本发明化合物与碱形成的盐，例如碱金属盐(例如钠盐或钾盐)、碱土金属盐(例如镁盐或钙盐)、铵盐(如低级的烷醇铵盐以及其它药学上可接受的胺盐)，例如甲胺盐、乙胺盐、丙胺盐、二甲基胺盐、三甲基胺盐、二乙基胺盐、三乙基胺盐、叔丁基胺盐、乙二胺盐、羟乙胺盐、二羟乙胺盐、三羟乙胺盐，以及分别由吗啉、哌嗪、赖氨酸形成的胺盐。
制备方法
下面更具体地描述本发明式I结构化合物的制备方法，但这些具体方法不对本发明构成任何限制。本发明化合物还可以任选将在本说明书中描述的或本领域已知的各种合成方法组合起来而方便地制得，这样的组合可由本发明所属领域的技术人员容易地进行。
典型地，本发明化合物的制备工艺流程如下，其中所用原料和试剂如无特殊说明，均可通过商业途径购买。
代表性地，所述化合物是如下制备的：
式I-a氨基化合物与式I-b反应得到式I-c，式I-c与环丙基酰胺反应得到式(I)；其中，G为卤素；L、A、B、R1如本发明第一方面所述。
在另一优选例中，式I-a的L为时，提供了式I-a-1所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、或其药学上可接受的盐的制备方法，所述方法包括以下步骤：
式I-a-1A引入甲硫基得到式I-a-1B，式I-a-1B经氧化后得到亚砜化合物式I-a-1E，亚砜化合物式I-a-1E再次氧化得到亚砜亚胺化合物式I-a-1C，式I-a-1B也可以一步氧化为亚砜亚胺化合物式I-a-1C，亚砜亚胺化合物式I-a-1C引入取代基得到式I-a-1D，式I-a-1D脱保护基得到式I-a-1；其中Z1和Z2相同或不同，且各自独立地选自下组：H、-COtBu、-Boc、-Ts、-Ns、-Bn、-PMB、-DMB；Z3为H或卤素；X、R2、R3、R4、R5如本发明第一方面所述。
在另一优选例中，提供了式I-a-2所示的单一手性构型的化合物或其药学上可接受的盐的制备方法，所述方法还包括以下步骤：
式I-a-2A强碱拔H后引入甲硫基得到式I-a-2B，式I-a-2B经合适的手性氧化方法氧化后得到单一手性构型的亚砜化合物式I-a-2C，式I-a-2C脱除叔丁酰基得到式I-a-2D，式I-a-2D再次氧化得到单一手性构型的亚砜亚胺化合物式I-a-2E，式I-a-2E经取代反应后得到单一手性构型的化合物式I-a-2；X、R2、R3、R4、R5 如本发明第一方面所述。
在另一优选例中，提供了式I-a-3所示的单一手性构型的化合物或其药学上可接受的盐的制备方法，所述方法还包括以下步骤：
羧酸化合物式I-a-3A与手性苄胺缩合得到酰胺化合物式I-a-3B，式I-a-3B经甲硫基取代后得到式I-a-3C，式I-a-2B经合适的手性氧化方法氧化后得到亚砜化合物式I-a-3D，式I-a-3D脱除苄基片段得到酰胺化合物式I-a-3E，式I-a-3E经重排反应得到氨基化合物式I-a-3F，式I-a-3F再次氧化得到单一手性构型的亚砜亚胺化合物式I-a-3G，式I-a-3G经取代反应后得到单一手性构型的化合物式I-a-3；其中G选自卤素；R2、R3、R4、R5、R10、m如本发明第一方面所述。
在另一优选例中，所述方法还包括如下步骤：
将所得产物进一步与第一物质反应，得到式(I)所示化合物；所述第一物质选自下组：HCl、H2SO4、甲磺酸、苯磺酸、对甲苯磺酸。
为确保各个合成步骤顺利进行，本发明所属领域的技术人员可提前使用TBS、TMS、TBDPS、Bn、THP、Tf等常见保护基对参与反应的化合物中的羟基进行保护和脱保护操作，使用Boc、Cbz、Bn、Ts、THP等常见保护基对参与反应的化合物中的NH或NH2进行保护和脱保护操作。
其中各式所表示化合物中可含有一个或多个手性中心，其存在对映异构体和非对映异构体，也可含有烯烃、C＝N双键等许多几何异构体。除非另有指明，以上所述所有手性(对映异构体和非对映异构体)、消旋体、顺式几何异构体、反式几何异构体、顺式和反式几何异构体混合物都包括在本发明内。对于对映异构体，采用一般的手性拆分方法或不对称合成方法可以得到两个对映体。对于非对映异构体，可以通过分步重结晶或者色谱分离等方法分离。
药物组合物和施用方法
本发明的药物组合物包含安全有效量范围内的本发明化合物或其药理上可接受的盐及药理上可以接受的赋形剂或载体。其中“安全有效量”指的是：化合物的量足以明显改善病情，而不至于产生严重的副作用。通常，药物组合物含有1-2000mg本发明化合物/剂，更佳地，含有10-1000mg本发明化合物/剂。较佳地，所述的“一剂”为一个胶囊或药片。
“药学上可以接受的载体”指的是：一种或多种相容性固体或液体填料或凝胶物质，它们适合于人使用，而且必须有足够的纯度和足够低的毒性。“相容性”在此指的是组合物中各组份能和本发明的化合物以及它们之间相互掺和，而不明显降低化合物的药效。药学上可以接受的载体部分例子有纤维素及其衍生物(如羧甲基纤维素钠、乙基纤维素钠、纤维素乙酸酯等)、明胶、滑石、固体润滑剂(如硬脂酸、硬脂酸镁)、硫酸钙、植物油(如豆油、芝麻油、花生油、橄榄油等)、多元醇(如丙二醇、甘油、甘露醇、山梨醇等)、乳化剂(如)、润湿剂(如十二烷基硫酸钠)、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂、无热原水等。
所述的药物组合物为注射剂、囊剂、片剂、丸剂、散剂或颗粒剂。
本发明化合物或药物组合物的施用方式没有特别限制，代表性的施用方式包括(但并不限于)：口服、瘤内、直肠、肠胃外(静脉内、肌肉内或皮下)、和局部给药。
用于口服给药的固体剂型包括胶囊剂、片剂、丸剂、散剂和颗粒剂。在这些固体剂型中，活性化合物与至少一种常规惰性赋形剂(或载体)混合，如柠檬酸钠或磷酸二钙，或与下述成分混合：(a)填料或增容剂，例如，淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸；(b)粘合剂，例如，羟甲基纤维素、藻酸盐、明胶、聚乙烯基吡咯烷酮、蔗糖和阿拉伯胶；(c)保湿剂，例如，甘油；(d)崩解剂，例如，琼脂、碳酸钙、马铃薯淀粉或木薯淀粉、藻酸、某些复合硅酸盐、和碳酸钠；(e)缓溶剂，例如石蜡；(f)吸收加速剂，例如，季胺化合物；(g)润湿剂，例如鲸蜡醇和单硬脂酸甘油酯；(h)吸附剂，例如，高岭土；和(i)润滑剂，例如，滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇、十二烷基硫酸钠，或 其混合物。胶囊剂、片剂和丸剂中，剂型也可包含缓冲剂。
固体剂型如片剂、糖丸、胶囊剂、丸剂和颗粒剂可采用包衣和壳材制备，如肠衣和其它本领域公知的材料。它们可包含不透明剂，并且，这种组合物中活性化合物或化合物的释放可以延迟的方式在消化道内的某一部分中释放。可采用的包埋组分的实例是聚合物质和蜡类物质。必要时，活性化合物也可与上述赋形剂中的一种或多种形成微胶囊形式。
用于口服给药的液体剂型包括药学上可接受的乳液、溶液、悬浮液、糖浆或酊剂。除了活性化合物外，液体剂型可包含本领域中常规采用的惰性稀释剂，如水或其它溶剂，增溶剂和乳化剂，例知，乙醇、异丙醇、碳酸乙酯、乙酸乙酯、丙二醇、1,3-丁二醇、二甲基甲酰胺以及油，特别是棉籽油、花生油、玉米胚油、橄榄油、蓖麻油和芝麻油或这些物质的混合物等。
除了这些惰性稀释剂外，组合物也可包含助剂，如润湿剂、乳化剂和悬浮剂、甜味剂、矫味剂和香料。
除了活性化合物外，悬浮液可包含悬浮剂，例如，乙氧基化异十八烷醇、聚氧乙烯山梨醇和脱水山梨醇酯、微晶纤维素、甲醇铝和琼脂或这些物质的混合物等。
用于肠胃外注射的组合物可包含生理上可接受的无菌含水或无水溶液、分散液、悬浮液或乳液，和用于重新溶解成无菌的可注射溶液或分散液的无菌粉末。适宜的含水和非水载体、稀释剂、溶剂或赋形剂包括水、乙醇、多元醇及其适宜的混合物。
用于局部给药的本发明化合物的剂型包括软膏剂、散剂、贴剂、喷射剂和吸入剂。活性成分在无菌条件下与生理上可接受的载体及任何防腐剂、缓冲剂，或必要时可能需要的推进剂一起混合。
本发明化合物可以单独给药，或者与其他药学上可接受的其他化合物(如抗炎药物)联合给药。
本发明治疗方法可以单独施用，或者与其它治疗手段或者治疗药物联用。
使用药物组合物时，是将安全有效量的本发明化合物适用于需要治疗的哺乳动物(如人)，其中施用时剂量为药学上认为的有效给药剂量，对于60kg体重的人而言，日给药剂量通常为1～2000mg，优选50～1000mg。当然，具体剂量 还应考虑给药途径、病人健康状况等因素，这些都是熟练医师技能范围之内的。
与现有技术相比，本发明具有以下主要优点：
(1)本发明化合物具有优异的TYK2抑制活性；
(2)本发明化合物对JAK1、JAK2、JAK3激酶均无抑制活性，JAK家族激酶选择性非常高；
(3)本发明化合物具有优异的IFN-α炎症通路抑制活性；
(4)本发明化合物没有hERG钾通道抑制活性，心脏毒性风险低；
(5)本发明化合物具有优异的药物代谢性质、成药性；
(6)本发明化合物具有优异的水溶解性。
下面结合具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法，通常按照常规条件如Sambrook等人，分子克隆：实验室手册(New York:Cold Spring Harbor Laboratory Press,1989)中所述的条件，或按照制造厂商所建议的条件。除非另外说明，否则百分比和份数按重量计算。
除非另行定义，文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。此外，任何与所记载内容相似或均等的方法及材料皆可应用于本发明方法中。文中所述的较佳实施方法与材料仅作示范之用。
在本发明中，化合物的结构是通过核磁共振(NMR)或/和质谱(MS)来确定的。NMR的测定是用Bruker AVANCE-400核磁仪。LCMS的测定用Waters2695液相质谱联用仪(MS型号：Micromass ZQ)。
HPLC的测定用安捷伦1100高压液相色谱仪(ZORBAX SP-C18 250x4.6mm色谱柱，Eclipse Plus-C18 250x4.6mm色谱柱)。
本发明的已知的起始原料可以采用或者按照本领域已知的方法来合成，或可购买自AcrosOrganics,Aldrich Chemical Company，J&Chem，韶远化学科技，达瑞化学品，安耐吉化学等公司。
实施例中无特殊说明，均可在氩气氛或氮气氛下进行。
微波反应使用的是CEM Discover-SP 909155型微波反应器。
实施例中无特殊说明，反应的温度为室温(20℃～35℃)。
实施例中薄层色谱法(TLC)使用的硅胶版采用的规格是0.2mm±0.03mm。纯化化合物使用的薄层层析分离纯化(prep-TLC)规格是0.4mm～0.5mm；柱层析一般使用烟台黄海硅胶200～300目硅胶为载体；采用的全自动中压快速纯化仪(Combi Flash Rf+UV-VIS)，分离柱型号有：Silica Flash Column 4g、12g、25g。采用的柱层析的洗脱剂的体系和薄层色谱法的展开体系包括：A：二氯甲烷和甲醇体系；B:石油醚和乙酸乙酯体系。溶剂的体积比根据化合物的极性不同而进行调节，也可加入少量氨水或者醋酸等碱性或酸性试剂进行调节。
实施例中纯化最终样品化合物采用的是高压制备液相色谱仪(生产商：岛津，型号：LC-20AP)，Ultimate XB-C18色谱柱(150x30mm，5μm)。流动相体系有：A：乙腈和水(含0.1％三氟乙酸)体系；B：乙腈和水(含0.1％乙酸)体系。
实施例1
N-(4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-5-丙酰基吡啶-2-基)环丙烷甲酰胺的制备
步骤一：3-(S-甲基亚砜亚胺基)-2-硝基吡啶(1b)的合成
3-(甲硫基)-2-硝基吡啶(1a)的合成参考WO2020/086616。
向3-(甲硫基)-2-硝基吡啶(1a)(1.26g,7.41mmol)溶于甲醇(20mL)溶液中加入氨基甲酸铵(867mg,11.1mmol)，降温至0℃，分批加入碘苯二乙酸(4.77g, 14.8mmol)，升至室温搅拌2小时。旋干溶剂，Flash分离(乙酸乙酯/石油醚＝4:1)得3-(S-甲基亚砜亚胺基)-2-硝基吡啶(1b)(1.3g，淡黄色油状物)，产率79％。
1H NMR(400MHz,CDCl3)δ8.71(d,J＝4.7Hz,1H),8.61(d,J＝7.9Hz,1H),7.78(dd,J＝7.4,5.1Hz,1H),3.00(brs,1H),3.39(s,3H).
MS m/z[M+H]+:202.
步骤二：3-(N,S-二甲基亚砜亚胺基)-2-硝基吡啶(1c)的合成
将3-(S-甲基亚砜亚胺基)-2-硝基吡啶(1b)(23.3g,115.9mmol)溶于DMF(230mL)中，冰浴冷却，氮气保护下分批加入氢化钠(6.96g,174mmol)，冰浴下继续搅拌20分钟后。缓慢滴加碘甲烷(19.8g,139.1mmol)，冰浴下继续搅拌30分钟。向反应液中加入冰水(200mL)、饱和氯化铵(200mL)，乙酸乙酯萃取，有机相用饱和食盐水洗，无水硫酸钠干燥，浓缩得3-(N,S-二甲基亚砜亚胺基)-2-硝基吡啶(1c)粗品(30g)。
MS m/z[M+H]+:216.
步骤三：3-(N,S-二甲基亚砜亚胺基)吡啶-2-氨(1d)的合成
将3-(N,S-二甲基亚砜亚胺基)-2-硝基吡啶(1c)粗品(30g)溶于乙醇/水(1/1,300mL)的混合溶剂中，加入氯化铵(62.6g,1.16mol)，升温至70℃，搅拌分批加入铁粉(22.7g,405.8mmol)，70℃继续搅拌1小时。将反应降至室温后抽滤，滤饼用甲醇/二氯甲烷(1:10)混合溶液淋洗，滤液浓缩后柱层析分离(甲醇/乙酸乙酯/石油醚＝1:9:10)得3-(N,S-二甲基亚砜亚胺基)吡啶-2-氨(1d)(7.3g，淡黄色固体)，两步产率34％。
1H NMR(400MHz,CDCl3)δ8.25(d,J＝3.5Hz,1H),7.99(d,J＝7.7Hz,1H),6.79(dd,J＝7.4,5.0Hz,1H),6.02(s,2H),3.07(s,3H),2.68(s,3H).
MS m/z[M+H]+:186.
步骤四：N-(4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-5-丙酰基吡啶-2-基)环丙甲酰胺(1)的合成
N-(4-氯-5-丙酰基吡啶-2-基)环丙甲酰胺(1e)的合成参考WO2020/086616。
将N-(4-氯-5-丙酰基吡啶-2-基)环丙甲酰胺(1e)(90mg,0.36mmol)溶于1,4-二氧六环(4mL)，加入3-(N,S-二甲基亚砜亚胺基)吡啶-2-氨(1d)(61mg,0.21 mmol)，Pb2(dba)3(33mg,0.035mmol)，BINAP(44mg,0.071mmol)和CsCO3(232mg,0.71mmol)。氮气保护下，110℃反应3小时。反应液降至室温后，用硅藻土抽滤，滤饼用乙酸乙酯淋洗。滤液浓缩后Flash分离(甲醇/二氯甲烷＝1:20)得粗品(30mg,黄色固体)，prep-HPLC制备得N-(4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-5-丙酰基吡啶-2-基)环丙甲酰胺(1)(12mg，白色固体)，产率8％。
1H NMR(400MHz,DMSO-d6)δ11.79(s,1H),10.92(s,1H),9.04(s,1H),8.90(s,1H),8.52(d,J＝4.4Hz,1H),8.21(d,J＝7.7Hz,1H),7.30–7.24(m,1H),3.17(s,3H),3.09(dd,J＝14.0,6.8Hz,2H),2.70(s,3H),2.06–1.98(m,1H),1.09(t,J＝7.1Hz,3H),0.80(d,J＝6.6Hz,4H).
MS(M+H)+:402.
实施例2：6-(环丙烷甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的制备
步骤一：6-氯-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(2b)的合成
4,6-二氯-N-(甲基-d3)哒嗪-3-甲酰胺(2a)的合成参考US2019/152948。
将3-(N,S-二甲基亚砜亚胺基)吡啶-2-氨(1d)(130mg,0.70mmol)溶于DMF中，降温至0℃后加入氢化钠(57mg,1.41mmol)，0℃搅拌5分钟，加入4,6-二氯-N-(甲基-d3)哒嗪-3-甲酰胺(2a)(145mg,0.7mmol)，室温下继续搅拌1小时。向反应液中加入饱和氯化铵溶液(15mL)，用乙酸乙酯萃取，合并有机相用饱和食盐水洗，无水硫酸钠干燥。浓缩后Flash分离(甲醇:二氯甲烷＝1:30)，得6-氯-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(2b)(89mg,白色固体)，产率35％。
1H NMR(400MHz,CDCl3)δ12.42(s,1H),9.09(s,1H),8.56(d,J＝4.4Hz, 1H),8.32(d,J＝7.7Hz,1H),8.25(s,1H),7.22–7.17(m,1H),3.24(s,3H),2.85(s,3H).
MS m/z[M+H]+:358.
步骤二：6-(环丙烷甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(2)的合成
将6-氯-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(2b)(89mg,230mmol)溶于1,4-二氧六环(2mL)中，加入环丙酰胺(40mg,46mmol)、Pd2(dba)3(43mg,0.046mmol)、xantphos(41mg,070mmol)和CsCO3(152mg,0.460mmol)，氮气氛围下，微波(110℃,100W)反应45分钟。反应液降至室温后，硅藻土过滤，滤饼用乙酸乙酯淋洗，滤液浓缩后Flash分离(甲醇/二氯甲烷＝1:10)，得到粗品，prep-HPLC制备得6-(环丙烷甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(2)(45mg,白色固体)，产率44％。
1H NMR(400MHz,dmso)δ11.87(s,1H),11.38(s,1H),9.46(s,1H),9.07(s,1H),8.53(d,J＝4.3Hz,1H),8.22(d,J＝7.7Hz,1H),7.28(dd,J＝7.3,5.0Hz,1H),3.22(s,3H),2.67(s,3H),2.14–2.05(m,1H),0.84(d,J＝6.4Hz,4H).
MS m/z[M+H]+:407.
实施例3：6-(环丙烷甲酰胺基)-4-((2-(N,S-二甲基亚砜亚胺基)苯基)氨基)-N-甲基哒嗪-3-甲酰胺的制备
步骤一：6-氯-4-((2-(N,S-二甲基亚砜亚胺基)苯基)氨基)-N-甲基哒嗪-3-甲酰胺(3c)的合成
2-(N,S-二甲基亚砜亚胺基)苯胺(3a)的合成参考WO2018/075937。
4,6-二氯-N-甲基哒嗪-3-甲酰胺(3b)的合成参考WO2020/086616。
将2-(N,S-二甲基亚砜亚胺基)苯胺(3a)(155mg,0.84mmol)、4,6-二氯-N-甲 基哒嗪-3-甲酰胺(3b)(175mg,0.84mmol)溶于四氢呋喃(2mL)中，氮气氛围冰水浴下，缓慢加入LiHMDS(2.53mL,2.53mmol)，缓慢升至室温下反应10分钟。反应液加1N HCl(1mL)淬灭反应，加水(20mL)稀释后用乙酸乙酯萃取(60mL)，合并有机相，用饱和食盐水洗，无水硫酸钠干燥。浓缩后Flash(乙酸乙酯:石油醚＝1:1)分离，得6-氯-4-((2-(N,S-二甲基亚砜亚胺基)苯基)氨基)-N-甲基哒嗪-3-甲酰胺(3c)(98mg,黄色固体)，产率33％。
1H NMR(400MHz,CDCl3)δ11.50(s,1H),8.17(s,1H),8.10(d,J＝7.8Hz,1H),7.65(t,J＝7.4Hz,1H),7.55(d,J＝7.9Hz,1H),7.41(t,J＝7.5Hz,1H),7.27(s,1H),3.11–3.03(m,6H),2.80(s,3H).
MS m/z[M+H]+:354.
步骤二：6-(环丙甲酰胺基)-4-((2-(N,S-二甲基亚砜亚胺基)苯基)氨基)-N-甲基哒嗪-3-甲酰胺(3)的合成
合成方法参考6-(环丙烷甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(实施例2)的合成，产率40％。
1H NMR(400MHz,dmso)δ11.33(s,1H),11.03(s,1H),9.02(d,J＝4.7Hz,1H),8.15(s,1H),7.91(d,J＝8.1Hz,1H),7.67(d,J＝14.1Hz,2H),7.41–7.35(m,1H),3.04(s,3H),2.82(d,J＝4.7Hz,3H),2.59(s,3H),2.03(dd,J＝10.9,5.3Hz,1H),0.81–0.75(m,4H).
MS m/z[M+H]+:403.
实施例4：6-(环丙烷甲酰胺基)-4-((2-(N-乙基-S-甲基亚砜亚胺基)苯基)氨基)-N-甲基哒嗪-3-甲酰胺的制备
步骤一：1-(N-乙基-S-甲基亚砜亚胺基)-2-硝基苯(4b)的合成
1-(S-甲基亚砜亚胺基)-2-硝基苯(4a)的合成参考WO2018/075937。
将1-(S-甲基亚砜亚胺基)-2-硝基苯(4a)(260mg,1mmol)溶于DMSO(5mL)中，加入KOH(112mg,2mmol)，室温搅拌5分钟，加入碘乙烷(360mg,2.3mmol)，室温搅拌3小时。加水(10mL)淬灭反应，乙酸乙酯萃取，合并有机相，饱和食盐水洗，无水硫酸钠干燥。浓缩后Flash柱分离(乙酸乙酯/石油醚＝40％–60％)，得到1-(N-乙基-S-甲基亚砜亚胺基)-2-硝基苯(4b)(200mg，黄色油状物)，产率68％。
MS m/z[M+H]+:229.
步骤二：2-(N-乙基-S-甲基亚砜亚胺基)苯胺(4c)的合成
将1-(N-乙基-S-甲基亚砜亚胺基)-2-硝基苯(4b)(200mg,0.877mmol)溶于乙醇/水(2/1,9mL)中，加入氯化铵(511mg,9.65mmol)，75℃分批加入铁粉(172mg,3.07mmol)。加毕，75℃继续搅拌1小时。降至室温后用硅藻土过滤，滤饼用乙醇淋洗。滤液浓缩后Flash分离(甲醇/二氯甲烷＝5％–10％)，得到2-(N-乙基-S-甲基亚砜亚胺基)苯胺(4c)(150mg，无色油状物)，产率86％。
1H NMR(400MHz,CDCl3)δ7.73(d,J＝8.0Hz,1H),7.33(t,J＝7.8Hz,1H),6.81(t,J＝7.6Hz,1H),6.72(d,J＝8.1Hz,1H),5.29(s,2H),3.05(s,3H),2.95–2.80(m,2H),1.21(t,J＝7.2Hz,3H).
MS m/z[M+H]+:199.
步骤三：6-氯-4-((2-(N-乙基-S-甲基亚砜亚胺基)苯基)氨基)-N-甲基哒嗪-3- 甲酰胺(4d)的合成
合成方法参考6-氯-4-((2-(N,S-二甲基亚砜亚胺基)苯基)氨基)-N-甲基哒嗪-3-甲酰胺(3c)的合成，产率26％。
MS m/z[M+H]+:368.
步骤四：6-(环丙甲酰胺基)-4-((2-(N-乙基-S-甲基亚砜亚胺基)苯基)氨基)-N-甲基哒嗪-3-甲酰胺(4)的合成
合成方法参考6-(环丙烷甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(实施例2)的合成，产率41.0％。
1H NMR(400MHz,DMSO-d6)δ11.32(s,1H),10.96(s,1H),9.01(d,J＝5.3Hz,1H),8.11(s,1H),7.92(d,J＝7.8Hz,1H),7.73–7.59(m,2H),7.38(t,J＝7.4Hz,1H),3.04(s,3H),2.98–2.85(m,2H),2.81(d,J＝4.8Hz,3H),2.09–1.97(m,1H),1.06(t,J＝7.2Hz,3H),0.85–0.70(m,4H).
MS m/z[M+H]+:417.
实施例5：6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-6-甲基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的制备
步骤一：N-(6-甲基-3-甲硫基吡啶-2-甲基)三甲基乙酰胺(5b)的合成
N-(6-甲基吡啶-2-甲基)三甲基乙酰胺(5a)的合成参考Org.Process Res.Dev.2010,14(1),263–271。
将N-(6-甲基吡啶-2-甲基)三甲基乙酰胺(5a)(5.5g,28.6mmol)溶于无水四氢呋喃(30mL)中，氮气氛围下降温至0℃，缓慢滴加正丁基锂的正己烷溶液(35mL,2.5M,85.9mmol)，升至室温搅拌2小时。将反应液降温至-78℃，缓慢滴加 二甲基二硫(5.5mL,57.2mL)，加毕，缓慢升至室温，继续搅拌1小时。冰水浴下，加入饱和氯化铵淬灭反应，乙酸乙酯萃取，有机相用饱和食盐水洗涤，无水硫酸钠干燥。浓缩后Flash分离(乙酸乙酯:石油醚＝1:1)，得到N-(6-甲基-3-甲硫基吡啶-2-甲基)三甲基乙酰胺(5b)(2.95g,白色固体)，产率43％。
MS m/z[M+H]+:239.
步骤二：N-(6-甲基-3-(S-甲基亚砜亚胺基)吡啶-2-甲基)三甲基乙酰胺(5c)的合成
合成方法参考3-(S-甲基亚砜亚胺基)-2-硝基吡啶的合成，产率12％。
1H NMR(400MHz,DMSO-d6)δ10.78(s,1H),8.11(d,J＝8.0Hz,1H),7.21(d,J＝8.0Hz,1H),5.04(s,1H),3.10(s,3H),2.48(s,3H),1.23(s,9H).
MS m/z[M+H]+:270.
步骤三：N-(6-甲基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-甲基)三甲基乙酰胺(5d)的合成
将N-(6-甲基-3-(S-甲基亚砜亚胺基)吡啶-2-甲基)三甲基乙酰胺(5c)(370mg,1.38mmol)溶于二氯甲烷(6mL)中，加入三甲氧鎓四氟硼酸盐(265mg,1.79mmol)，室温搅拌1小时。加水淬灭反应，搅拌10分钟。水相用二氯甲烷萃取，合并有机相，无水硫酸钠干燥。浓缩后板层析分离(甲醇:二氯甲烷＝1:10)，得到N-(6-甲基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-甲基)三甲基乙酰胺(5d)(190mg，棕色粘稠液体)，产率49％。
MS m/z[M+H]+:284.
步骤四：3-(N,S-二甲基亚砜亚胺基)-6-甲基吡啶-2-氨(5e)的合成
将N-(6-甲基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-甲基)三甲基乙酰胺(5d)(190mg,0.67mmol)溶于2N的盐酸溶液(4mL)中，100℃搅拌30分钟。降至室温，使用饱和碳酸氢钠水溶液调pH＝8～9。水相用乙酸乙酯萃取，合并有机相，使用饱和食盐水洗涤，无水硫酸钠干燥。浓缩后板层析分离(甲醇:二氯甲烷＝1:10)，得到3-(N,S-二甲基亚砜亚胺基)-6-甲基吡啶-2-氨(5e)(79mg，黄色液体)，产率59％。
1H NMR(400MHz,DMSO-d6)δ7.69(d,J＝7.9Hz,1H),6.73(s,2H),6.58(d,J＝7.8Hz,1H),3.01(s,3H),2.46(s,3H),2.29(s,3H).
MS m/z[M+H]+:200.
步骤五：6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-6-甲基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(5f)的合成
将3-(N,S-二甲基亚砜亚胺基)-6-甲基吡啶-2-氨(5e)(63mg,0.316mmol)溶于无水DMF(1mL)中，氮气氛围下降温至0℃，加入氢化钠(25mg,60％w/w,0.632mmol)后搅拌20分钟，加入4,6-二氯-N-甲基哒嗪-3-甲酰胺(3b)(65mg,0.316mmol)，升至室温搅拌2小时。加入饱和氯化铵淬灭反应，用乙酸乙酯萃取，合并有机相，使用饱和食盐水洗涤，无水硫酸钠干燥。浓缩后Flash分离(甲醇:二氯甲烷＝1:10)，得到6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-6-甲基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(5f)(40mg，白色固体)，产率34％。
1H NMR(400MHz,DMSO-d6)δ12.03(s,1H),9.28(d,J＝3.8Hz,1H),8.97(s,1H),8.12(d,J＝7.9Hz,1H),7.21(d,J＝7.9Hz,1H),3.19(s,3H),2.85(d,J＝4.6Hz,3H),2.68(s,3H),2.54(s,3H).
MS m/z[M+H]+:369.
步骤六：6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-6-甲基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(5)的合成
合成方法参考6-(环丙烷甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(实施例2)的合成，产率33％。
1H NMR(400MHz,DMSO-d6)δ11.88(s,1H),11.36(s,1H),9.82(s,1H),9.08(d,J＝4.6Hz,1H),8.08(d,J＝7.9Hz,1H),7.12(d,J＝7.9Hz,1H),3.19(s,3H),2.84(d,J＝4.7Hz,3H),2.66(s,3H),2.51(s,3H),2.11(dt,J＝12.5,6.2Hz,1H),0.88–0.81(m,4H).
MS m/z[M+H]+:418.
实施例6：4-((6-氨基甲酰基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺的制备
步骤一：6-氯-3-(甲硫基)吡啶-2-氨(6b)的合成
N-(6-氯-3-(甲硫基)吡啶-2-基)三甲基乙酰胺(6a)的合成参考J.Org.Chem.1983,48(20),3401–3408。
合成方法参考3-(N,S-二甲基亚砜亚胺基)-6-甲基吡啶-2-氨的合成，产率89％。
1H NMR(400MHz,CDCl3)δ7.50(d,J＝7.8Hz,1H),6.63(d,J＝7.8Hz,1H),5.25(s,2H),2.34(s,3H).
MS m/z[M+H]+:175.
步骤二：N,N-(二叔丁氧羰基)-6-氯-3-(甲硫基)吡啶-2-氨(6c)的合成
将6-氯-3-(甲硫基)吡啶-2-氨(6b)(6.0g,34.4mmol)置于圆底瓶中，缓慢加入Boc酸酐(21.7g,99.7mmol)，室温搅拌10分钟后，加入DMAP(840mg,6.88mmol)，室温继续搅拌1小时。加入石油醚稀释溶液，浓缩后，过硅胶短柱除去Boc酸酐，得14.7g粗产品。向粗产品中加入石油醚打浆，抽滤并用石油醚淋洗，干燥后得到N,N-(二叔丁氧羰基)-6-氯-3-(甲硫基)吡啶-2-氨(6c)(12.3g,白色固体)，产率96％
1H NMR(400MHz,CDCl3)δ7.55(d,J＝8.2Hz,1H),7.28(d,J＝9.2Hz,1H),2.45(s,3H),1.42(s,18H).
MS m/z[M+Na]+:397.
步骤三：N,N-(二叔丁氧羰基)-6-氯-3-(S-甲基亚砜亚胺基)吡啶-2-氨(6d)的合成
合成方法参考3-(S-甲基亚砜亚胺基)-2-硝基吡啶的合成，产率84％。
1H NMR(400MHz,CDCl3)δ8.43(d,J＝8.1Hz,1H),7.52(d,J＝8.2Hz,1H),3.17(s,3H),1.80(s,1H),1.50(s,9H),1.47(s,9H).
MS m/z[M+H]+:406.
步骤四：N,N-(二叔丁氧羰基)-6-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-氨(6e)的合成
合成方法参考N-(6-甲基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-甲基)三甲基乙酰胺的合成，粗品未进行分离直接进行下一步反应。
步骤五：6-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-氨(6f)的合成
合成方法参考3-(N,S-二甲基亚砜亚胺基)-6-甲基吡啶-2-氨的合成，两步产率34％。
1H NMR(400MHz,DMSO-d6)δ7.83(d,J＝8.0Hz,1H),7.22(s,2H),6.77(d,J＝8.0Hz,1H),3.08(s,3H),2.49(s,3H).
MS m/z[M+H]+:220.
步骤六：6-氯-4-((6-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(6g)的合成
合成方法参考6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-6-甲基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的合成，产率39％。
1H NMR(400MHz,DMSO-d6)δ12.20(s,1H),9.34(d,J＝4.5Hz,1H),8.77(s,1H),8.22(d,J＝8.1Hz,1H),7.42(d,J＝8.1Hz,1H),3.23(s,3H),2.84(d,J＝4.7Hz,3H),2.68(s,3H).
MS m/z[M+H]+:389.
步骤七：6-氯-4-((6-氰基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(6h)的合成
将6-氯-4-((6-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(6g)(133mg,0.343mmol)、Zn(CN)2(22mg,0.189mmol)、Pd2(dba)3(31mg,0.0343mmol)和xantphos(40mg,0.0686mmol)溶于无水DMF(2mL)中，氮气氛围下，80℃、80W微波反应45分钟。降至室温后，加水淬灭反应，乙酸乙酯萃取，合并有机相，使用饱和食盐水洗，无水硫酸钠干燥。浓缩后板层析分 离(乙酸乙酯:石油醚＝2:1)，得到6-氯-4-((6-氰基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(6h)(118mg，黄色固体)，产率91％。
1H NMR(400MHz,DMSO-d6)δ12.25(s,1H),9.37(d,J＝4.4Hz,1H),8.77(s,1H),8.41(d,J＝7.4Hz,1H),7.93(d,J＝7.4Hz,1H),3.28(s,3H),2.88(s,3H),2.69(s,3H).
MS m/z[M+H]+:380.
步骤八：4-((6-氰基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(6i)的合成
合成方法参考6-(环丙烷甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的合成，产率21％。
1H NMR(400MHz,DMSO-d6)δ12.09(s,1H),11.47(s,1H),9.47(s,1H),9.18(d,J＝4.8Hz,1H),8.38(d,J＝7.9Hz,1H),7.86(d,J＝7.8Hz,1H),3.30(s,3H),2.85(d,J＝4.7Hz,3H),2.68(s,3H),2.18–2.08(m,1H),0.87–0.83(m,4H).
MS m/z[M+H]+:429.
步骤九：4-((6-氨基甲酰基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(6)的合成
将4-((6-氰基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(6i)(15mg,0.035mmol)溶于DMSO(1mL)中，加入无水碳酸钾(12mg,0.088mmol)，室温搅拌5分钟后，加入30％的过氧化氢水溶液(39mg,0.35mmol)，室温继续搅拌30分钟。将反应液倒入蒸馏水中，使用乙酸乙酯进行萃取，合并有机相，使用饱和食盐水洗涤，无水硫酸钠干燥。浓缩后prep-HPLC分离，得到4-((6-氨基甲酰基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(6)(4.5mg，白色固体)，产率29％。
1H NMR(400MHz,DMSO-d6)δ11.99(s,1H),11.60(s,1H),9.48(s,1H),9.13(s,1H),8.38(d,J＝8.0Hz,1H),7.97(s,1H),7.87(d,J＝7.9Hz,1H),7.75(s,1H),3.27(s,3H),2.85(d,J＝4.8Hz,3H),2.69(s,3H),2.14–2.08(m,1H),0.89–0.81(m,4H).
MS m/z[M+H]+:447.
实施例7：4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺的制备
步骤一：6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-6-((二苯基亚甲基)氨基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(7a)的合成
将6-氯-4-((6-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(6g)(4.1g,10.6mmol)、Pd2(dba)3(484mg,0.53mmol)、xantphos(611mg,1.06mmol)和Cs2CO3(10.3g,31.7mmol)溶于无水DMF(30mL)中，加入二苯甲酮亚胺(3.8g,21.1mmol)，氮气氛围下，125℃搅拌4小时。加水淬灭反应，使用二氯甲烷进行萃取，合并有机相，分别用蒸馏水和食盐水洗涤，无水硫酸钠干燥，柱层析分离(乙酸乙酯:石油醚＝1:1～甲醇:二氯甲烷＝1:20)，得6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-6-((二苯基亚甲基)氨基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(7a)(4.17g,土黄色固体)，产率74％。
MS m/z[M+H]+:534.
步骤二、三：4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(7)的合成
将6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-6-((二苯基亚甲基)氨基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(7a)(4.67g,8.75mmol)溶于二甲苯(50mL)中，加入环丙酰胺(1.48g,17.4mmol)、Pd2(dba)3(500mg,0.875mmol)、xantphos(760mg, 1.31mmol)、Cs2CO3(5.66g,17.4mmol)，氮气氛围下145℃搅拌3小时。降至室温后，加甲醇/二氯甲烷(1:10)混合溶剂稀释，硅藻土过滤，滤饼用甲醇/二氯甲烷(1:10)混合溶剂淋洗。浓缩后得6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-6-((二苯基亚甲基)氨基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(7b)粗产品，未进行分离直接进行下一步反应。
将6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-6-((二苯基亚甲基)氨基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(7b)粗品溶于四氢呋喃(40mL)中，冰浴下加入6N盐酸(30mL)，升至室温搅拌1小时。缓慢分批加入无水碳酸钾，调节pH＝9～10，抽滤后浓缩。柱层析分离(甲醇:二氯甲烷＝1:20–1:7)，得4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(7)(1.87g,土黄色固体)，产率51％。
1H NMR(400MHz,DMSO-d6)δ11.55(s,1H),11.31(s,1H),9.51(s,1H),9.01(d,J＝4.7Hz,1H),7.74(d,J＝8.4Hz,1H),6.54(s,2H),6.24(d,J＝8.7Hz,1H),3.06(s,3H),2.84(d,J＝4.4Hz,3H),2.63(s,3H),2.16–2.06(m,1H),0.92–0.80(m,4H).
MS m/z[M+H]+:419.
实施例8：4-((5-氰基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺)-N-甲基哒嗪-3-甲酰胺的制备
步骤一：5-溴-3-(N,S-二甲基亚砜亚胺基)吡啶-2-氨(8a)的合成
将3-(N,S-二甲基亚砜亚胺基)吡啶-2-氨(1d)(500mg,2.7mmol)溶于乙腈(15mL)中，缓慢加入NBS(504mg,2.83mmol)，室温搅拌1小时，TLC检测反应完全。旋干乙腈，加水淬灭反应，乙酸乙酯萃取，饱和食盐水洗，无水硫酸钠干燥，浓缩后Flash分离(乙酸乙酯/石油醚＝40–90％)，得到5-溴-3-(N,S-二甲基亚砜亚胺基)吡啶-2-氨(8a)(640mg，白色固体)，产率89％。
1H NMR(400MHz,CDCl3)δ8.29(d,J＝2.1Hz,1H),8.10(d,J＝2.0Hz,1H),6.07(brs,2H),3.08(s,3H),2.68(s,3H).
MS m/z[M+H]+:264.
步骤二：4-((5-溴-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-氯-N-甲基哒嗪-3-甲酰胺(8b)的合成
合成方法参考6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-6-甲基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的合成，产率61％。
1H NMR(400MHz,CDCl3)δ12.43(s,1H),8.97(s,1H),8.59(s,1H),8.42(s,1H),8.28(brs,1H),3.26(s,3H),3.07(d,J＝5.1Hz,3H),2.83(s,3H).
MS m/z[M+H]+:433.
步骤三、四：4-((5-氰基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺)-N-甲基哒嗪-3-甲酰胺(8)的合成
将4-((5-溴-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-氯-N-甲基哒嗪-3-甲酰胺(8b)(205mg,0.472mmol)、Zn(CN)2(28mg,0.236mmol)、Pd2(dba)3(43mg,0.0472mmol)和xantphos(55mg,0.0944mmol)溶于无水DMF(3mL)中，氮气条件下，60℃、50W微波反应1小时，然后80℃、80W反应15分钟。反应液降至室温，向反应体系中加入环丙酰胺(44mg,0.519mmol)、Pd2(dba)3(43mg,0.0472mmol)、xantphos(55mg,0.0944mmol)和Cs2CO3(308mg,0.944mmol)，氮气氛围下，微波110℃、50W反应1小时。加水淬灭反应，乙酸乙酯萃取，饱和食盐水洗，无水硫酸钠干燥，浓缩后Flash分离(甲醇/二氯甲烷＝5–7％)，得到4-((5-氰基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺)-N-甲基哒嗪-3-甲酰胺(8)(114mg，白色固体)，产率56％。
1H NMR(400MHz,DMSO-d6)δ12.20(s,1H),11.50(s,1H),9.46(s,1H),9.16(s,1H),8.93(s,1H),8.49(s,1H),3.29(s,3H),2.84(d,J＝4.4Hz,3H),2.66(s,3H),2.15–2.07(s,1H),0.92–0.80(m,4H).
MS m/z[M+H]+:429.
实施例9：4-((5-氨基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺的制备
步骤一：6-((6-氯-3-(甲基氨基甲酰基)哒嗪-4-基)氨基)-5-(N,S-二甲基亚砜亚胺基)烟酸-2,4,6-三氯苯酯(9a)的合成
将4-((5-溴-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-氯-N-甲基哒嗪-3-甲酰胺(8b)(560mg,1.3mmol)、甲酸2,4,6-三氯苯酯(349mg,1.55mmol)、Pd(OAc)2(63mg,0.26mmol)、xantphos(243mg,0.42mmol)和三乙胺(263mg,2.6mmol)加入到甲苯(28mL)溶液中中，氮气氛围下100℃搅拌2小时。反应液降至室温，硅藻土过滤，乙酸乙酯淋洗。将滤液浓缩，Flash分离(乙酸乙酯/石油醚＝40–80％)，得到6-((6-氯-3-(甲基氨基甲酰基)哒嗪-4-基)氨基)-5-(N,S-二甲基亚砜亚胺基)烟酸-2,4,6-三氯苯酯(9a)(380mg，淡黄色固体)，产率51％。
1H NMR(400MHz,DMSO-d6)δ12.47(s,1H),9.42(d,J＝4.7Hz,1H),9.37(d,J＝1.8Hz,1H),9.02(s,1H),8.75(d,J＝1.9Hz,1H),7.95(s,2H),5.74(s,1H),3.36(s,3H),2.87(d,J＝4.7Hz,3H),2.72(s,3H).
MS m/z[M+H]+:577.
步骤二：6-((6-氯-3-(甲基氨基甲酰基)哒嗪-4-基)氨基)-5-(N,S-二甲基亚砜亚胺基)烟酸(9b)的合成
将6-((6-氯-3-(甲基氨基甲酰基)哒嗪-4-基)氨基)-5-(N,S-二甲基亚砜亚胺基)烟酸-2,4,6-三氯苯酯(9a)(175mg,0.3mmol)溶于DMSO(6.5mL)中，冰浴下加入40％氢氧化钠的水溶液(500mg,40％w/w)，加毕室温搅拌20分钟。使用1N盐酸调pH＝3～4，二氯甲烷萃取，合并有机相，无水硫酸钠干燥。浓缩后得到6-((6-氯-3-(甲基氨基甲酰基)哒嗪-4-基)氨基)-5-(N,S-二甲基亚砜亚胺基)烟酸(9b)粗品(179mg，淡黄色固体)，未分离直接用于下一步。
MS m/z[M+H]+:399.
步骤三：叔丁基(6-((6-氯-3-(甲基氨基甲酰基)哒嗪-4-基)氨基)-5-(N,S-二甲基亚砜亚胺基)吡啶-3-基)氨基甲酸酯(9c)的合成
向6-((6-氯-3-(甲基氨基甲酰基)哒嗪-4-基)氨基)-5-(N,S-二甲基亚砜亚胺基)烟酸(9b)粗品(179mg)的叔丁醇(12mL)溶液中，加入三乙胺(50mg,0.495mmol)和DPPA(136mg,0.495mmol)，N2氛围下85℃搅拌2小时。反应液降至室温后，浓缩Flash分离(乙酸乙酯/石油醚＝40–90％)，得到叔丁基(6-((6-氯-3-(甲基氨基甲酰基)哒嗪-4-基)氨基)-5-(N,S-二甲基亚砜亚胺基)吡啶-3-基)氨基甲酸酯(9c)(69mg，淡黄色固体)，产率33％。
MS m/z[M+H]+:470.
步骤四：叔丁基(6-((6-(环丙甲酰胺基)-3-(甲基氨基甲酰基)哒嗪-4-基)氨基)-5-(N,S-二甲基亚砜亚胺基)吡啶-3-基)氨基甲酸酯(9d)的合成
合成方法参考6-(环丙烷甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的合成，产率29％。
MS m/z[M+H]+:519.
步骤五：4-((5-氨基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(9)的合成
将叔丁基(6-((6-(环丙甲酰胺基)-3-(甲基氨基甲酰基)哒嗪-4-基)氨基)-5-(N,S-二甲基亚砜亚胺基)吡啶-3-基)氨基甲酸酯(9d)(22mg,0.042mmol)溶于二氯甲烷(1.5mL)，加入4M的盐酸二氧六环溶液(1.5mL,6mmol)，室温搅拌1小时。旋干溶剂，加水(1.5mL)稀释，使用33％碳酸钾水溶液调节pH>11，乙酸乙酯萃取，合并有机相，无水硫酸钠干燥。过滤浓缩后得到粗品，prep-HPLC制备得到4-((5-氨基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(9)(6.7mg，白色固体)，产率38％。
1H NMR(400MHz,DMSO-d6)δ11.34(s,1H),11.23(s,1H),9.00(d,J＝4.9Hz,1H),8.92(s,1H),7.91(d,J＝2.8Hz,1H),7.53(d,J＝2.8Hz,1H),5.66(s,2H),3.10(s,3H),2.82(d,J＝4.8Hz,3H),2.63(s,3H),2.11–2.03(m,1H),0.82(d,J＝6.7Hz,4H).
MS m/z[M+H]+:419.
实施例10：4-((5-氨基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺的制备
步骤一：4-((5-溴-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(10a)的合成
合成方法参考5-溴-3-(N,S-二甲基亚砜亚胺基)吡啶-2-氨的合成，产率16％。
MS m/z[M+H]+:485.
步骤二：6-((6-(环丙甲酰胺基)-3-(甲基氨基甲酰基)哒嗪-4-基)氨基)-5-(N,S-二甲基亚砜亚胺基)烟酸-2,4,6-三氯苯酯(10b)的合成
合成方法参考6-((6-氯-3-(甲基氨基甲酰基)哒嗪-4-基)氨基)-5-(N,S-二甲基亚砜亚胺基)烟酸-2,4,6-三氯苯酯的合成，产率82％。
MS m/z[M+H]+:629.
步骤三：6-((6-(环丙甲酰胺基)-3-(甲基氨基甲酰基)哒嗪-4-基)氨基)-5-(N,S-二甲基亚砜亚胺基)烟酸(10c)的合成
合成方法参考6-((6-氯-3-(甲基氨基甲酰基)哒嗪-4-基)氨基)-5-(N,S-二甲基亚砜亚胺基)烟酸的合成，粗品未经分离直接进行下一步。
MS m/z[M+H]+:402.
步骤四：叔丁基(6-((6-(环丙甲酰胺基)-3-((甲基-d3)氨基甲酰基))哒嗪-4-基)氨基)-5-(N,S-二甲基亚砜亚胺基)吡啶-3-基)氨基甲酸酯(10d)的合成
合成方法参考叔丁基(6-((6-氯-3-(甲基氨基甲酰基)哒嗪-4-基)氨基)-5-(N,S-二甲基亚砜亚胺基)吡啶-3-基)氨基甲酸酯的合成，两步产率25％。
MS m/z[M+H]+:522.
步骤五：4-((5-氨基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺(10)的合成
合成方法参考4-((5-氨基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺的合成，产率16％。
1H NMR(400MHz,DMSO-d6)δ11.34(s,1H),11.23(s,1H),8.97(s,1H),8.92(s,1H),7.91(d,J＝2.7Hz,1H),7.53(d,J＝2.7Hz,1H),5.66(s,2H),3.10(s,3H),2.63(s,3H),2.10–2.04(m,1H),0.82(d,J＝6.6Hz,4H).
MS m/z[M+H]+:422.
实施例11：6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-5-羟基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的制备
步骤一：6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-5-羟基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(11a)的合成
将4-((5-溴-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-氯-N-甲基哒嗪-3-甲酰胺(8b)(200mg,0.463mmol)、联硼酸频那醇酯(151mg,0.594mmol)、Pd(dppf)Cl2(34mg,0.046mmol)、无水乙酸钾(133mg,1.400mmol)溶于二氧六环中，氮气氛围下，100℃搅拌1小时。降至室温后，向反应液中加入30％的过氧化氢水溶液(103mg,0.909mmol)，室温搅拌30分钟。加入乙酸乙酯和水稀释反应液，水相用乙酸乙酯进行萃取，合并有机相，使用饱和食盐水洗涤，无水硫酸钠干燥。浓缩后柱层析分离(甲醇:二氯甲烷＝1:20)，得到6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-5-羟基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(11a)(124mg,黄色固体)，产率73％。
1H NMR(400MHz,DMSO-d6)δ11.79(s,1H),10.45(s,1H),9.26(d,J＝4.6Hz,1H),8.56(s,1H),8.21(d,J＝2.8Hz,1H),7.69(d,J＝2.8Hz,1H),3.19(s, 3H),2.84(d,J＝4.7Hz,3H),2.67(s,3H).
MS m/z[M+H]+:371.
步骤二：6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-5-羟基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(11)的合成
合成方法参考6-(环丙烷甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的合成，产率69％。
1H NMR(400MHz,DMSO-d6)δ11.52(s,1H),11.28(s,1H),9.07(s,1H),9.04(d,J＝4.9Hz,1H),8.10(d,J＝2.9Hz,1H),7.66(d,J＝2.9Hz,1H),3.16(s,3H),2.83(d,J＝4.8Hz,3H),2.64(s,3H),2.12–2.03(m,1H),0.83(d,J＝6.6Hz,4H).
MS m/z[M+H]+:420.
实施例12：6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-5-氟吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的制备
6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-5-氟吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的制备(12)的制备参考实施例5中6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-6-甲基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的制备，以N-(5-氟吡啶-2-基)三甲基乙酰胺(12a)代替N-(6-甲基吡啶-2-甲基)三甲基乙酰胺作为起始原料。
步骤一：N-(5-氟-3-甲硫基吡啶-2-基)三甲基乙酰胺(12b)的合成，产率26％。
N-(5-氟吡啶-2-基)三甲基乙酰胺(12a)的合成参考Org.Lett.2013,15(13),3460–3463。
1H NMR(400MHz,DMSO-d6)δ9.50(s,1H),8.16(d,J＝2.2Hz,1H),7.70–7.63(d,J＝8.0,2.2Hz,1H),2.42(s,3H),1.21(s,9H).
MS m/z[M+H]+:243.
步骤二：N-(3-(S-甲基亚砜亚胺基)-5-氟吡啶-2-基)三甲基乙酰胺(12c)的合成，产率28％。
1H NMR(400MHz,DMSO-d6)δ10.57(s,1H),8.66(s,1H),8.12(d,J＝7.4Hz,1H),7.68(d,J＝13.8Hz,1H),3.17(s,3H),1.22(s,9H).
MS m/z[M+H]+:274.
步骤三：N-(3-(N,S-二甲基亚砜亚胺基)-5-氟吡啶-2-基)三甲基乙酰胺(12d)的合成，产率14％。
1H NMR(400MHz,DMSO-d6)δ10.30(s,0.65H),9.81(s,0.35H),8.78(s,0.35H),8.68(d,J＝2.4Hz,0.65H),8.31(d,J＝7.5Hz,0.35H),8.09(dd,J＝7.6,2.4Hz,0.65H),3.25(s,3H),2.56(s,3H),1.23(d,J＝11.5Hz,9H).
MS m/z[M+H]+:288.
步骤四：3-(N,S-二甲基亚砜亚胺基)-5-氟吡啶-2-氨(12e)的合成，产率47％。
1H NMR(400MHz,DMSO-d6)δ8.34(s,1H),7.79(d,J＝7.6Hz,1H),6.82(s,2H),3.19(s,3H),2.57(s,3H).
MS m/z[M+H]+:204.
步骤五：6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-5-氟吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的制备(12f)的合成，产率32％。
1H NMR(400MHz,DMSO-d6)δ12.03(s,1H),9.31(s,1H),8.71(s,2H),8.12(d,J＝5.7Hz,1H),3.27(s,3H),2.85(d,J＝4.4Hz,3H),2.68(s,3H).
MS m/z[M+H]+:373.
步骤六：6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-5-氟吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的制备(12)的合成，产率29％。
1H NMR(400MHz,DMSO-d6)δ11.82(s,1H),11.39(s,1H),9.29(s,1H),9.11(d,J＝4.8Hz,1H),8.60(d,J＝3.0Hz,1H),8.08(dd,J＝7.7,3.0Hz,1H),3.26(s,3H),2.84(d,J＝4.8Hz,3H),2.66(s,3H),2.15-2.05(m,1H),0.90–0.78(m,4H).
MS m/z[M+H]+:422.
实施例13：4-((5-溴-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺的制备
步骤一：6-氯-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(13a)的合成
合成方法参考6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-6-甲基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的合成，产率40％。
1H NMR(400MHz,DMSO-d6)δ12.07(s,1H),9.28(s,1H),8.88(s,1H),8.63(d,J＝3.5Hz,1H),8.24(d,J＝7.6Hz,1H),7.35(dd,J＝7.3,5.1Hz,1H),3.21(s,3H),2.84(d,J＝4.5Hz,3H),2.68(s,3H).
MS m/z[M+H]+:355.
步骤二：6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(13b)的合成
合成方法参考6-(环丙烷甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的合成，产率44％。
1H NMR(400MHz,DMSO-d6)δ11.85(s,1H),11.37(s,1H),9.45(s,1H),9.08(d,J＝5.3Hz,1H),8.52(d,J＝4.7Hz,1H),8.21(d,J＝7.7Hz,1H),7.27(dd,J＝7.8,4.9Hz,1H),3.20(s,3H),2.83(d,J＝4.6Hz,3H),2.66(s,3H),2.13–2.04 (m,1H),0.83(d,J＝7.0Hz,4H).
MS m/z[M+H]+:404.
步骤三：4-((5-溴-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(13)的合成
将6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(13b)(490mg,1.21mmol)溶于乙腈(10mL)和二氯甲烷(10mL)混合溶剂中，冰水浴下加入NBS(183mg,1.03mmol)，室温搅拌2小时。加饱和氯化铵(35mL)淬灭反应，加水稀释，用乙酸乙酯萃取，合并有机相，用饱和食盐水洗，无水硫酸钠干燥。浓缩后Flash分离(甲醇/二氯甲烷＝10％)，得到4-((5-溴-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(13)(100mg，淡黄色固体)，产率17％。
1H NMR(400MHz,DMSO-d6)δ11.88(s,1H),11.42(s,1H),9.34(s,1H),9.12(d,J＝4.8Hz,1H),8.65(d,J＝2.4Hz,1H),8.26(d,J＝2.4Hz,1H),3.27(s,3H),2.84(d,J＝4.8Hz,3H),2.65(s,3H),2.15–2.05(m,1H),0.89–0.80(m,4H).
MS m/z[M+H]+:482.
实施例14：6-(环丙基酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-5-甲氧基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的制备
步骤一：N-(5-甲氧基-3-甲硫基吡啶-2-基)三甲基乙酰胺(14b)的合成
N-(5-甲氧基-吡啶-2-基)三甲基乙酰胺(14a)的合成参考US2011/178053。
14b合成方法参考N-(6-甲基-3-甲硫基吡啶-2-甲基)三甲基乙酰胺的合成，产 率58％。
1H NMR(400MHz,CDCl3)δ7.95(d,J＝2.3Hz,1H),7.77(s,1H),7.14(d,J＝2.1Hz,1H),3.86(s,3H),2.42(s,3H),1.34(s,9H).
MS m/z[M+H]+:255.
步骤二：5-甲氧基-3-甲硫基吡啶-2-氨(14c)的合成
合成方法参考3-(N,S-二甲基亚砜亚胺基)-6-甲基吡啶-2-氨的合成，产率84％。
1H NMR(400MHz,CDCl3)δ7.70–7.67(m,1H),7.20–7.17(m,1H),4.65(s,2H),3.78(s,3H),2.39(s,3H).
MS m/z[M+H]+:171.
步骤三：N,N-(二叔丁氧羰基)-5-甲氧基-3-甲硫基吡啶-2-氨14d的合成
合成方法参考N,N-(二叔丁氧羰基)-6-氯-3-甲硫基吡啶-2-氨的合成，产率70％。
1H NMR(400MHz,CDCl3)δ7.93(s,1H),7.07(s,1H),3.89(s,3H),2.43(s,3H),1.41(s,18H).
MS m/z[M+H]+:371.
步骤四：N,N-(二叔丁氧羰基)-3-(S-甲基亚砜亚胺基)-5-甲氧基吡啶-2氨(14e)的合成
合成方法参考3-(S-甲基亚砜亚胺基)-2-硝基吡啶的合成，产率85％。
1H NMR(400MHz,CDCl3)δ8.36(s,1H),7.94(s,1H),3.94(s,3H),3.16(s,3H),2.04(s,1H),1.47(d,J＝9.8Hz,18H).
MS m/z[M+H]+:402.
步骤五：N,N-(二叔丁氧羰基)-3-(N,S-二甲基亚砜亚胺基)-5-甲氧基吡啶-2氨(14f)的合成
合成方法参考N-(6-甲基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-甲基)三甲基乙酰胺的合成，产率80％。
MS m/z[M+H]+:416.
步骤六：3-(N,S-二甲基亚砜亚胺基)-5-甲氧基吡啶-2氨(14g)的合成
合成方法参考6-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-氨的合成，产率23％。
1H NMR(400MHz,CDCl3)δ8.04(s,1H),7.61(s,1H),5.64(s,2H),3.82(s,3H),3.10(s,3H),2.68(s,3H).
MS m/z[M+H]+:202.
步骤七：6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-5-甲氧基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(14h)的合成
合成方法参考6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-6-甲基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的合成，产率14％。
MS m/z[M+H]+:385.
步骤八：6-(环丙基酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-5-甲氧基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(14)的合成
合成方法参考6-(环丙烷甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的合成，产率79％。
1H NMR(400MHz,CDCl3)δ11.65(s,1H),11.32(s,1H),9.17(s,1H),9.06(d,J＝4.7Hz,1H),8.31(d,J＝2.8Hz,1H),7.75(d,J＝2.8Hz,1H),3.90(s,3H),3.21(s,3H),2.84(d,J＝4.7Hz,3H),2.66(s,3H),2.14–2.05(m,1H),0.84(d,J＝7.1Hz,4H).
MS m/z[M+H]+:434.
实施例15：6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-5-甲基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的制备
步骤一：3-(N,S-二甲基亚砜亚胺基)-5-甲基吡啶-2-氨(15a)的合成
将5-溴-3-(N,S-二甲基亚砜亚胺基)吡啶-2-氨(8a)(100mg,0.38mmol)、四三苯基膦钯(88mg,0.076mmol)、碳酸铯(124mg,0.38mmol)溶于二氧六环(1.8mL)和水(0.2mL)的混合溶剂中，向反应液中加入3M三甲基环氧硼烷的四氢呋喃溶液(0.2mL,0.6mmol)，氮气氛围下100℃反应3小时。降至室温，加水淬灭反应，乙酸乙酯萃取，饱和食盐水洗，无水硫酸钠干燥。浓缩后板层析分离(甲醇:二氯甲烷＝1:10)，得3-(N,S-二甲基亚砜亚胺基)-5-甲基吡啶-2-氨(15a)(50mg,白色固体)，产率66％。
1H NMR(400MHz,CDCl3)δ8.09(s,1H),7.82(s,1H),5.82(s,2H),3.07(s,3H),2.68(s,3H),2.26(s,3H).
MS m/z[M+H]+:200.
步骤二：6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-5-甲基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(15b)的合成
合成方法参考6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-6-甲基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的合成，产率22％。
MS m/z[M+H]+:369.
步骤三：6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-5-甲基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(15)的合成
合成方法参考6-(环丙烷甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的合成，产率62％。
1H NMR(400MHz,DMSO-d6)δ11.77(s,1H),11.34(s,1H),9.38(s,1H),9.06(d,J＝4.3Hz,1H),8.39(s,1H),8.05(s,1H),3.19(s,3H),2.84(d,J＝4.1Hz,3H),2.66(s,3H),2.34(s,3H),2.14–2.04(m,1H),0.84(d,J＝6.4Hz,4H).
MS m/z[M+H]+:418.
实施例16：6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-5-(3-甲氧基丙氧基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的制备
步骤一：N,N-(二叔丁氧羰基)-5-溴-3-(N,S-二甲基亚砜亚胺基)吡啶-2-氨(16a)的合成
合成方法参考N,N-(二叔丁氧羰基)-6-氯-3-甲硫基吡啶-2-氨的合成，产率91％。
1H NMR(400MHz,CDCl3)δ8.76(s,1H),8.44(s,1H),3.14s,3H),2.63(s,3H),1.52(s,9H),1.44(s,9H).
MS m/z[M+H]+:464.
步骤二：N,N-(二叔丁氧羰基)-3-(N,S-二甲基亚砜亚胺基)-5-羟基吡啶-2-氨(16b)的合成
合成方法参考6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-5-羟基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的合成，产率96％。
1H NMR(400MHz,CDCl3)δ8.38(s,1H),7.83(s,1H),3.16(s,3H),2.70(s,3H),1.53(s,9H),1.44(s,9H).
MS m/z[M+H]+:402.
步骤三：3-(N,S-二甲基亚砜亚胺基)-5-(3-甲氧基丙氧基)吡啶-2-氨(16c)的合成
向N,N-(二叔丁氧羰基)-3-(N,S-二甲基亚砜亚胺基)-5-羟基吡啶-2-氨(16b)(500mg,1.25mmol)的无水DMF(10mL)中加入无水碳酸钾(1.04g,7.5mmol)，室温搅拌10分钟后，向反应液中加入1-溴-3-甲氧基丙烷(230mg,1.5mmol)， 120℃搅拌1小时。将反应液降至室温，加水(50mL)稀释后，用乙酸乙酯萃取，合并有机相，使用饱和食盐水洗，无水硫酸钠干燥，浓缩后得到黄色油状粗品。将黄色油状粗品溶于二氯甲烷(4mL)中，0℃加入4M氯化氢的二氧六环溶液(4mL)，升至室温搅拌1小时。浓缩旋干溶剂，加水稀释，加入饱和碳酸氢钠调节pH＝8～9，水相用乙酸乙酯萃取。合并有机相，用饱和食盐水洗，无水硫酸钠干燥。浓缩后Flash分离(甲醇/二氯甲烷＝3–5％)，得3-(N,S-二甲基亚砜亚胺基)-5-(3-甲氧基丙氧基)吡啶-2-氨(16c)(202mg,黄色固体)，产率59％。
1H NMR(400MHz,DMSO-d6)δ8.03(d,J＝2.9Hz,1H),7.45(d,J＝2.9Hz,1H),6.40(s,2H),3.99(t,J＝6.4Hz,2H),3.45(t,J＝6.3Hz,2H),3.24(s,3H),3.08(s,3H),2.50(s,3H),1.95-1.87(m,2H).
MS m/z[M+H]+:274.
步骤四：6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-5-(3-甲氧基丙氧基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(16d)的合成
合成方法参考6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-6-甲基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的合成，产率39％。
MS m/z[M+H]+:443.
步骤五：6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-5-(3-甲氧基丙氧基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(16)的合成
合成方法参考6-(环丙烷甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的合成，产率58％。
1H NMR(400MHz,DMSO-d6)δ11.65(s,1H),11.32(s,1H),9.16(s,1H),9.06(d,J＝4.9Hz,1H),8.29(d,J＝2.7Hz,1H),7.75(d,J＝2.7Hz,1H),4.16(t,J＝6.2Hz,2H),3.48(t,J＝6.2Hz,2H),3.25(s,3H),3.21(s,3H),2.84(d,J＝4.7Hz,3H),2.66(s,3H),2.13–2.06(m,1H),2.02–1.92(m,2H),0.84(d,J＝7.1Hz,4H).
MS m/z[M+H]+:492.
实施例17：6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-5-(2-(环氧丁烷-3-基)乙氧基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的制备
步骤一、二、三：3-(N,S-二甲基亚砜亚胺基)-5-(2-(环氧丁烷-3-基)乙氧基)吡啶-2-氨(17c)的合成
将N,N-(二叔丁氧羰基)-3-(N,S-二甲基亚砜亚胺基)-5-羟基吡啶-2-氨(16b)(300mg,0.748mmol)、3-羟乙基氧杂环丁烷(76mg,0.748mmol)、三苯基膦(393mg,1.5mmol)溶于无水四氢呋喃(5mL)中，氮气氛围下加入DIAD(303mg,1.5mmol)，室温反应2小时。加水淬灭反应，乙酸乙酯萃取，饱和食盐水洗，无水硫酸钠干燥。浓缩后Flash分离(甲醇/二氯甲烷＝4–5％)，得到N,N-(二叔丁氧羰基)-3-(N,S-二甲基亚砜亚胺基)-5-(2-(环氧丁烷-3-基)乙氧基)吡啶-2-氨(17a)粗品(954mg)。
将N,N-(二叔丁氧羰基)-3-(N,S-二甲基亚砜亚胺基)-5-(2-(环氧丁烷-3-基)乙氧基)吡啶-2-氨(17a)粗品溶于二氯甲烷中(10mL)，加入4N HCl的二氧六环溶液(10mL)，室温反应30分钟，浓缩得4-((6-氨基-5-(N,S-二甲基亚砜亚胺基)吡啶-3-基)-氧基)-2-(氯甲基)-1-醇(17b)粗品。
将4-((6-氨基-5-(N,S-二甲基亚砜亚胺基)吡啶-3-基)-氧基)-2-(氯甲基)-1-醇(17b)粗品溶于乙醇(10mL)中，加入氢氧化钾(210mg,3.74mmol)，回流4小时，LCMS检测反应完全。反应液降至室温，旋干乙醇，加水淬灭反应，乙酸乙酯萃取，饱和食盐水洗，无水硫酸钠干燥，浓缩后Flash分离(甲醇/二氯甲烷＝3～10％)，得到3-(N,S-二甲基亚砜亚胺基)-5-(2-(环氧丁烷-3-基)乙氧基)吡啶-2-氨(17c)(62mg，黄色固体)，三步产率29％。
1H NMR(400MHz,CDCl3)δ7.99(d,J＝2.9Hz,1H),7.57(d,J＝3.0Hz,1H),5.65(s,2H),4.84(dd,J＝7.8,6.0Hz,2H),4.49(t,J＝6.2Hz,2H),3.93(t,J＝6.1Hz,2H),3.22(dt,J＝14.5,7.2Hz,1H),3.09(s,3H),2.67(s,3H),2.21–2.13(m,2H).
MS m/z[M+H]+:286.
步骤四：6-(氯-4-((3-(N,S-二甲基亚砜亚胺基)-5-(2-(环氧丁烷-3-基)乙氧基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(17d)的合成
合成方法参考6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-6-甲基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的合成，产率18％。
MS m/z[M+H]+:455.
步骤五：6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-5-(2-(环氧丁烷-3-基)乙氧基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(17)的合成
合成方法参考6-(环丙烷甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的合成，产率60％。
1H NMR(400MHz,DMSO-d6)δ11.64(s,1H),11.32(s,1H),9.16(s,1H),9.06(d,J＝4.9Hz,1H),8.27(d,J＝3.0Hz,1H),7.71(d,J＝3.0Hz,1H),4.67(dd,J＝7.9,5.9Hz,2H),4.36(t,J＝6.1Hz,2H),4.09(td,J＝6.4,2.4Hz,2H),3.20(s,3H),3.17–3.11(m,1H),2.83(d,J＝4.8Hz,3H),2.65(s,3H),2.14–2.04(m,3H),0.87–0.78(m,4H).
MS m/z[M+H]+:504.
实施例18：6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-5-(2-吗啉基乙氧基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的制备
步骤一：5-(2-溴乙氧基)-3-(N,S-二甲基亚砜亚胺基)吡啶-2-氨(18a)的合成
将N,N-(二叔丁氧羰基)-3-(N,S-二甲基亚砜亚胺基)-5-羟基吡啶-2-氨(16b)(400mg,1.0mmol)溶于乙腈(20mL)中，加入无水碳酸钾(688mg,5.0mmol)和1,3-二溴乙烷(1.87g,10.0mmol)，80℃搅拌45分钟。反应液降至室温，过滤，滤饼用乙腈淋洗。滤液浓缩后柱层析分离(乙酸乙酯/石油醚＝10–65％)，得到5-(2-溴乙氧基)-3-(N,S-二甲基亚砜亚胺基)吡啶-2-氨(18a)(462mg,无色油状)，产率91％。
1H NMR(400MHz,CDCl3)δ8.40(d,J＝2.9Hz,1H),7.83(d,J＝2.5Hz,1H),4.42(t,J＝5.9Hz,2H),3.69(t,J＝5.9Hz,2H),3.15(s,3H),2.62(s,3H),1.51(s,9H),1.43(s,9H).
MS m/z[M+H]+:508.
步骤二：N,N-(二叔丁氧羰基)-3-(N,S-二甲基亚砜亚胺基)-5-(2-吗啉基乙氧基)吡啶-2-氨(18b)的合成
将5-(2-溴乙氧基)-3-(N,S-二甲基亚砜亚胺基)吡啶-2-氨(18a)(300mg,0.59mmol)溶于DMF(4mL)中，加入无水碳酸钾(245mg,1.77mmol)和吗啡啉(154mg,1.77mmol)，80℃搅拌1小时。反应液降至室温，过滤，滤饼用乙酸乙酯淋洗。滤液浓缩后柱层析分离(甲醇/二氯甲烷＝0–6％)，得到N,N-(二叔丁氧羰基)-3-(N,S-二甲基亚砜亚胺基)-5-(2-吗啉基乙氧基)吡啶-2-氨(18b)(273mg,无色油状)，产率90％。
MS m/z[M+H]+:515.
步骤三：3-(N,S-二甲基亚砜亚胺基)-5-(2-吗啉基乙氧基)吡啶-2-氨(18c)的合成
0℃下，向N,N-(二叔丁氧羰基)-3-(N,S-二甲基亚砜亚胺基)-5-(2-吗啉基乙氧基)吡啶-2-氨(18b)(287mg,0.558mmol)的二氯甲烷(5mL)溶液中缓慢滴加4M氯化氢的二氧六环溶液(2.5mL)，加完后室温搅拌1小时。向反应液中加入饱和碳酸氢钠调节pH＝8～9，旋干溶剂，柱层析分离(甲醇/二氯甲烷＝0–9％)，得到3-(N,S-二甲基亚砜亚胺基)-5-(2-吗啉基乙氧基)吡啶-2-氨(18c)(156mg，淡黄色固体)，产率89％
MS m/z[M+H]+:315.
步骤四：6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-5-(2-吗啉基乙氧基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(18d)的合成
合成方法参考6-氯-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的合成，产率41％。
1H NMR(400MHz,CDCl3)δ12.21(s,1H),8.83(s,1H),8.27(d,J＝3.0Hz,1H),8.21(s,1H),7.91(d,J＝3.0Hz,1H),4.21(t,J＝5.5Hz,2H),3.75(t,J＝4.7Hz,4H),3.22(s,3H),2.87–2.81(s,5H),2.59(d,J＝4.9Hz,4H).
MS m/z[M+H]+:487.
步骤五：6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-5-(2-吗啉基乙氧基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(18)的合成
合成方法参考6-(环丙烷甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的合成，产率28％。
1H NMR(400MHz,DMSO-d6)δ11.65(s,1H),11.32(s,1H),9.16(s,1H),9.04(s,1H),8.31(d,J＝2.9Hz,1H),7.77(d,J＝2.9Hz,1H),4.27–4.18(m,2H),3.61–3.54(m,4H),3.20(s,3H),2.70(t,J＝5.5Hz,2H),2.65(s,3H),2.47–2.42(m,4H),2.12–2.04(m,1H),0.89–0.77(m,4H).
MS m/z[M+H]+:536.
实施例19：4-((5-(3-氰基丙氧基)-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨 基)-6-(环丙甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺的制备
步骤一：6-氨基-5-(N,S-二甲基亚砜亚胺基)-3-羟基吡啶(19a)的合成
合成方法参考6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-5-羟基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的合成，产率63％。
1H NMR(400MHz,DMSO-d6)δ9.29(s,1H),7.86(d,J＝2.9Hz,1H),7.36(d,J＝2.9Hz,1H),6.16(s,2H),3.05(s,3H),2.48(s,3H).
MS m/z[M+H]+:202。
步骤二：4-((6-氨基-5-(N,S-二甲基亚砜亚胺基)吡啶-3-基)氧基丁腈(19b)的合成
向6-氨基-5-(N,S-二甲基亚砜亚胺基)-3-羟基吡啶(19a)(195mg,0.968mmol)的DMF(4mL)溶液中加入4-溴丁腈(172mg,1.16mmol)加入无水碳酸钾(535mg,3.87mmol)，升至40℃搅拌30分钟。反应液降至室温后过滤，乙酸乙酯淋洗，滤液浓缩后柱层析分离(甲醇/二氯甲烷＝1–2.5％)，得4-((6-氨基-5-(N,S-二甲基亚砜亚胺基)吡啶-3-基)氧基丁腈(19b)(148mg，黄色固体)，产率57％
1H NMR(400MHz,DMSO-d6)δ8.06(d,J＝3.0Hz,1H),7.49(d,J＝3.1Hz,1H),6.44(s,2H),4.03(t,J＝6.0Hz,2H),3.09(s,3H),2.65(t,J＝7.2Hz,2H),2.51(s,3H),1.99(tt,J＝7.2,6.0Hz,2H).
MS m/z[M+H]+:269.
步骤三：6-氯-4-((5-(3-氰基丙氧基)-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基) 氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(19c)的合成
合成方法参考6-氯-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的合成，产率49％。
1H NMR(400MHz,CDCl3)δ12.23(s,1H),8.84(s,1H),8.27(s,1H),8.22(s,1H),7.89(s,1H),4.21(t,J＝5.7Hz,2H),3.23(s,3H),2.84(s,3H),2.64(t,J＝6.9Hz,2H),2.26–2.17(m,2H).
MS m/z[M+H]+:441.
步骤四：4-((5-(3-氰基丙氧基)-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺(19)的合成
合成方法参考6-(环丙烷甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的合成，产率28％。
1H NMR(400MHz,DMSO-d6)δ11.67(s,1H),11.33(s,1H),9.19(s,1H),9.04(s,1H),8.31(d,J＝2.9Hz,1H),7.77(d,J＝2.9Hz,1H),4.24-4.14(m,2H),3.21(s,3H),2.69(t,J＝7.1Hz,2H),2.66(s,3H),2.13–2.00(m,3H),0.88–0.79(m,4H).
MS m/z[M+H]+:490.
实施例20：6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-5-((2-甲氧基乙基)氨基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的制备
步骤一：(6-((6-氯-3-(甲基氨基甲酰基)哒嗪-4-基)氨基)-5-(N,S-二甲基亚砜亚胺基)吡啶-3-基)硼酸(20a)的合成
将4-((5-溴-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-氯-N-甲基哒嗪-3-甲酰胺(8b)(140mg,0.324mmol)、联硼酸频那醇酯(107mg,0.421mmol)、Pd(dppf)Cl2(24mg,0.032mmol)、无水乙酸钾(92mg,0.972mmol)溶于二氧六环(4mL)中，氮气氛围下，105℃搅拌1小时。降至室温后，向反应液中加入30％的过氧化氢水溶液(103mg,0.909mmol)，室温搅拌30分钟。加水稀释反应液，用二氯甲烷进行萃取，合并有机相，使用饱和食盐水洗涤，无水硫酸钠干燥。浓缩后使用乙酸乙酯打浆，得到(6-((6-氯-3-(甲基氨基甲酰基)哒嗪-4-基)氨基)-5-(N,S-二甲基亚砜亚胺基)吡啶-3-基)硼酸(20a)(108mg,灰色固体)，产率83％。
MS m/z[M+H]+:399.
步骤二：6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-5-((2-甲氧基乙基)氨基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(20b)的合成
向(6-((6-氯-3-(甲基氨基甲酰基)哒嗪-4-基)氨基)-5-(N,S-二甲基亚砜亚胺基) 吡啶-3-基)硼酸(20a)(50mg,0.126mmol)的二氯甲烷溶液(2mL)中，依次加入一水乙酸铜(10mg,0.063mmol)、4A分子筛(20mg)和2-甲氧基乙胺(19mg,0.252mmol)，在氧气氛围下，40℃搅拌过夜。反应液浓缩后板层析分离(甲醇:二氯甲烷＝1:10)，得到6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-5-((2-甲氧基乙基)氨基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(20b)(5mg,黄色固体)，产率9％。
MS m/z[M+H]+:428.
步骤三：6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-5-((2-甲氧基乙基)氨基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(20)的合成
合成方法参考6-(环丙烷甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的合成，产率45％。
1H NMR(400MHz,DMSO-d6)δ11.37(s,1H),11.23(s,1H),9.00(s,1H),8.92(s,1H),7.98(d,J＝2.9Hz,1H),7.49(d,J＝2.9Hz,1H),6.29(s,1H),3.50(t,J＝5.3Hz,2H),3.30–3.27(m,5H),3.11(s,3H),2.83(d,J＝4.8Hz,3H),2.64(s,3H),2.10–2.05(m,1H),0.84–0.77(m,4H).
MS m/z[M+H]+:477.
实施例21：4-((5-溴-3-(N,S-二甲基亚砜亚胺基)-6-甲基吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺的制备的制备
将6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-6-甲基吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺(5)(10mg,0.024mmol)溶于乙腈(0.5mL)中，0℃下加入NBS(4.3mg,0.024mmol)的乙腈(0.5mL)溶液，0℃搅拌1小时。加水淬灭反应，乙酸乙酯萃取，饱和食盐水洗，无水硫酸钠干燥。浓缩后制备得到21(6mg，黄色固体)，产率50％。
1H NMR(400MHz,DMSO-d6)δ11.95(s,1H),11.41(s,1H),9.84(s,1H), 9.12(d,J＝4.9Hz,1H),8.17(s,1H),3.26(s,3H),2.84(d,J＝4.7Hz,3H),2.64(s,3H),2.63(s,3H),2.15–2.07(m,1H),0.86(d,J＝6.3Hz,4H).
MS m/z[M+H]+:496.
实施例22：4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)-5-氟吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺的制备
将4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(7)(168mg,0.402mmol)溶于DMF(4mL)中，0℃下加入Selectfluor(284mg,0.802mmol)，35℃搅拌1小时，50℃搅拌1小时。将DMF减压蒸干，板层析(甲醇:二氯甲烷＝1:15)分离后prep-HPLC制备，得4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)-5-氟吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(22)(12mg,白色固体)，产率7％
1H NMR(400MHz,DMSO-d6)δ11.48(s,1H),11.32(s,1H),9.22(s,1H),9.03(d,J＝4.8Hz,1H),7.60(d,J＝10.3Hz,1H),6.95(s,2H),3.09(s,3H),2.82(d,J＝4.7Hz,3H),2.60(s,3H),2.13–2.05(m,1H),0.84(d,J＝6.5Hz,4H).
MS m/z[M+H]+:437.
实施例23：4-(6-氨基-5-氯-3-(N，S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙烷甲酰胺基)-N-甲基哒嗪-3-甲酰胺的制备
将4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(7)(9mg,0.022mmol)溶于加无水DMF(1mL)中，冰浴下加入NCS(3.5mg,0.024mmol)，加毕于在60℃下反应3小时。反应液降至室温，加饱和碳酸氢钠(20mL)和水(20mL)淬灭反应，乙酸乙酯萃取，饱和食盐水洗，无水硫酸钠干燥。浓缩后prep-HPLC制备，得到4-(6-氨基-5-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙烷甲酰胺基)-N-甲基哒嗪-3-甲酰胺(23)(4mg，白色固体)，产率41％。
1H NMR(400MHz,DMSO-d6)δ11.59(s,1H),11.36(s,1H),9.41(s,1H),9.06(d,J＝4.9Hz,1H),7.78(s,1H),6.88(s,2H),3.12(s,3H),2.82(d,J＝4.7Hz,3H),2.60(s,3H),2.17–2.02(m,1H),0.85(d,J＝6.9Hz,4H).
MS m/z[M+H]+:453.
实施例24：4-((6-氨基-5-溴-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺的制备
将4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(7)(15mg,0.0359mmol)溶于二氯甲烷(1mL)中，0℃下加入NBS(6.3mg,0.0359mmol)，0℃搅拌3小时。浓缩后Flash分离(甲醇/二氯甲烷＝0–5.5％)，得到4-((6-氨基-5-溴-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(24)(15mg，黄色固体)，产率44％。
1H NMR(400MHz,DMSO-d6)δ11.60(s,1H),11.35(s,1H),9.47(s,1H),9.05(d,J＝5.0Hz,1H),7.90(s,1H),6.77(s,2H),3.13(s,3H),2.82(d,J＝4.8Hz,3H),2.61(s,3H),2.10(q,J＝6.2Hz,1H),0.86(d,J＝6.6Hz,4H).
MS m/z[M+H]+:497.
实施例25：4-(6-氨基-5-氯-3-(N，S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙烷甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺的制备
步骤一：6-氯-4-((6-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(25a)的合成
向6-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-氨(6f)(4.9g,22.37mmol)的四氢呋喃溶液(120mL)中，分批加入氢化钠(2.7g,67.1mmol)，搅拌15分钟，加入4,6-二氯-N-(甲基-d3)哒嗪-3-甲酰胺(2a)(5.6g,26.8mmol)，加毕65℃下搅拌1小时。加氯化铵(80mL)和水(40mL)淬灭反应，二氯甲烷萃取(300mL)，饱和食盐水洗(50mL)，无水硫酸钠干燥。浓缩，粗品用甲基叔丁基醚打浆，抽滤，滤饼用甲基叔丁基醚淋洗，干燥后得6-氯-4-((6-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(25a)(6.8g,土棕色固体)，产率77％。
1H NMR(400MHz,DMSO-d6)δ12.22(s,1H),9.34(s,1H),8.78(s,1H),8.22(d,J＝8.2Hz,1H),7.42(d,J＝8.1Hz,1H),3.24(s,3H),2.68(s,3H).
MS m/z[M+H]+:393.
步骤二：6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-6-((二苯基亚甲基)氨基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(25b)的合成
合成方法参考6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-6-((二苯基亚甲基)氨基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的合成，产率82％。
1H NMR(400MHz,DMSO-d6)δ11.95(s,1H),9.24(s,1H),8.47(s,1H),8.05(d,J＝8.3Hz,1H),7.41(s,10H),6.79(d,J＝8.3Hz,1H),3.16(s,3H),2.62(s,3H).
MS m/z[M+H]+:538.
步骤三：6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-6-((二苯基亚甲基)氨基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(25c)的合成
合成方法参考6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-6-((二苯基亚甲基)氨基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的合成，粗品未分离直接进行下一步反应。
MS m/z[M+H]+:586.
步骤四：4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺(25d)的合成
合成方法参考4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺的合成，两步产率63％。
1H NMR(400MHz,DMSO-d6)δ11.55(s,1H),11.32(s,1H),9.49(s,1H),8.99(s,1H),7.73(d,J＝8.5Hz,1H),6.56(s,2H),6.23(d,J＝8.7Hz,1H),3.05(s,3H),2.61(s,3H),2.09(s,1H),0.85(d,J＝6.7Hz,4H).
MS m/z[M+H]+:422.
步骤五：4-(6-氨基-5-氯-3-(N，S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙烷甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺(25)的合成
合成方法参考4-(6-氨基-5-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙烷甲酰胺基)-N-甲基哒嗪-3-甲酰胺的合成，产率50％。
1H NMR(400MHz,DMSO-d6)δ11.61(s,1H),11.37(s,1H),9.43(s,1H),9.04(s,1H),7.79(s,1H),6.89(s,2H),3.13(s,3H),2.61(s,3H),2.15–2.08(m,1H),0.86(d,J＝7.1Hz,4H).
MS m/z[M+H]+:456.
实施例26：4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)-5-甲基吡啶-2-基)氨基)-6-(环丙烷甲酰胺基)-N-甲基哒嗪-3-甲酰胺的制备
将4-((6-氨基-5-溴-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(24)(160mg，0.322mmol)溶于二氧六环(4mL)，加入四三苯基膦钯(110mg，0.096mmol)、无水碳酸钾(230mg，1.66mmol)和甲基硼酸(496mg，1.66mmol)，氮气氛围下微波(120℃,120W)反应1小时。反应液降至室温后，加入二氯甲烷搅拌后抽滤，滤饼用二氯甲烷淋洗，滤液浓缩后Flash分离(甲醇/二氯甲烷＝1:20)，得4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)-5-甲基吡啶-2-基)氨基)-6-(环丙烷甲酰胺基)-N-甲基哒嗪-3-甲酰胺(26)(89mg,黄色固体)，产率64％。
1H NMR(400MHz,DMSO-d6)δ11.51(s,1H),11.30(s,1H),9.51(s,1H),9.00(d,J＝4.9Hz,1H),7.58(s,1H),6.36(s,2H),3.04(s,3H),2.82(d,J＝4.6Hz,3H),2.60(s,3H),2.09(dd,J＝11.3,5.5Hz,1H),2.06(s,3H),0.85(d,J＝7.0Hz,4H).
MS m/z[M+H]+:433.
实施例27：4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)-5-甲氧基吡啶-2-基)氨基)-6-(环丙烷甲酰胺基)-N-甲基哒嗪-3-甲酰胺的制备
步骤一：4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)-5-羟基吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(27a)的合成
向4-((6-氨基-5-溴-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(24)(100mg,0.20mmol)的甲苯(3mL)悬浮液中加 入联硼酸频那醇酯(77mg,0.30mmol,1.5eq)、乙酸钾(49mg,0.50mmol)和Pd(PPh)2Cl2(28mg,0.04mmol，氮气置氛围下100℃反应1小时，补加Pd(PPh)2Cl2(28mg,0.04mmol,0.2eq)后继续反应1小时。反应液降至室温，加入四氢呋喃(3mL)和过氧化氢(0.10mL,0.88mmol)，室温搅拌30分钟。加水(20mL)淬灭反应，加入二氯甲烷稀释反应液，抽滤，滤饼加二氯甲烷淋洗。滤饼用Flash分离(甲醇/二氯甲烷＝1:10)，得4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)-5-羟基吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(27a)(30mg,棕黄色固体)，产率28％。
1H NMR(400MHz,DMSO-d6)δ11.27(s,1H),11.23(s,1H),9.88(s,1H),9.12(s,1H),8.99(d,J＝4.7Hz,1H),7.24(s,1H),6.29(s,2H),3.01(s,3H),2.81(d,J＝4.6Hz,3H),2.59(s,3H),2.12–2.04(m,1H),0.83(d,J＝7.2Hz,4H).
MS m/z[M+H]+:435.
步骤二：4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)-5-甲氧基吡啶-2-基)氨基)-6-(环丙烷甲酰胺基)-N-甲基哒嗪-3-甲酰胺(27)的合成
将4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)-5-羟基吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(27a)(10mg,0.023mmol)溶于DMF(0.6mL)中，加入碳酸钾(5mg,0.034mmol)和碘甲烷(3.3mg,0.023mmol)，室温搅拌20分钟。反应液加水(5mL)淬灭，乙酸乙酯萃取，合并有机相，用饱和食盐水洗，无水硫酸钠干燥。浓缩后prep-HPLC制备得4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)-5-甲氧基吡啶-2-基)氨基)-6-(环丙烷甲酰胺基)-N-甲基哒嗪-3-甲酰胺(27)(2.2mg,白色固体)，产率22％。
1H NMR(400MHz,DMSO-d6)δ11.35(s,1H),11.26(s,1H),9.13(s,1H),9.00(d,J＝4.8Hz,1H),7.27(s,1H),6.54(s,2H),3.81(s,3H),3.05(s,3H),2.82(d,J＝4.5Hz,3H),2.60(s,3H),2.12–2.04(m,1H),0.83(d,J＝6.6Hz,4H).
MS m/z[M+H]+:449.
实施例28：(R)-4-((6-氨基-5-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙基甲酰基)-N-(甲基-d3)哒嗪-3-甲酰胺的制备
步骤一：(R)-N-(6-c氯-3-(甲基亚磺酰基)吡啶-2-基)三甲基乙酰胺(28b)的合成
(1R,2S)-1-(3,5-二氯-2-羟基苯亚甲基)氨基-2-茚满醇(28a)的合成参考Comptes Rendus Chimie,2014,17(5),403-412。
将(1R,2S)-1-氨基-2-茚满醇(61.5g,0.413mmol)和3,5-二氯水杨醛(78.8g,0.413mmol)溶于无水甲醇(1.5L)中，70℃搅拌1小时。减压除去甲醇，用石油醚打浆，抽滤后干燥，得(1R,2S)-1-(3,5-二氯-2-羟基苯亚甲基)氨基-2-茚满醇(28a)(131g,黄色固体)，产率99％。
1H NMR(400MHz,DMSO-d6)δ14.79(s,1H),8.70(s,1H),7.56(t,J＝2.0Hz,1H),7.48(t,J＝1.9Hz,1H),7.31(q,J＝7.7,7.3Hz,2H),7.24(d,J＝5.8Hz,2H),5.55(d,J＝4.8Hz,1H),5.06(d,J＝5.3Hz,1H),4.60(t,J＝4.6Hz,1H),3.15(dd,J＝16.1,5.7Hz,1H),2.91(dd,J＝16.1,4.0Hz,1H).
MS m/z[M+H]+:322.
将(1R,2S)-1-(3,5-二氯-2-羟基苯亚甲基)氨基-2-茚满醇(28a)(4.62g,14.4mmol)和乙酰丙酮氧化矾(2.38g,9.0mmol)加入甲苯和二氯甲烷混合溶剂(10:1, 930mL)中，搅拌20分钟至完全溶解，加入N-(6-氯-3-(甲硫基)吡啶-2-基)三甲基乙酰胺(6a)(46.4g,179.8mmol)，搅拌20分钟。冰浴下滴加过氧化氢(26.5g,234.0mmol)，加毕室温搅拌2小时，补加过氧化氢(3.6mL,36.0mmol)，继续反应1小时。向反应液中加入饱和亚硫酸钠溶液(150mL)淬灭反应，乙酸乙酯萃取，合并有机相，用饱和食盐水洗，无水硫酸钠干燥。浓缩后用异丙醇(40ml)和石油醚(280mL)混合溶液打浆，抽滤，滤液用Flash分离(乙酸乙酯/石油醚＝1:1)，得到(R)-N-(6-氯-3-(甲基亚磺酰基)吡啶-2-基)三甲基乙酰胺(28b)(51g,淡黄色固体)，ee值96.5％，产率72％。
1H NMR(400MHz,CDCl3)δ8.59(s,1H),8.11(d,J＝8.2Hz,1H),7.27(d,J＝8.2Hz,1H),2.94(s,3H),1.26(s,9H).
MS m/z[M+H]+:275.
步骤二：(R)-6-氯-3-(甲基亚磺酰基)-吡啶-2-氨(28c)的合成
将(R)-N-(6-c氯-3-(甲基亚磺酰基)吡啶-2-基)三甲基乙酰胺(28b)(50.2g,0.183mol)加入3N盐酸水溶液(610mL,1.832mol)中，50℃搅拌5小时。冰浴下，用碳酸钾水溶液(40％)调pH＝9～10，水相用乙酸乙酯萃取，合并有机相，用饱和食盐水洗，无水硫酸钠干燥。浓缩后用二氯甲烷/石油醚(2:3,100mL)混合溶液打浆，抽滤，滤饼用石油醚淋洗，得到(R)-6-氯-3-(甲基亚磺酰基)-吡啶-2-氨(28c)(28.7g,白色固体)，ee值98.2％，产率80％。
1H NMR(400MHz,CDCl3)δ7.42(d,J＝7.8Hz,1H),6.69(d,J＝7.8Hz,1H),6.07(s,2H),2.89(s,3H).
MS m/z[M+H]+:191.
步骤三：(R)-6-氯-3-(S-甲基亚砜亚胺基)吡啶-2-氨(28d)的合成
合成方法参考3-(S-甲基亚砜亚胺基)-2-硝基吡啶的合成，产率70％。
1H NMR(400MHz,CDCl3)δ7.98(d,J＝8.1Hz,1H),6.76(d,J＝8.1Hz,1H),6.35(s,2H),3.11(s,3H),2.46(s,1H).
MS m/z[M+H]+:206.
步骤四：(R)-6-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-氨(28e)的合成
将(R)-6-氯-3-(S-甲基亚砜亚胺基)吡啶-2-氨(28d)(11.63g,56.7mmol)、甲基硼酸(8.16g,136.1mmol)和乙酸铜(15.5g,85mmol)溶于无水DMF(69mL)和吡 啶(46mL)的混合溶液中，氧气氛围下80℃反应4小时。反应液降至室温，抽滤，滤饼用乙酸乙酯淋洗，滤液加水(200mL)和氨水(60mL)，用乙酸乙酯萃取，合并有机相，用饱和食盐水洗，无水硫酸钠干燥。浓缩后柱层析分离(乙酸乙酯/石油醚＝40–50％)，得到(R)-6-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-氨(28e)(8.69g,浅黄色固体)，ee值98.2％，产率70％。
1H NMR(400MHz,CDCl3)δ7.91(d,J＝8.0Hz,1H),6.78(d,J＝8.1Hz,1H),6.26(s,2H),3.07(s,3H),2.68(s,3H).
MS m/z[M+H]+:220.
步骤五：(R)-6-氯-4-((6-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(28f)的合成
合成方法参考6-氯-4-((6-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的合成，产率79％。
1H NMR(400MHz,DMSO-d6)δ12.21(s,1H),9.32(s,1H),8.78(s,1H),8.22(d,J＝8.1Hz,1H),7.42(d,J＝8.1Hz,1H),3.24(s,3H),2.68(s,3H).
MS m/z[M+H]+:393.
步骤六：(R)-6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-6-((二苯基亚甲基)氨基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(28g)的合成
合成方法参考6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-6-((二苯基亚甲基)氨基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的合成，产率68％。
MS m/z[M+H]+:538.
步骤七：(R)-6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-6-((二苯基亚甲基)氨基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(28h)的合成
合成方法参考6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-6-((二苯基亚甲基)氨基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的合成，产率91％。
MS m/z[M+H]+:586.
步骤八：(R)-4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺(28i)的合成
合成方法参考4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺的合成，产率69％。
1H NMR(400MHz,DMSO-d6)δ11.55(s,1H),11.30(s,1H),9.50(s,1H),8.98(s,1H),7.73(d,J＝8.6Hz,1H),6.54(s,2H),6.23(d,J＝8.6Hz,1H),3.05(s,3H),2.61(s,3H),2.14–2.05(m,1H),0.90–0.82(m,4H).
MS m/z[M+H]+:422.
步骤九：(R)-4-((6-氨基-5-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙基甲酰基)-N-(甲基-d3)哒嗪-3-甲酰胺(28)的合成
合成方法参考4-(6-氨基-5-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙烷甲酰胺基)-N-甲基哒嗪-3-甲酰胺的合成，ee值98.2％，产率50％。
1H NMR(400MHz,DMSO-d6)δ11.59(s,1H),11.34(s,1H),9.43(s,1H),9.01(s,1H),7.78(s,1H),6.86(s,2H),3.12(s,3H),2.61(s,3H),2.15–2.06(m,1H),0.85(d,J＝6.1Hz,4H).
MS m/z[M+H]+:456.
手性片断(R)-6-氯-3-(甲基亚磺酰基)-吡啶-2-氨(28c)的不对称合成也可通过以下路线实现：
步骤一：(R)-3,6-二氯-N-(1-(4-甲氧基苯基)乙基)-2-吡啶甲酰胺(28j)的合成
将3,6-二氯-2-吡啶甲酸(5g,26.04mmol)溶于无水DMF(20mL)中，分批加入N,N-羰基二咪唑(4.64g,28.65mmol)，加毕室温搅拌20分钟。反应液降温至0℃，滴加(R)-(+)-1-(4-甲氧基苯)乙胺(4.33g,28.65mmol)，控制内温小于10℃，滴加完毕后室温继续搅拌1.5小时。加水(60mL)淬灭反应，并继续搅拌1小时，抽滤，滤饼用蒸馏水淋洗。将滤饼溶于二氯甲烷中，用1％HCl洗涤，无水硫酸钠干燥。浓缩后得到(R)-3,6-二氯-N-(1-(4-甲氧基苯基)乙基)-2-吡啶甲酰胺(28j)(7.77g,白色固体)，产率92％。
1H NMR(400MHz,CDCl3)δ7.80(d,J＝7.3Hz,1H),7.76(d,J＝8.4Hz,1H),7.39–7.31(m,3H),6.90(d,J＝8.5Hz,2H),5.28–5.20(m,1H),3.81(s,3H),1.61(d,J＝6.9Hz,3H).
MS m/z[M+H]+:325.
步骤二：(R)-6-氯-N-(1-(4-甲氧基苯基)乙基)-3-(甲硫基)-2-吡啶甲酰胺(28k)的合成
将(R)-3,6-二氯-N-(1-(4-甲氧基苯基)乙基)-2-吡啶甲酰胺(28j)(7.2g,22.15mmol)溶于DMF(35mL)中，室温条件下缓慢滴入20％甲硫醇钠水溶液(11.6g,33.23mmol)，滴加完后室温下继续搅拌1小时。加水(100mL)淬灭反应，室温搅拌2小时，抽滤，滤饼用蒸馏水淋洗。将滤饼溶于二氯甲烷，使用饱和盐水洗涤，无水硫酸钠干燥.浓缩后柱层析分离(乙酸乙酯:石油醚＝1:1)，得到(R)-6-氯-N-(1-(4-甲氧基苯基)乙基)-3-(甲硫基)-2-吡啶甲酰胺(28k)(4.84g,白色固体)，产率65％。
1H NMR(400MHz,CDCl3)δ8.03(d,J＝7.5Hz,1H),7.58(d,J＝8.4Hz,1H),7.41–7.29(m,3H),6.89(d,J＝8.0Hz,2H),5.31–5.19(m,1H),3.80(s,3H),2.40(s,3H),1.60(d,J＝7.6Hz,3H).
MS m/z[M+H]+:337.
步骤三：6-氯-N-((R)-1-(4-甲氧基苯基)乙基)-3-((R)-甲基亚磺酰基)-2-吡啶甲酰胺(28l)的合成
合成方法参考(R)-N-(6-氯-3-(甲基亚磺酰基)吡啶-2-基)三甲基乙酰胺的合成，后处理使用乙醇进行重结晶，产率64％，d.e.值99.9％。
1H NMR(400MHz,CDCl3)δ8.55(d,J＝8.3Hz,1H),7.97(d,J＝8.0Hz,1H),7.63(d,J＝8.2Hz,1H),7.24(d,J＝8.5Hz,2H),6.83(d,J＝8.4Hz,2H),5.17–5.07(m,1H),3.73(s,3H),2.87(s,3H),1.55(d,J＝6.9Hz,3H).
MS m/z[M+H]+:353.
步骤四：(R)-6-氯-3-(甲基亚磺酰基)-2-吡啶甲酰胺(28m)的合成
将6-氯-N-((R)-1-(4-甲氧基苯基)乙基)-3-((R)-甲基亚磺酰基)-2-吡啶甲酰胺(28l)(6.0g，17.05mmol)溶于三氟乙酸(20mL)中，40℃搅拌1.5小时。减压蒸除溶剂，并加入二氯甲烷(50mL)稀释。将混合液缓慢滴入到饱和碳酸氢钠溶液 (100mL)中，水相使用二氯甲烷萃取，合并有机相，用饱和盐水洗涤，无水硫酸钠干燥。浓缩后，使用二氯甲烷/石油醚的混合溶液(1:10,100mL)打浆，抽滤得(R)-6-氯-3-(甲基亚磺酰基)-2-吡啶甲酰胺(28l)(3.4g,白色固体)，产率92％。
1H NMR(400MHz,CDCl3)δ8.65(d,J＝8.3Hz,1H),7.81–6.76(m,2H),6.03(s,1H),2.92(s,3H).
MS m/z[M+H]+:219.
步骤五：(R)-6-氯-3-(甲基亚磺酰基)-吡啶-2-氨(28c)的合成
将(R)-6-氯-3-(甲基亚磺酰基)-2-吡啶甲酰胺(28l)(55g，0.252mol)溶于二氧六环(250mL)中，加入预冷至0℃的10％氢氧化钠水溶液(250mL)，室温下滴加7.5％的次氯酸钠水溶液(180g,0.378mol)，加毕70℃搅拌1小时。将反应液降至室温，滴入饱和亚硫酸钠溶液(10mL)淬灭反应，直到淀粉碘化钾试纸不变色，加入饱和食盐水稀释。使用乙酸乙酯萃取，合并有机相，饱和盐水洗涤，无水硫酸钠干燥。浓缩后加入二氯甲烷(100mL)和石油醚(100mL)打浆，抽滤并使用石油醚淋洗，干燥后得到(R)-6-氯-3-(甲基亚磺酰基)-吡啶-2-氨(28c)(39.4g,白色固体)，产率82％。
1H NMR(400MHz,CDCl3)δ7.42(d,J＝7.8Hz,1H),6.69(d,J＝7.8Hz,1H),6.07(s,2H),2.89(s,3H).
MS m/z[M+H]+:191.
实施例29：(R)-4-((6-氨基-5-氯-3-(S-甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺的制备
步骤一：6-氯-3-(S-甲基-N-(4-硝基苯磺酰基)-亚砜亚胺基)吡啶-2-氨(29a)的合成
将N,N-(二叔丁氧羰基)-6-氯-3-(S-甲基亚砜亚胺基)吡啶-2-氨(6d)(2.05g,5.06mmol)溶于无水吡啶(30mL)中，室温缓慢加入对硝基苯磺酰氯(1.34g,6.07mmol)，继续搅拌2小时。加水(60mL)淬灭反应，用乙酸乙酯萃取，合并有机相，分别使用1N盐酸、饱和食盐水洗，无水硫酸钠干燥，浓缩后得粗品(黄色固体，3.3g)。
将粗品溶于二氯甲烷(10mL)中，冰水浴下加入4M氯化氢的二氧六环溶液(10mL)，室温搅拌1小时。浓缩后加水稀释，用饱和碳酸钾溶液调节pH＝8～9，使用乙酸乙酯萃取。合并有机相，无水硫酸钠干燥，浓缩后Flash分离(乙酸乙酯:石油醚＝1:1)，得6-氯-3-(S-甲基-N-(4-硝基苯磺酰基)-亚砜亚胺基)吡啶-2-氨(29a)(1.68g,黄色固体)，产率85％。
1H NMR(400MHz,DMSO-d6)δ8.34(d,J＝8.8Hz,2H),8.00(d,J＝8.8Hz,2H),7.89(d,J＝8.3Hz,1H),7.28(s,2H),6.82(d,J＝8.3Hz,1H),3.65(s,3H).
MS m/z[M+H]+:391.
步骤二：6-氯-4-((6-氯-3-(S-甲基-N-(4-硝基苯磺酰基)亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(29b)的合成
合成方法参考6-氯-4-((6-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的合成，产率50％。
1H NMR(400MHz,DMSO-d6)δ12.29(s,1H),9.50(s,1H),8.71(s,1H),8.38(d,J＝8.4Hz,1H),8.20(d,J＝8.6Hz,2H),7.93(d,J＝8.7Hz,2H),7.54(d,J＝8.3Hz,1H),3.82(s,3H).
MS m/z[M+H]+:563.
步骤三：6-氯-4-((6-((二苯基亚甲基)氨基)-3-(S-甲基-N-((4-硝基苯磺酰基)亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(29c)的合成
合成方法参考6-氯-4-((3-(N,S-二甲基亚砜亚胺基)-6-((二苯基亚甲基)氨基)吡啶-2-基)氨基)-N-甲基哒嗪-3-甲酰胺的合成，溶剂用二氧六环代替DMF，反应温度为110℃，产率25％。
1H NMR(400MHz,DMSO-d6)δ11.89(s,1H),9.40(s,1H),8.27(s,1H),8.21(d,J＝8.5Hz,1H),8.03(d,J＝8.4Hz,2H),7.68(d,J＝8.4Hz,2H),7.59–7.45(m,10H),6.98(d,J＝8.5Hz,1H),3.76(s,3H).
MS m/z[M+H]+:708.
步骤四：6-(环丙甲酰胺基)-4-((6-((二苯基亚甲基)氨基)-3-(S-甲基-N-((4-硝基苯磺酰基)亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(29d)的合成
合成方法参考6-(环丙烷甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的合成，反应完成处理后未进行分离，粗品直接进行下一步。
MS m/z[M+H]+:757.
步骤五：4-((6-氨基-3-(S-甲基-N-(4-硝基苯磺酰基)-亚亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺(29e)的合成
合成方法参考4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺的合成，使用29d粗品代替6-(环丙甲酰胺基)-4-((3-(N,S-二甲基亚砜亚胺基)-6-((二苯基亚甲基)氨基)吡啶-2-基)氨基)-N- 甲基哒嗪-3-甲酰胺，两步产率43％。
MS m/z[M+H]+:593.
步骤六：(R)-4-((6-氨基-5-氯-3-(S-甲基亚亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺(29)的合成
向4-((6-氨基-3-(S-甲基-N-(4-硝基苯磺酰基)-亚亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺(29e)(1.1g,1.86mmol)的无水DMF(20mL)溶液中加入NCS(248mg,1.86mmol)，60℃搅拌1小时。降至室温后，向反应液中加入饱和亚硫酸钠水溶液(10mL)和水(80mL)淬灭反应，搅拌10分钟后抽滤。滤饼用水淋洗，干燥后用二氯甲烷打浆，过滤得氯代粗产品(380mg，土黄色固体)。
向对甲氧基苯硫酚(2.18g,15.6mmol)的乙腈(5mL)溶液中加入氢氧化钾(851mg,15.2mmol)的水溶液(1mL)，搅拌5分钟后，加入氯代粗产品(380mg)，室温下继续搅拌1小时。加入饱和碳酸钾溶液淬灭反应，用乙酸乙酯萃取，合并有机相，使用无水硫酸钠干燥。浓缩后Flash分离(甲醇:二氯甲烷＝1:10)，得到4-((6-氨基-5-氯-3-(S-甲基亚亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺外消旋化合物(250mg，黄色固体)，产率30％。外消旋化合物进行SFC手性拆分，得到(S)-4-((6-氨基-5-氯-3-(S-甲基亚亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺(29f)(85mg,白色固体,产率10％)和(R)-4-((6-氨基-5-氯-3-(S-甲基亚亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺(29)(85mg,淡黄色固体,产率10％)。
29f:1H NMR(400MHz,DMSO-d6)δ11.70(s,1H),11.36(s,1H),9.41(s,1H),9.04(s,1H),7.87(s,1H),6.83(s,2H),4.50(s,1H),3.09(s,3H),2.17–2.06(m,1H),0.85(d,J＝6.0Hz,4H).
MS m/z[M+H]+:442.
29:1H NMR(400MHz,DMSO-d6)δ11.71(s,1H),11.36(s,1H),9.41(s,1H),9.04(s,1H),7.87(s,1H),6.83(s,2H),4.50(s,1H),3.09(s,3H),2.17–2.06(m,1H),0.85(d,J＝5.2Hz,4H).
MS m/z[M+H]+:442.
实施例30：(R)-4-((6-氨基-5-溴-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙基甲酰基)-N-(甲基-d3)哒嗪-3-甲酰胺(30)的制备
将(R)-4-((6-氨基-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺(28i)(7.95g,18.9mmol)溶于NMP(48mL)中，冰浴冷却下分批加入NBS(3.38g,19mmol)，冰浴下搅拌半小时。反应毕，冰浴下加入Na2SO3饱和水溶液(6.5mL),搅拌10分钟，分批加入冰水(500mL)，析出固体，搅拌1小时。抽滤，水(50mL)漂洗滤饼。将滤饼溶于DCM/MeOH(10/1,300mL)，无水硫酸钠干燥，过滤，浓缩。EtOH/DCM(1/10,30mL)打浆，得5.2g灰白色固体。母液拌硅胶，柱层析(甲醇/二氯甲烷＝2～5％)，得4.3g,白色固体。合并两批固体，加入EA(97mL)，油浴75度，加热半小时，慢慢降至室温，抽滤，得8.15g灰白色固体。收率86％。
1H NMR(400MHz,DMSO-d6)δ11.60(s,1H),11.35(s,1H),9.46(s,1H),9.02(s,1H),7.89(s,1H),6.77(s,2H),3.12(s,3H),2.60(s,3H),2.14-2.06(m,1H),0.85(d,J＝6.5Hz,4H).
MS m/z[M+H]+:500.
实施例31：6-(环丙甲酰胺基)-4-((5-(N,S-二甲基亚砜亚胺基)-1H-吡咯并[2,3-b]吡啶-6-基)氨基)-N-甲基哒嗪-3-甲酰胺的制备
步骤一：6-(环丙甲酰胺基)-4-((5-(N,S-二甲基亚砜亚胺基)-1H-吡咯并[2,3-b]吡啶-6-基)氨基)-N-甲基哒嗪-3-甲酰胺(31)的合成
2-(2-乙氧基乙烯基)-4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷的合成参考WO2012/010538,2012,A2。
将4-((6-氨基-5-溴-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙甲酰胺基)-N-甲基哒嗪-3-甲酰胺(24)(12mg,0.0241mmol)、2-(2-乙氧基乙烯基)-4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷(5.7mg,0.0290mmol)、Pd(dppf)Cl2(1.8mg,0.00241mmol)、一水合氢氧化锂(3.0mg,0.0723mmol)溶于无水DMF(0.5mL)中，氮气氛围下70℃搅拌1小时。反应液降至室温，加入25％的盐酸水溶液(53mg)，50℃反应1小时。加水淬灭反应，乙酸乙酯萃取，饱和食盐水洗，无水硫酸钠干燥。浓缩后Flash分离(甲醇/二氯甲烷＝4–7％)后，prep-HPLC制备得6-(环丙甲酰胺基)-4-((5-(N,S-二甲基亚砜亚胺基)-1H-吡咯并[2,3-b]吡啶-6-基)氨基)-N-甲基哒嗪-3-甲酰胺(31)(1.2mg,黄色固体)，产率11％。
1H NMR(400MHz,DMSO-d6)δ11.93(s,1H),11.66(s,1H),11.33(s,1H),9.11(s,1H),9.04(d,J＝5.0Hz,1H),8.48(s,1H),7.48(d,J＝3.4Hz,1H),6.62(d,J＝3.4Hz,1H),3.14(s,3H),2.84(d,J＝4.6Hz,3H),2.67(s,3H),2.12–2.04(m,1H),0.90–0.73(m,4H).
MS m/z[M+H]+:443.
实施例32：4-((3-氯-5-(N,S-二甲基亚砜亚胺基)-1H-吡咯并[2,3-b]吡啶-6-基)氨基)-6-(环丙基酰胺基)-N-甲基哒嗪-3-甲酰胺的制备
将6-(环丙甲酰胺基)-4-((5-(N,S-二甲基亚砜亚胺基)-1H-吡咯并[2,3-b]吡啶-6-基)氨基)-N-甲基哒嗪-3-甲酰胺(31)(16mg,0.0362mmol)溶于DMF(0.5mL)中，室温下加入NCS(6mg,0.0434mmol)，80℃搅拌1.5小时，降至室温，反应 液直接prep-HPLC制备得4-((3-氯-5-(N,S-二甲基亚砜亚胺基)-1H-吡咯并[2,3-b]吡啶-6-基)氨基)-6-(环丙基酰胺基)-N-甲基哒嗪-3-甲酰胺(32)(5.3mg,淡黄色固体)，产率31％。
1H NMR(400MHz,DMSO-d6)δ12.24(s,1H),11.74(s,1H),11.38(s,1H),9.14(s,1H),9.09(d,J＝4.6Hz,1H),8.35(s,1H),7.71(s,1H),3.19(s,3H),2.84(d,J＝4.5Hz,3H),2.67(s,3H),2.13–2.05(s,1H),0.92–0.74(m,4H).
MS m/z[M+H]+:477.
实施例33：6-(环丙基酰胺基)-4-((2,3-二氯-5-(N,S-二甲基亚砜亚胺基)-1H-吡咯并[2,3-b]吡啶-6-基)氨基)-N-甲基哒嗪-3-甲酰胺的制备
将6-(环丙甲酰胺基)-4-((5-(N,S-二甲基亚砜亚胺基)-1H-吡咯并[2,3-b]吡啶-6-基)氨基)-N-甲基哒嗪-3-甲酰胺(31)(21mg,0.0475mmol)溶于DMF(1mL)中，室温下加入NCS(14mg,0.104mmol)，80℃搅拌1小时，降至室温，加水淬灭反应，乙酸乙酯萃取，饱和食盐水洗，无水硫酸钠干燥，浓缩后Flash分离(甲醇/二氯甲烷＝3～5％)后，prep-HPLC制备得6-(环丙基酰胺基)-4-((2,3-二氯-5-(N,S-二甲基亚砜亚胺基)-1H-吡咯并[2,3-b]吡啶-6-基)氨基)-N-甲基哒嗪-3-甲酰胺(33)(1.0mg,棕黄色固体)，产率4％。
1H NMR(400MHz,DMSO-d6)δ13.29(s,1H),11.74(s,1H),11.37(s,1H),9.05(s,2H),8.27(s,1H),3.18(s,3H),2.84(d,J＝4.7Hz,3H),2.66(s,3H),2.09(s,1H),0.90–0.79(m,4H).
MS m/z[M+H]+:511.
实施例34：4-((3-溴-5-(N,S-二甲基亚砜亚胺基)-1H-吡咯并[2,3-b]吡啶-6-基)氨基)-6-(环丙基酰胺基)-N-甲基哒嗪-3-甲酰胺的制备
将6-(环丙甲酰胺基)-4-((5-(N,S-二甲基亚砜亚胺基)-1H-吡咯并[2,3-b]吡啶-6-基)氨基)-N-甲基哒嗪-3-甲酰胺(31)(67mg,0.151mmol)溶于二氯甲烷(2mL)中，室温下加入NBS(26.6mg,0.151mmol)，室温搅拌2小时，旋干溶剂，Flash分离(甲醇/二氯甲烷＝2～5％)，得到4-((3-溴-5-(N,S-二甲基亚砜亚胺基)-1H-吡咯并[2,3-b]吡啶-6-基)氨基)-6-(环丙基酰胺基)-N-甲基哒嗪-3-甲酰胺(34)(60mg,黄色固体)，产率76％。
1H NMR(400MHz,DMSO-d6)δ12.29(s,1H),11.73(s,1H),11.37(s,1H),9.14(s,1H),9.08(d,J＝4.7Hz,1H),8.27(s,1H),7.73(s,1H),3.19(s,3H),2.84(d,J＝4.7Hz,3H),2.67(s,3H),2.18–2.02(m,1H),0.89–0.75(m,4H).
MS m/z[M+H]+:521.
实施例35：(R)-4-((6-氨基-5-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙基甲酰基)-N-(甲基-d3)哒嗪-3-甲酰胺草酸盐的制备
将(R)-4-((6-氨基-5-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙基甲酰基)-N-(甲基-d3)哒嗪-3-甲酰胺(28)(100mg，0.22mmol)溶于DCM/MeOH(9:1,6mL)中，加入二水合草酸(27mg,0.22mmol)的甲醇溶液(0.2mL)室温搅拌10min。减压蒸除溶剂，并加入DCM/THF(1:1,3mL)。析出固体，抽滤，DCM/THF(1:1,1mL)漂洗，PE(3mL)漂洗。得到72mg淡黄色固体。收 率56.7％。
1H NMR(400MHz,DMSO-d6)δ11.61(s,1H),11.36(s,1H),9.43(s,1H),9.04(s,1H),7.79(s,1H),6.90(s,2H),3.14(s,3H),2.62(s,3H),2.15-2.07(m,1H),0.86(d,J＝6.4Hz,4H).
实施例36：(R)-4-((6-氨基-5-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙基甲酰基)-N-(甲基-d3)哒嗪-3-甲酰胺盐酸盐的制备
将(R)-4-((6-氨基-5-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙基甲酰基)-N-(甲基-d3)哒嗪-3-甲酰胺(28)(500mg，1.10mmol)加入MeCN(5mL)中，悬浊液状态。室温下滴入37％HCl aq.(271mg,2.75mmol),置于85℃油浴中加热至回流，滴入水(2mL)，回流状态下溶清。然后置于室温搅拌1h。固体析出，抽滤，滤饼用MeCN漂洗(1mL*2),滤饼50℃减压干燥，得到黄色固体336mg。收率57.9％。
1H NMR(400MHz,DMSO-d6)δ12.03(s,1H),11.92(s,1H),9.49(s,1H),9.23(s,1H),7.92(s,1H),7.86(s,2H),3.92(s,3H),2.83(s,3H),2.21-2.14(m,1H),0.90(d,J＝6.7Hz,4H).
实施例37：(R)-4-((6-氨基-5-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙基甲酰基)-N-(甲基-d3)哒嗪-3-甲酰胺硫酸盐的制备
将(R)-4-((6-氨基-5-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙基甲酰基)-N-(甲基-d3)哒嗪-3-甲酰胺(28)(500mg，1.10mmol)加入THF(5mL)中，悬浊液状态。室温下滴入20％H2SO4aq.(646mg,1.32mmol),置于70℃油浴中回流状态下滴入水(0.5mL),回流状态下溶清，然后置于室温环境搅拌1h，固体析出，抽滤，滤饼用THF漂洗(1mL*2),滤饼50℃减压干燥，得到黄色固体495mg。Y＝81.5％,HPLC:99.0％
1H NMR(400MHz,DMSO-d6)δ11.81(s,1H),11.45(s,1H),9.33(s,1H),9.29(s,1H),7.89(s,1H),7.62(s,2H),3.90(s,3H),2.85(s,3H),2.16-2.08(m,1H),0.87(d,J＝6.7Hz,4H).
实施例38：(R)-4-((6-氨基-5-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙基甲酰基)-N-(甲基-d3)哒嗪-3-甲酰胺甲磺酸盐的制备
将(R)-4-((6-氨基-5-氯-3-(N,S-二甲基亚砜亚胺基)吡啶-2-基)氨基)-6-(环丙基甲酰基)-N-(甲基-d3)哒嗪-3-甲酰胺(28)(100mg，0.22mmol)溶于DCM/MeOH(9:1,6mL)中，加入甲基磺酸(42mg,0.44mmol)室温搅拌10min。减压蒸除溶剂，并加入DCM/THF(1:1,3mL)。析出固体，抽滤，DCM/THF(1:1,1mL)漂洗，PE(3mL)漂洗。得到110mg黄色固体。收率:77.4％。
1H NMR(400MHz,DMSO-d6)δ11.82(s,1H),11.47(s,1H),9.34(s,1H),9.30(s,1H),7.90(s,1H),7.63(s,2H),3.91(s,3H),2.86(s,3H),2.35(d,J＝1.0Hz,6H),2.12(d,J＝5.7Hz,1H),0.88(d,J＝6.7Hz,4H).
实施例39：6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((3-(S-甲基-N-(甲基-d3)亚砜亚胺基)吡啶-2-基)氨基)哒嗪-3-甲酰胺的制备
合成方法使用CD3I代替MeI参照实施例1和实施例2进行制备。
1H NMR(400MHz,dmso)δ11.86(s,1H),11.37(s,1H),9.46(s,1H),9.06(s,1H),8.53(d,J＝4.0Hz,1H),8.22(d,J＝7.6Hz,1H),7.32-7.24(m,1H),3.21(s,3H),2.09(dd,J＝13.2,7.3Hz,1H),0.85(d,J＝6.7Hz,4H).
MS m/z[M+H]+:410.
实施例40:(R)-4-((6-氨基-5-氯-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺的制备
步骤一：(R)-6-氯-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-氨(40a)的合成
(R)-6-氯-3-(S-甲基亚砜亚胺基)吡啶-2-氨(28d)(29.7g,144.88mmol),溶于600mL四氢呋喃，加入NaI(2.18g，14.5mmol)，水浴下分批加入叔丁醇钠(13.91g，144.88mmol)，搅拌20min后滴入溶有CD3I(21g，144.88mmol)的四氢呋喃(50mL)溶液，滴完室温搅拌过夜。反应液滴入饱和氯化铵溶液淬灭，加水稀释，分液，水层用乙酸乙酯萃取，合并有机相，浓缩后加入乙酸乙酯溶解，分液，水层用乙酸乙酯萃取，合并有机相后加饱和食盐水洗，无水硫酸钠干燥，浓缩后柱层析分离(石油醚：乙酸乙酯＝2：1)得(R)-6-氯-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-氨(22.5g，类白色固体)，产率70％。
1H NMR(400MHz,DMSO-d6)δ7.84(d,J＝8.0Hz,1H),7.24(s,2H),6.78(d,J＝8.0Hz 1H),3.09(s,3H).
MS m/z[M+H]+:223.
步骤二：(R)-6-氯-4-((6-氯-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(40b)的合成
(R)-6-氯-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-氨(40a)(36.7g，0.165mol)溶于1L四氢呋喃，N2保护下降温至0～5℃，分批加入NaH(19.8g，60％w/w，0.496mol)后搅拌25min，分批加入4,6-二氯-N-(甲基-d3)哒嗪-3-甲酰胺(41.3g，0.198mol)，搅拌15min后升温至70℃反应2h。冰浴下加入饱和氯化铵溶液淬灭，加水稀释，加乙酸乙酯萃取，分液，合并有机相用饱和食盐水洗，无水硫酸钠干燥。浓缩后加乙醇冷打浆30min，抽滤，滤饼用乙醇淋洗，抽干得(R)-6-氯-4-((6-氯-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(40.25g，61.8％)。
1H NMR(400MHz,DMSO-d6)δ12.23(s,1H),9.33(s,1H),8.79(d,J＝1.4Hz,1H),8.23(dd,J＝8.0,1.4Hz,1H),7.43(dd,J＝8.1,1.4Hz,1H),3.24(s,3H).
MS m/z[M+H]+:395
步骤三：(R)-6-氯-4-((6-((二苯亚甲基)氨基)-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(40c)的合成
N2氛围下往DMAC(400mL)中加入Pd2(dba)3(4.6g，0.005mol)、XantPhos(5.78g,0.01mol)、(R)-6-氯-4-((6-氯-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(40b)(40g，0.1mol)、K2CO3(34.5g，0.25mol)、二苯亚胺(27.6g，0.15mol)，130℃反应5h。冷却后加入饱和氯化铵溶液淬灭，加水稀释，加乙酸乙酯溶解，硅藻土过滤，乙酸乙酯淋洗滤饼。分液，水相用乙酸乙酯萃取，合并有机相用饱和食盐水洗，无水硫酸钠干燥，浓缩后加MTBE打浆30min，抽滤，滤饼用MTBE淋洗，抽干得(R)-6-氯-4-((6-((二苯亚甲基)氨基)-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(38g，69.5％)。
1H NMR(400MHz,DMSO-d6)δ11.96(s,1H),9.24(s,1H),8.48(s,1H),8.06(d,J＝8.2Hz,1H),7.43(m,10H),6.79(d,J＝8.0Hz,1H),3.16(s,3H).
MS m/z[M+H]+:540
步骤四：(R)-6-(环丙烷甲酰胺)-4-((6-((二苯亚甲基)氨基)-3-(S-甲基-N-(甲 基-d3)磺酰亚胺)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(40d)的合成
N2氛围下往二甲苯:DMAC＝10:1(33mL)中加入Pd2(dba)3(238mg，0.26mmol)、XantPhos(300mg,0.52mol)、(R)-6-氯-4-((6-((二苯亚甲基)氨基)-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(40c)(2.8g，5.19mmol)、K2CO3(1.79g，12.98mmol)、环丙酰胺(882mg，10.38mmol)，130℃反应2h。冷却后加入饱和氯化铵溶液淬灭，加水稀释，加二氯甲烷溶解，硅藻土过滤，二氯甲烷淋洗滤饼。分液，水相用二氯甲烷萃取，合并有机相用饱和食盐水洗，无水硫酸钠干燥，浓缩后加石油醚打浆10min，抽滤，滤饼用石油醚淋洗，抽干得(R)-6-(环丙烷甲酰胺)-4-((6-((二苯亚甲基)氨基)-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺粗品，未进行分离直接进行下一步反应。
MS m/z[M+H]+:589
步骤五：(R)-4-((6-氨基-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺(40e)的合成
将(R)-6-(环丙烷甲酰胺)-4-((6-((二苯亚甲基)氨基)-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(40d)粗品溶于四氢呋喃(30mL)，冰浴下加入12N HCl(0.6mL)，升至室温搅拌1.5h。加水稀释，加乙酸乙酯萃取，有机相加水洗，合并水层，缓慢加入10％碳酸钾溶液调pH值9～10，加甲醇:二氯甲烷＝10：1萃取，分液，合并有机相加饱和食盐水洗，无水硫酸钠干燥，浓缩后加乙醇加热至回流，冰浴打浆20min，抽滤，滤饼用乙醇淋洗，抽干得(R)-4-((6-氨基-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺(1.4g，65％)
1H NMR(400MHz,DMSO-d6)δ11.56(s,1H),11.32(s,1H),9.51(s,1H),9.00(s,1H),7.75(d,J＝8.8Hz,1H),6.55(s,2H),6.24(d,J＝8.6Hz,1H),3.06(s,3H),2.15-2.03(m,1H),0.86(m,4H).
MS m/z[M+H]+:425
步骤六：(R)-4-((6-氨基-5-氯-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺(40)的合成
(R)-4-((6-氨基-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺(40e)(1.4g，3.30mmol)溶于DMAC(14mL)，N2保护下冰浴降温(0～5℃)，分批加入1,3-二氯-5,5-二甲基海因(683mg，3.47mmol)，反应15min。加冰水及饱和亚硫酸钠溶液淬灭，抽滤，滤饼用水淋洗后加二氯甲烷:甲醇＝10:1溶解，分液，有机相用饱和食盐水洗，无水硫酸钠干燥，浓缩后Flash分离(甲醇/二氯甲烷＝3％)，得到(R)-4-((6-氨基-5-氯-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺(669mg，类白色固体)，产率44％。
1H NMR(400MHz,DMSO-d6)δ11.62(s,1H),11.37(s,1H),9.43(s,1H),9.04(s,1H),7.79(s,1H),6.89(s,2H),3.13(s,3H),2.16-2.07(m,1H),0.87(m,4H).
MS m/z[M+H]+:459
实施例41：(R)-4-((6-氨基-5-溴-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺的制备
(R)-4-((6-氨基-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺(40e)(113mg，0.26mmol)溶于DMF(1.4mL)，N2保护下冰浴降温至0～5℃，加入NBS(50mg，0.28mmol)，反应30min。加饱和亚硫酸钠溶液淬灭，加水稀释，加乙酸乙酯萃取，分液，合并有机相加饱和食盐水洗，无水硫酸钠干燥，浓缩后Flash分离(甲醇/二氯甲烷＝3％)，得到(R)-4-((6-氨基-5-溴-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺(62mg，淡黄色固体)，产率46％。
1H NMR(400MHz,DMSO-d6)δ11.62(s,1H),11.37(s,1H),9.48(s,1H),9.04(s,1H),7.91(s,1H),6.79(s,2H),3.13(s,3H),2.12(s,1H),0.88(m,4H).
MS m/z[M+H]+:503
实施例42：(R)-4-((6-氨基-5-碘-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺的制备
(R)-4-((6-氨基-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺(40e)(2.1g，2.59mmol)溶于DMAC(6mL)，分批加入NIS(759mg，3.41mmol)，50℃反应1h。冰浴下加饱和亚硫酸钠溶液淬灭，加水稀释，加二氯甲烷：甲醇＝10：1萃取，分液，合并有机相加饱和食盐水洗，无水硫酸钠干燥，浓缩后Flash分离(甲醇/二氯甲烷＝3％)，得到(R)-4-((6-氨基-5-碘-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺(912mg，淡黄色固体)，产率64％。
1H NMR(400MHz,DMSO-d6)δ11.61(s,1H),11.37(s,1H),9.54(s,1H),9.04(s,1H),8.06(s,1H),6.60(s,2H),3.12(s,3H),2.17-2.07(m,1H),0.87(d,J＝6.0Hz,4H).
MS m/z[M+H]+:551
实施例43：(R)-4-((6-氨基-5-环丙基-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺的制备
N2气氛围下，(R)-4-((6-氨基-5-碘-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2- 基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺(42)(203mg,0.367mmol)溶于无水1.4-二氧六环(4mL)，加入环丙基硼酸(63mg,0.734mmol)、Pd(PPh3)4(81mg,0.07mmol)和K2CO3(127mg,0.92mmol)，微波(120℃,120W)反应2.5h。反应液降至室温后，硅藻土过滤，滤饼用二氯甲烷：甲醇＝10：1淋洗，滤液浓缩后Flash分离(甲醇/二氯甲烷＝7％)得(R)-4-((6-氨基-5-环丙基-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺(32mg，淡黄色固体)，产率18.7％。
1H NMR(400MHz,DMSO-d6)δ11.55(s,1H),11.32(s,1H),9.57(s,1H),8.99(s,1H),7.42(s,1H),6.49(s,2H),3.05(s,3H),2.12(s,1H),1.66(s,1H),0.88(m,6H),0.51(d,J＝4.4Hz,2H).
MS m/z[M+H]+:465
实施例44：(R)-4-((6-氨基-3-(S-甲基-N-(甲基-d3)磺酰亚胺)-5-乙烯基吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺的制备
N2气氛围下，(R)-4-((6-氨基-5-碘-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺(42)(103mg,0.187mmol)溶于无水1.4-二氧六环(2mL)，加入乙烯三氟硼酸钾(50mg,0.37mmol)、Pd(PPh3)4(46mg,0.04mmol)和K2CO3(52mg,0.37mmol)，微波(120℃,120W)反应1h。反应液降至室温后，硅藻土过滤，滤饼用二氯甲烷淋洗，滤液浓缩后Flash分离(甲醇/二氯甲烷＝3％)得(R)-4-((6-氨基-3-(S-甲基-N-(甲基-d3)磺酰亚胺)-5-乙烯基吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺(40mg，淡黄色固体)，产率47％。
1H NMR(400MHz,DMSO-d6)δ11.68(s,1H),11.36(s,1H),9.67(s,1H),9.02(s,1H),7.92(s,1H),6.81(dd,J＝17.6,10.6Hz,1H),6.59(s,2H),5.63(d,J＝16.9Hz,1H),5.25(d,J＝10.2Hz,1H),3.12(s,3H),2.12(s,1H),0.87(m,4H).
MS m/z[M+H]+:451
实施例45：(R)-4-((6-氨基-3-(S-甲基-N-(甲基-d3)磺酰亚胺)-5-(丙炔-1-基)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺的制备
(R)-4-((6-氨基-5-碘-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺(42)(100mg,0.182mmol)溶于DMF(2mL)，加入CuI(4mg,0.0182mmol)、Pd(PPh3)2Cl2(13mg,0.0182mmol)、KF(16mg,0.273mmol)和三乙胺(0.7mL)，N2氛围下加入溶有1-(三甲基硅基)丙炔(31mg，0.273mmol)的DMF溶液(0.5mL)50℃反应1h。反应液降至室温后，加饱和氯化铵溶液淬灭，加水稀释，二氯甲烷萃取，合并有机相，用饱和食盐水洗，无水硫酸钠干燥。浓缩后Flash分离(甲醇/二氯甲烷＝3％)得(R)-4-((6-氨基-3-(S-甲基-N-(甲基-d3)磺酰亚胺)-5-(丙炔-1-基)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺(64mg，黄色固体)，产率76％。
1H NMR(400MHz,DMSO-d6)δ11.67(s,1H),11.36(s,1H),9.55(s,1H),9.02(s,1H),7.71(s,1H),6.67(s,2H),3.10(s,3H),2.10(m,,4H),0.87(m,4H).
MS m/z[M+H]+:463
实施例46：(R)-4-((6-氨基-5-(环丙基乙炔基)-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺的制备
(R)-4-((6-氨基-5-碘-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺(42)(100mg,0.182mmol)溶于DMF(2mL)，加入CuI(4mg,0.0182mmol)、Pd(PPh3)2Cl2(13mg,0.0182mmol)、KF(16mg,0.273mmol)和三乙胺(0.7mL)，N2氛围下加入溶有环丙基(三甲基硅基)乙炔(38mg，0.273mmol)的DMF(0.5mL)溶液,室温搅拌过夜。反应液加饱和氯化铵溶液淬灭，加水稀释，二氯甲烷萃取，分液，合并有机相，用饱和食盐水洗，无水硫酸钠干燥。浓缩后Flash分离(甲醇/二氯甲烷＝3％)得(R)-4-((6-氨基-5-(环丙基乙炔基)-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺(74mg，淡黄色固体)，产率83％。
1H NMR(400MHz,DMSO-d6)δ11.68(s,1H),11.36(s,1H),9.56(s,1H),9.02(s,1H),7.70(s,1H),6.59(s,2H),3.10(s,3H),2.12(s,1H),1.56(s,1H),0.96-0.74(m,8H).
MS m/z[M+H]+:489
实施例47：(R)-4-((6-氨基-5-氯-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺盐酸盐的合成
将(R)-4-((6-氨基-5-氯-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺(200mg,0.44mmol)加入DMF(2mL)中室温搅拌，加入浓HCl(108mg,1.09mmol)，置于90℃油浴中搅拌5min，浑浊，加入乙腈(10mL),回流5min，悬浊液室温搅拌1.5h，抽滤，乙腈漂洗(0.5mL*2),滤饼50℃减压干燥1h，得到二盐酸盐，淡黄色固体：230mg，收率：99.2％。
1H NMR(400MHz,DMSO-d6)δ11.88(s,1H),11.82(s,1H),9.44(d,J＝2.2Hz,1H),9.24(s,1H),7.91(d,J＝2.6Hz,1H),7.77(s,2H),3.91(s,3H),2.21-2.11(m,1H),0.94-0.86(m,4H).
MS m/z[M+H]+:459
实施例48：(R)-4-((6-氨基-5-氯-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺硫酸盐的合成
将(R)-4-((6-氨基-5-氯-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺(200mg,0.44mmol)加入DMF(1mL)中室温搅拌，悬浊液，加入浓H2SO4(109mg,1.09mmol)，乙腈(1mL)室温搅拌溶解，置于90℃油浴中搅拌5min，加入乙腈(6mL),回流5min，固体析出，室温搅拌1.5h，抽滤，乙腈漂洗(0.5mL*2),滤饼50℃减压干燥1h，得到二硫酸盐，类白色固体：268mg，收率：93.8％。
1H NMR(400MHz,DMSO-d6)δ11.82(s,1H),11.46(s,1H),9.34(s,1H),9.30(s,1H),8.92(s,4H),7.90(s,1H),7.64(s,2H),3.92(s,3H),2.15-2.08(m,1H),0.90-0.82(m,4H).
MS m/z[M+H]+:459
实施例49：(R)-4-((6-氨基-5-氯-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺甲磺酸盐的合成
将(R)-4-((6-氨基-5-氯-3-(S-甲基-N-(甲基-d3)磺酰亚胺)吡啶-2-基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺(200mg,0.44mmol)加入DMF(0.5mL)中室温搅拌，悬浊液，加入甲磺酸(105mg,1.09mmol)，乙腈(1mL)室温搅拌溶解，置于90℃油浴中搅拌5min，加入乙腈(8mL),回流5min，固体析出，室温搅拌1.5h，抽滤，乙腈漂洗(0.5mL*2),滤饼50℃减压干燥1h，得到二甲磺酸盐，类白色固体：268mg，收率：94.4％。
1H NMR(400MHz,DMSO-d6)δ11.82(s,1H),11.46(s,1H),9.34(s,1H),9.30(s,1H),7.90(s,1H),7.63(s,2H),3.92(s,3H),2.35(s,6H),2.17-2.09(m,,1H),0.90-0.82(m,4H).
MS m/z[M+H]+:459
生物学评价
测试例1：TYK2激酶活性抑制实验
1.1实验原理及目的
野生型鼠源B淋巴细胞(BaF3)引入TYK2激酶基因，构建Ba/F3-FL-TYK2-E957D稳定细胞株。Ba/F3-FL-TYK2-E957D的生长和增殖脱离IL-3的依赖,转而依赖外源转入的TYK2激酶。如果化合物选择性抑制TYK2激酶的活性,就会对此细胞株增殖产生抑制作用。
本实验测试化合物对Ba/F3-FL-TYK2-E957D细胞增殖的抑制作用，检测细胞的凋亡情况，计算出IC50值。根据IC50大小评价化合物对TYK2激酶的抑制活性。
1.2实验方法
1.2.1储备液配制
受试化合物，粉末于常温保存，用DMSO配制成10mM储备液，-20℃避光保存待用。
1.2.2实验步骤
配制化合物
将化合物配成终浓度1000倍的稀释溶液。用培养基稀释化合物，配成终浓度20倍的化合物。每孔加2ul 1000倍的化合物到98ul培养基中。
铺板
将细胞(桑迪亚医药技术(上海)有限责任公司提供)用重悬，使用自动细胞计数器计数。根据BaF3播种密度，每孔2000个细胞，将细胞悬浮液稀释至所需密度。每个孔铺95ul细胞，37℃培养稳定平衡。每孔加5ul 20倍的化合物，以加入同样体积的DMSO的孔作为对照。37℃，5％CO2培养72小时。
检测
将细胞板平衡到室温。每孔加试剂，振2分钟，静置10分钟。用SpectraMax Paradigm检测。
数据分析
(1)使用GraphPad Prism 5计算IC50。
(2)％Inh＝(Max signal-Compound signal)/(Max signal-Min signal)x 100。
(3)Max signal为阳性对照孔，只有和化合物同等体积的DMSO。
(4)Min signal为阴性对照孔，只有培养基
结果见下表1
表1 本发明代表性化合物对TYK2激酶的抑制活性

其中，化合物BMS-986165的结构式为
测试结果表明，本发明提供的化合物具有优异的TYK2抑制活性，大部分化合物的TYK2抑制活性均优于阳性对照BMS-986165，IC50值达到pM级。特别是实施例28、实施例32、实施例40、实施例41、实施例42和实施例44比BMS-986165的TYK2抑制活性提高4到7倍，实施例45和实施例46比BMS-986165的TYK2抑制活性提高超过20倍。
测试例2：JAK家族激酶选择性实验
2.1实验原理及目的
JAK家族有4种激酶，分别为TYK2、JAK1、JAK2、JAK3。野生型鼠源B淋巴细胞(BaF3)引入JAK家族激酶基因，分别构建4种BaF3工程细胞株(Ba/F3-FL-TYK2-E957D、Ba/F3-TEL-JAK1、Ba/F3-TEL-JAK2、Ba/F3-TEL-JAK3)。此类工程细胞株的生长和增殖脱离IL-3的依赖,转而依赖外源转入的JAK家族激酶。如果化合物选择性抑制某个JAK激酶的活性,就会对相应的细胞株增殖产生抑制作用。
本实验测试化合物对Ba/F3-FL-TYK2-E957D、Ba/F3-TEL-JAK1、 Ba/F3-TEL-JAK2、Ba/F3-TEL-JAK3四种细胞增殖的抑制作用，检测细胞的凋亡情况，计算出IC50值。根据IC50大小评价化合物对TYK2、JAK1、JAK2、JAK3激酶的抑制活性，从而评估化合物的JAK家族激酶选择性。
2.2实验方法
2.2.1储备液配制
受试化合物，粉末于常温保存，用DMSO配制成10mM储备液，-20℃避光保存待用。
2.2.2实验步骤
配制化合物
将化合物配成终浓度1000倍的稀释溶液。用培养基稀释化合物，配成终浓度20倍的化合物。每孔加2ul 1000倍的化合物到98ul培养基中。
铺板
将细胞(桑迪亚医药技术(上海)有限责任公司提供)用重悬，使用自动细胞计数器计数。根据BaF3播种密度，每孔2000个细胞，将细胞悬浮液稀释至所需密度。每个孔铺95ul细胞，37℃培养稳定平衡。每孔加5ul 20倍的化合物，以加入同样体积的DMSO的孔作为对照。37℃，5％CO2培养72小时。
检测
将细胞板平衡到室温。每孔加试剂，振2分钟，静置10分钟。用SpectraMax Paradigm检测。
数据分析
(1)使用GraphPad Prism 5计算IC50。
(2)％Inh＝(Max signal-Compound signal)/(Max signal-Min signal)x 100。
(3)Max signal为阳性对照孔，只有和化合物同等体积的DMSO。
(4)Min signal为阴性对照孔，只有培养基
结果见下表2
表2 本发明代表性化合物对TYK2激酶的选择性

测试结果表明，本发明提供的化合物具有优异的TYK2抑制活性，同时对JAK1、JAK2、JAK3激酶均无抑制活性，JAK家族激酶选择性非常高。
现有JAK激酶抑制剂的基础研究和临床结果表明，非选择性激酶抑制剂带来严重的副作用，包括血栓、贫血和严重感染，因此，激酶亚型选择性差是下一代JAK抑制剂研发亟待克服的难点。而本发明化合物具有优异的激酶选择性，表现出很高的用药安全性。
测试例3：人类全血中IFN-α诱导的STAT磷酸化
3.1实验原理及目的
TYK2附着的细胞因子受体可介导1型干扰素(IFN-α)的信号传递，而IFN-α已被确认为自身免疫系统最重要的致炎因子。将人全血用IFN-α诱导，全血中淋巴细胞的TYK2引发STAT磷酸化，介导后续炎症信号。因此TYK2抑制剂对IFN-α的信号传递有抑制作用，TYK2抑制活性越强，STAT磷酸化水平越低，相应的抗炎作用越强。
本实验测试化合物对人类全血中IFN-α诱导的STAT磷酸化的抑制能力，计算出IC50值。根据IC50大小评价化合物对IFN-α炎症通路的抑制活性，在组织水平评估化合物的抗炎活性。
3.2.实验过程
3.2.1储备液配制
受试化合物，粉末于常温保存，用DMSO配制成10mM储备液，-80℃冰箱保存。
阳性对照化合物BMS-986165，粉末于常温保存，用DMSO配制成10mM储备液，-80℃冰箱保存。
3.2.2溶液的配制
1X Fix/Lysis溶液配制：将5X Fix/Lysis与ddH2O按照1：4稀释37℃孵箱预热，等待使用。
流式细胞染色缓冲液配制：向500mL磷酸盐缓冲液(PBS)中加入1g牛血清白蛋白(BSA)与1mL EDTA(0.5M)溶液，于4℃冰箱保存。
化合物稀释溶液：向500mL磷酸盐缓冲液(PBS)中加入0.5g牛血清白蛋白(BSA)，于4℃冰箱保存。
3.2.3实验步骤
化合物及细胞因子的准备
将10mM的受试化合物和阳性化合物BMS-986165用DMSO稀释成5mM的工作液，进一步用DMSO按3倍梯度稀释成8个浓度。将8浓度梯度的待测化合物和BMS-986165每个浓度点用化合物稀释液稀释25倍后，待用。
用化合物稀释液将50μg/mL IFN-alpha稀释到400ng/mL，待用。
人全血的处理
用300μL的电动排枪在96孔板中加入67.5μL的人全血。加入已准备好的受试化合物3.5μL，混匀后放入细胞培养箱中。60分钟孵育结束后，加入400ng/mL IFN-α(Biolegend 592702，终浓度为20ng/ml)。同样混匀后放入细胞培养箱中继续孵育15分钟。
细胞因子刺激后，每孔中加入5μl PE-CD3(BD 555333)抗体，混匀后继续在4度冰箱孵育。结束后，用排枪将全血转移至96孔的深孔板中，加入预热好的1X Fix/Lysis溶液，于37℃孵箱中裂解和固定细胞12分钟。洗涤，加入400μL的Perm III溶液，涡旋后冰上孵育30分钟。然后细胞经100μL的APC-pSTAT5(1：100)抗体常温染色50分钟。之后经流式仪器检测。在对CD3阳性信号群进行门控后，通过中位荧光强度定量pSTAT5的表达量。
结果见下表3
表3本发明代表性化合物对IFN-α炎症通路的抑制活性

测试结果表明，本发明提供的化合物对人类全血中IFN-α诱导的STAT磷酸化有很高抑制活性，表明本发明化合物能在组织水平强烈抑制IFN-α炎症通路。与对照BMS-986165相比，本发明表现出更好的IFN-α炎症通路抑制活性，特别是，实施例28和实施例29其抗炎活性提高了6倍左右。
测试例4：本发明化合物hERG钾通道抑制实验
4.1、实验目的
应用全自动膜片钳在转染hERG钾通道的稳定细胞株上测试本发明化合物对hERG钾电流的阻断作用。
4.2、实验方法
4.2.1、细胞准备
CHO-hERG细胞培养于175cm2培养瓶中，待细胞密度生长到60-80％，移走培养液，用7ml PBS(Phosphate Buffered Saline磷酸盐缓冲液)洗一遍，然后加入3ml Detachin消化。
待消化完全后加入7ml培养液中和，然后离心，移除上清液，再加入5ml培养液重悬，以确保细胞密度为2-5×106/ml。
4.2.2、溶液配制
4.2.3电生理记录过程
单细胞高阻抗封接和全细胞模式形成过程全部有Qpatch仪器自动完成，在获得记录模式后，细胞钳制在-80毫伏，在给予一个5秒的+40毫伏去极化刺激前，先给予一个50毫秒的-50毫伏前置电压，然后复极化到-50毫伏维持5秒，再回到-80毫伏。每15秒施加此电压刺激，记录2min后给予细胞外液记录5min，然后开始给药过程，化合物浓度从最低测试浓度开始，每个测试浓度给予2.5min，连续给完所有浓度后，给予阳性对照化合物3μM Cisapride。每个浓度至少测试3个细胞(n≥3)。
4.2.4、化合物准备
将20mM的化合物母液用细胞外液进行稀释，取5μL 20mM的化合物母液加入2495μL细胞外液，500倍稀释至40μM，然后在含0.2％DMSO的细胞外液中依次进行3倍连续稀释得到需要测试的最终浓度。
最高测试浓度为40μM，依次分别为40，13.33，4.44，1.48，0.49，0.16μM共6个浓度。
最终测试浓度中的DMSO含量不超过0.2％，此浓度的DMSO对hERG钾通道没有影响。
4.3、数据分析
实验数据由XLFit软件进行分析。
4.4、实验结果结果见下表4
表4本发明代表性化合物对hERG钾通道的抑制活性
测试结果表明，本发明提供的化合物没有hERG钾通道抑制活性，心脏毒性风险低。
测试例5：本发明化合物体内药代动力学实验
5.1大鼠体内药代动力学实验
实验方法：健康雄性SD大鼠，随机分组，每组3只，口服给予被试化合物。灌胃实验前禁食12h，自由饮水，给药后4h统一进食。给药前(0h)和后0.25，0.5，1.0，2.0，4.0，6.0，8.0和24h；在以上设定时间点经颈静脉取血0.2mL， 置EDTA-K2试管中，全血采集后暂存于冰水浴中，30min内11000rpm离心5min，分离血浆，于–70℃冰箱中冷冻待测。
测试例5.1结果：见下表5.1。
表5.1本发明代表性化合物大鼠代谢参数
5.2比格犬体内药代动力学实验
实验方法：健康雄性比格犬，随机分组，每组3只，口服给予被试化合物。灌胃实验前禁食12h，自由饮水，给药后4h统一进食。给药后0.083，0.25，0.5，1.0，2.0，4.0，6.0，8.0，10和24h；在以上设定时间点经前肢或后肢取血约600μL，置EDTA-K2试管中，全血采集后暂存于冰水浴中，30min内至少3500rpm离心10min，分离血浆，于–70℃冰箱中冷冻待测。
测试例5.2结果：见下表5.2。
表5.2本发明代表性化合物犬代谢参数
测试结果表明，本发明提供的化合物药物代谢性质良好，成药性好，其血浆暴露量(AUC)高。本发明提供的化合物大鼠和犬的口服生物利用度(F％)和血浆暴露量与BMS-986165相比有显著优势，表现出优异的口服吸收性质和优异的代谢特征。
测试例6：本发明化合物水中溶解度(pH＝7条件下)
测试例6结果：见下表6。
表6本发明代表性化合物溶解度
测试结果表明，本发明提供的化合物水溶解性质明显优于BMS-986165.
水溶解度是评价小分子口服药物成药性的重要指标。药物只有溶解才能通过胃肠吸收进入体循环。水溶性差的药物吸收缓慢，生物利用度低，影响血药浓度和药理作用的发挥，直接导致临床失败率高。本发明提供的化合物相比BMS-986165有着更高的溶解度，从而具有更好的口服吸收性质和成药性质。
在本发明提及的所有文献都在本申请中引用作为参考，就如同每一篇文献被单独引用作为参考那样。此外应理解，在阅读了本发明的上述讲授内容之后，本领域技术人员可以对本发明作各种改动或修改，这些等价形式同样落于本申请所附权利要求书所限定的范围。

Claims (10)

  1. 一种式(I)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、或其药学上可接受的盐，
    其中，R1选自下组：H、取代或未取代的C1-C6烷基、取代或未取代的C3-C6环烷基，所述取代指被选自下组的一个或多个取代基取代：氘、卤素；
    A为NH或CH2；
    B为CH或N；
    L选自下组：
    R2选自下组：H、-CD3、C1-C6烷基、C3-C6环烷基；
    X为CH或N；
    Y为NH、O或S；
    R3、R4、R5各自独立地选自下组：H、-NH2、-OH、C1-C6烷氧基、C1-C6烷基、卤代C1-C6烷基、C3-C6环烷基、-CONH2、-CN、卤素、-O(CH2)nR9、C2-C6烯基、C2-C6炔基、C3-C6环烷基取代的C2-C6炔基和-NR8(CH2)nR9；
    n为1、2、3、4或5；
    R9选自下组：-OH、C1-C6烷氧基、C4-C6环烷氧基、含1、2或3个选自N、O或S的杂原子的4-8元杂环基和-CN；
    R8为H或C1-C6烷基；
    R6、R7各自独立地选自下组：H、C1-C6烷基、卤素。
  2. 如权利要求1所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、或其药学上可接受的盐，其特征在于，R1为全氘代的C1-C6烷基；
    A为NH；
    B为CH或N。
  3. 如权利要求1所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、或其药学上可接受的盐，其特征在于，L为
    R2选自下组：H、-CD3、C1-C6烷基；
    X为N；
    R3、R4、R5各自独立地选自下组：H、-NH2、-OH、C1-C6烷氧基、C1-C6烷基、C3-C6环烷基、-CONH2、-CN、卤素、-O(CH2)nR9、C2-C6烯基、C2-C6炔基、C3-C6环烷基取代的C2-C6炔基、和-NR8(CH2)nR9；
    n为1、2、3、4或5；
    R9选自下组：C1-C6烷氧基、C4-C6环烷氧基、含1、2或3个选自N、O或S的杂原子的4-8元杂环基和-CN；
    R8为H或C1-C6烷基。
  4. 如权利要求1所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、或其药学上可接受的盐，其特征在于，R1为全氘代的C1-C6烷基；
    A为NH；
    B为N；
    L为
    R2选自下组：H、-CD3、C1-C6烷基；
    X为N；
    R3为-NH2；
    R4选自下组：卤素、C3-C6环烷基、C2-C6烯基、C2-C6炔基、C3-C6环烷基取代的C2-C6炔基；
    R5为H。
  5. 如权利要求1所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、或其药学上可接受的盐，其特征在于，R1为全氘代的C1-C6烷基；
    A为NH；
    B为N；
    L为
    R2为-CD3；
    X为N；
    R3为-NH2；
    R4选自下组：卤素、C3-C6环烷基、C2-C6烯基、C2-C6炔基、C3-C6环烷基取代的C2-C6炔基；
    R5为H。
  6. 如权利要求1所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、或其药学上可接受的盐，其特征在于，所述化合物选自下组：


  7. 一种权利要求1所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、或其药学上可接受的盐的制备方法，其特征在于，包括如下步骤：
    式I-c与环丙基酰胺反应得到式(I)化合物；
    其中，R1、A、B、L如权利要求1所定义；
    G为卤素。
  8. 一种药物组合物，其特征在于，包含药学上可接受的载体和一种或多种安全有效量的权利要求1所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式、或其药学上可接受的盐。
  9. 一种权利要求1所述的化合物或其互变异构体、内消旋体、外消旋体、 对映异构体、非对映异构体、或其混合物形式、或其药学上可接受的盐的用途，其特征在于，用于制备药物，所述药物用于预防和/或治疗由TYK2介导相关疾病。
  10. 如权利要求9所述用途，其特征在于，所述由TYK2介导相关疾病为哺乳动物体内炎性或自身免疫疾病。
PCT/CN2023/079387 2022-03-04 2023-03-02 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用 Ceased WO2023165574A1 (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2023227024A AU2023227024A1 (en) 2022-03-04 2023-03-02 Compounds used as TYK2 inhibitors, preparation method therefor, and pharmaceutical use thereof
KR1020247032854A KR20240158943A (ko) 2022-03-04 2023-03-02 Tyk2 억제제로 사용되는 화합물, 이의 제조 방법 및 이의 의약에서의 응용
JP2024552772A JP2025508011A (ja) 2022-03-04 2023-03-02 Ｔｙｋ２阻害剤として使用される化合物、その調製方法およびその医薬上の応用
CA3245417A CA3245417A1 (en) 2022-03-04 2023-03-02 COMPOUND USED AS A TYK2 INHIBITOR, ITS PREPARATION PROCESS AND PHARMACEUTICAL USE
CN202380025084.1A CN119317622A (zh) 2022-03-04 2023-03-02 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
EP23762972.0A EP4488268A4 (en) 2022-03-04 2023-03-02 COMPOUND USED AS A TYK2 INHIBITOR, ITS PREPARATION PROCESS AND PHARMACEUTICAL USE
US18/843,972 US20250179022A1 (en) 2022-03-04 2023-03-02 Compound used as tyk2 inhibitor, preparation method therefor, and pharmaceutical use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202210210857.0 2022-03-04
CN202210210857 2022-03-04
CN202310020684.0A CN116693449A (zh) 2022-03-04 2023-01-06 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
CN202310020684.0 2023-01-06

Publications (1)

Publication Number Publication Date
WO2023165574A1 true WO2023165574A1 (zh) 2023-09-07

Family

ID=87832804

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/079387 Ceased WO2023165574A1 (zh) 2022-03-04 2023-03-02 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用

Country Status (8)

Country Link
US (1) US20250179022A1 (zh)
EP (1) EP4488268A4 (zh)
JP (1) JP2025508011A (zh)
KR (1) KR20240158943A (zh)
CN (2) CN116693449A (zh)
AU (1) AU2023227024A1 (zh)
CA (1) CA3245417A1 (zh)
WO (1) WO2023165574A1 (zh)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110178053A1 (en) 2008-06-12 2011-07-21 Sanofi-Aventis Azacarboline derivatives, preparation method thereof and therapeutic use of same
WO2012010538A2 (en) 2010-07-21 2012-01-26 F. Hoffmann-La Roche Ag Novel processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
WO2014074660A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES
WO2014074661A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES
CN104159891A (zh) * 2012-01-10 2014-11-19 霍夫曼-拉罗奇有限公司 哒嗪酰胺化合物和它们作为syk 抑制剂的用途
WO2018075937A1 (en) 2016-10-21 2018-04-26 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
US20190152948A1 (en) 2017-11-21 2019-05-23 Bristol-Myers Squibb Company Sulfone pyridine alkyl amide-substituted heteroaryl compounds
WO2020086616A1 (en) 2018-10-22 2020-04-30 Fronthera U.S. Pharmaceuticals Llc Tyk2 inhibitors and uses thereof
WO2020156311A1 (zh) * 2019-01-28 2020-08-06 江苏豪森药业集团有限公司 一种哒嗪类衍生物抑制剂、其制备方法和应用
WO2022135430A1 (en) * 2020-12-22 2022-06-30 InventisBio Co., Ltd. Heteroaryl compounds, preparation methods and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR094537A1 (es) * 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
CN113563309B (zh) * 2020-04-28 2024-12-13 浙江海正药业股份有限公司 吡啶类衍生物及其制备方法和用途

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110178053A1 (en) 2008-06-12 2011-07-21 Sanofi-Aventis Azacarboline derivatives, preparation method thereof and therapeutic use of same
WO2012010538A2 (en) 2010-07-21 2012-01-26 F. Hoffmann-La Roche Ag Novel processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
CN104159891A (zh) * 2012-01-10 2014-11-19 霍夫曼-拉罗奇有限公司 哒嗪酰胺化合物和它们作为syk 抑制剂的用途
CN104884454A (zh) * 2012-11-08 2015-09-02 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα应答调节剂的酰胺取代的杂环化合物
WO2014074661A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES
CN104781252A (zh) * 2012-11-08 2015-07-15 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα应答调节剂的被烷基-酰胺取代的吡啶化合物
WO2014074660A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES
WO2018075937A1 (en) 2016-10-21 2018-04-26 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
US20190152948A1 (en) 2017-11-21 2019-05-23 Bristol-Myers Squibb Company Sulfone pyridine alkyl amide-substituted heteroaryl compounds
WO2019103952A1 (en) 2017-11-21 2019-05-31 Bristol-Myers Squibb Company Sulfone pyridine alkyl amide-substituted heteroaryl compounds
CN111315737A (zh) * 2017-11-21 2020-06-19 百时美施贵宝公司 经砜吡啶烷基酰胺取代的杂芳基化合物
WO2020086616A1 (en) 2018-10-22 2020-04-30 Fronthera U.S. Pharmaceuticals Llc Tyk2 inhibitors and uses thereof
CN113490664A (zh) * 2018-10-22 2021-10-08 埃斯克疗法股份有限公司 Tyk2抑制剂和其用途
WO2020156311A1 (zh) * 2019-01-28 2020-08-06 江苏豪森药业集团有限公司 一种哒嗪类衍生物抑制剂、其制备方法和应用
WO2022135430A1 (en) * 2020-12-22 2022-06-30 InventisBio Co., Ltd. Heteroaryl compounds, preparation methods and uses thereof

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CELL, vol. 181, no. 1, 2020, pages 63 - 80
COMPTES RENDUS CHIMIE, vol. 17, no. 5, 2014, pages 403 - 412
J CLIN INVEST., vol. 130, no. 4, 2020, pages 1863 - 1878
J. MED. CHEM., vol. 62, no. 20, 2019, pages 8973 - 8995
J. ORG. CHEM., vol. 48, no. 20, 1983, pages 3401 - 3408
NATURE REVIEWS DRUG DISCOVERY, vol. 20, 2021, pages 39 - 63
ORG. LETT., vol. 15, no. 13, 2013, pages 3460 - 3463
ORG. PROCESS RES. DEV., vol. 14, no. 1, 2010, pages 263 - 271
SAMBROOK ET AL.: "Molecular Cloning: Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
SCIENCE TRANSLATIONAL MEDICINE, vol. 502, no. 11, 2019, pages 1736
See also references of EP4488268A4

Also Published As

Publication number Publication date
EP4488268A1 (en) 2025-01-08
KR20240158943A (ko) 2024-11-05
AU2023227024A1 (en) 2024-10-24
CA3245417A1 (en) 2025-06-13
JP2025508011A (ja) 2025-03-21
CN119317622A (zh) 2025-01-14
US20250179022A1 (en) 2025-06-05
CN116693449A (zh) 2023-09-05
EP4488268A4 (en) 2025-12-31

Similar Documents

Publication Publication Date Title
CN110582491B (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN114787161B (zh) 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
JP2023126907A (ja) Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
CN105492444B (zh) 作为rock抑制剂的三环吡啶-甲酰胺衍生物
WO2024083256A1 (zh) pan-KRAS降解剂及其制备方法和应用
WO2023016529A1 (zh) 作为atr抑制剂的萘啶衍生物及其制备方法
CN110256421A (zh) Kras-g12c抑制剂
WO2019000682A1 (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN110520423A (zh) 作为激酶抑制剂的氨基三唑并吡啶
TW201734021A (zh) 布魯頓氏（ｂｒｕｔｏｎ）酪胺酸激酶抑制劑及其使用方法
WO2020094111A1 (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其用途
WO2024002024A1 (zh) 三环类化合物及其用途
CN107108555A (zh) 三环阻转异构体化合物
TW201348213A (zh) 喹唑啉二酮衍生物
WO2024199108A1 (zh) 作为wrn解旋酶抑制剂的化合物
CN111356695B (zh) 新的三环化合物
WO2021047547A1 (zh) 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用
WO2023165581A1 (zh) 一种吡啶类衍生物及其用途
CN110407854A (zh) 新的四环化合物
WO2021047555A1 (zh) 芳香杂环衍生物作为免疫调节剂的制备及其应用
CN119823121A (zh) 具有cbl-b抑制作用的化合物及其用途
CN114096533B (zh) 一种三并环类化合物，包含其的药物组合物，其制备方法及其用途
KR20240148437A (ko) 이미다조피리다진계 유도체, 이의 제조 방법, 약학 조성물 및 용도
CN116693449A (zh) 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
CN114222744B (zh) 可用作IL-12、IL-23和/或IFNα反应调节剂的咪唑并哒嗪化合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23762972

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202380025084.1

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 18843972

Country of ref document: US

Ref document number: 2024552772

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 202437070858

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20247032854

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020247032854

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: AU2023227024

Country of ref document: AU

Ref document number: 2023762972

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023762972

Country of ref document: EP

Effective date: 20241004

ENP Entry into the national phase

Ref document number: 2023227024

Country of ref document: AU

Date of ref document: 20230302

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 202380025084.1

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 18843972

Country of ref document: US